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Diabetes affects one quarter of individuals in hospital and contributes to worse clinical and economic 
outcomes. Acute hyperglycaemia causes immune dysfunction, proinflammatory and prothrombotic 
changes, and endothelial dysfunction, leading to increased risk of hospital-acquired infections, and 
cardiovascular and renal complications. Acute hypoglycaemia also causes proinflammatory and 
prothrombotic changes, endothelial dysfunction, and neuroglycopaenia-related complications. ‘Adverse 
glycaemia’ describes both extremes of hypoglycaemia and hyperglycaemia (defined as glucose <4 or >15 
mmol/L), that are associated with adverse pathophysiology and adverse outcomes in hospital. Adverse 
glycaemia remains common in hospital patients due to various barriers including clinical inertia. This 
thesis aimed to develop and investigate a strategy of proactive care and early diabetes intervention to 
address adverse glycaemia in hospital.  
 
A glucose alert system, comprising a novel clinical escalation tool coupled with alert-capable networked 
glucose meters, was developed to decrease clinical inertia (Chapter 3). In a 14-week, pre- and post- 
implementation study, the glucose alert system increased nursing and medical staff actions in response to 
adverse glycaemia, and this translated to a reduction in the incidence of hyperglycaemia. 
 
Networked glucose meter technology was then implemented on eight noncritical medical and surgical 
care wards at the Royal Melbourne Hospital, enabling detailed baseline assessment of inpatient glycaemia 
(Chapter 4). In this first detailed glucometric analysis of an Australian hospital, our cohort was found to 
have a higher incidence of hyperglycaemia but a lower incidence of hypoglycaemia compared to 
benchmarks in the United States hospitals. A novel glucometric measure of ‘adverse glycaemic days’, 
defined as patient-days with glucose <4 or >15 mmol/L, was proposed as a useful metric for 
benchmarking, and as a tangible concept for educating health professionals about safe glycaemic control 
in hospital. 
 
A comprehensive early intervention model of diabetes care was developed and investigated in the 
Randomised study of a Proactive Inpatient Diabetes Service (RAPIDS) (Chapter 5). The early 
intervention model included remote glycaemic surveillance and proactive management of all diabetes 
patients, by an inpatient diabetes team within 24 hours of admission. RAPIDS, a 24-week cluster 
randomised trial with a baseline period, involving 1002 consecutive patients, is amongst the largest 
randomised trials of inpatient diabetes care to date. Early intervention decreased the incidence of adverse 
glycaemic days by 28%, and decreased severe hyperglycaemia (patient-days with mean glucose >15 
mmol/L) by 55%. This intervention was associated with an 80% relative risk reduction (and 4% absolute 
risk reduction) of developing hospital-acquired infection. 
 
Lastly, a prediction tool to enable early identification of diabetes inpatients at high risk for persistent 
adverse glycaemia was developed (Chapter 6). A prediction tool based on four clinical factors available at 
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admission (glucose at admission, glucose-lowering treatment regimen, glycosylated haemoglobin and 
glucocorticoid medication), accurately identified high-risk patients, and may assist delivery of targeted 
management. 
 
The studies describe models of clinical care which may be implemented as stand-alone or as a bundle of 
interventions. The findings support the strategy of proactive care to improve inpatient glucose. Proactive 
and early intervention models of care which improve glycaemia may improve the care of individuals with 
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1. CHAPTER ONE: LITERATURE REVIEW 
1.1 Diabetes Mellitus 
Diabetes mellitus is a group of metabolic conditions characterised by a defect in insulin secretion, insulin 
action, or a combination of both, leading to hyperglycaemia. Insulin, produced by β cells in the islets of 
Langerhans in the endocrine pancreas, is secreted in response to hyperglycaemia, or in response to other 
pancreatic and incretin hormones.  Insulin acts at the peripheral tissues and liver to promote glucose 
uptake, glycogen synthesis, and lipogenesis.  In diabetes, lack of insulin action causes impairment in 
glucose uptake in the peripheral tissues, and causes gluconeogenesis and glycogenolysis in the 
hepatocytes, leading to hyperglycaemia. Extreme insulin deficiency promotes lipolysis and ketogenesis, 
leading to ketoacidosis.  
 
The acute sequelae of hyperglycaemia include osmotic diuresis which causes polyuria, polydipsia, and 
dehydration, leading to metabolic disturbances. With extreme insulin deficiency, glycaemic emergencies 
such as Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycaemic State (HHS) may develop. 
Other acute sequelae of hyperglycaemia include impaired immunity, endothelial dysfunction, as well as 
prothrombotic and pro-inflammatory changes [1], leading to acute cardiovascular and renal pathology, 
and increased risk of infection. 
 
Chronic sequelae of hyperglycaemia include microvascular complications (chronic kidney disease, 
retinopathy, peripheral neuropathy and autonomic neuropathy), and macrovascular complications 
(ischaemic heart disease, cerebrovascular disease, peripheral arterial disease, diabetic foot ulcers and 
lower limb amputations). Cardiovascular disease is the leading cause of death in Australia; diabetic 
kidney disease is the leading cause of end stage kidney disease; diabetic retinopathy is the most common 
cause of blindness in working-age adults [2-4]. Other emerging chronic complications of diabetes include 
cognitive impairment, and increased risk of fractures. 
 
Although more than 60 subtypes of diabetes have been described [5], the predominant subtypes 
encountered in routine hospital practice include: type 1, type 2, type 3c, drug-induced, and gestational 
diabetes. Type 1 diabetes (T1D) accounts for 5-10% of individuals with diabetes, and occurs due to 
destruction of  cells via immune-mediated mechanisms, leading to absolute insulin deficiency. 
Individuals with T1D are dependent on exogenous insulin therapy and can develop life-threatening DKA 
in the absence of insulin. Individuals with T1D are also more prone to hypoglycaemia compared to those 




Type 2 diabetes (T2D) accounts for approximately 90% of diabetes worldwide, and its aetiology relates to 
insulin resistance and relative (rather than absolute) insulin deficiency. Although treatment of T2D 
includes diet, lifestyle measures and glucose lowering medications (GLM), some individuals will become 
insulin dependent. Although it was traditionally believed that people with T2D had low risk of DKA, 
some individuals can develop this complication with severe illness and/or during treatment with sodium 
glucose cotransporter (SGLT) inhibitors [7]. 
 
Diseases of exocrine pancreas (e.g. recurrent pancreatitis, pancreatic cancer, pancreatectomy and cystic 
fibrosis) can lead to type 3c diabetes due to β cell deficiency or due to paracrine effects of pancreatic 
inflammation. Individuals with type 3c diabetes are more likely to be insulin dependent, and at risk of 
hypoglycaemia due to concurrent defects in glucagon-producing  cells and nutrient malabsorption due to 
exocrine pancreatic deficiency [8].  Diabetes can also develop due to medications such as glucocorticoids 
[9], immunomodulators (e.g. tacrolimus, cyclosporine, and sirolimus) and antipsychotic medications (e.g. 
olanzapine, clozapine). Lastly, gestational diabetes mellitus may be encountered in hospitals with 
maternity services, but is not a focus of this thesis and will not be explored further. 
 
Accurate identification and classification of diabetes subtypes is critical for provision of appropriate 
treatment, particularly during hospitalisation where treatment adjustments are often necessary. It is 
particularly important to determine if an individual is likely to be insulin deficient, so as to ensure insulin 
treatment is not withheld to avoid iatrogenic in-hospital DKA.  
 
In 2017, global estimates suggest that approximately 425 million (or 9% of people aged 20 to 79 years) 
are living with diabetes and it is estimated one in two are undiagnosed. Additionally, 1.1 million children 
and adolescents (aged 0 to 19 years) has type 1 diabetes [10]. It has been quoted that “If diabetes were a 
country, it would be the third largest country in the world” [11]. The global epidemic of diabetes is 
unprecedented; tripling in the last 20 years and projected to further increase by 50% in the next 25 years. 
By 2045, an estimated 630 million adults will be living with diabetes, with four out of five living in a low 
or medium income country [10].  Additionally, 325 million adults (or 7% of people aged 20 to 79 years) 
are estimated to have impaired glucose tolerance, a prediabetes condition. Therefore, 16% of the adult 
population have a disorder of glucose metabolism (diabetes or prediabetes). In the United States (US) of 
America where the prevalence is particularly high, diabetes and prediabetes are estimated to be present in 
14.3% and 38.0% respectively [12]. 
 
In Australia the prevalence of diabetes mirrors the global trend. An estimated 1.1 million people are 
living with diabetes and 2.5 million are living with prediabetes [13, 14]. In 2011, diabetes was the 
underlying cause of death in 3% of the Australian population, and underlying or associated cause of death 
in 10% [15]. The co-related chronic diseases comprising diabetes, cardiovascular disease (CVD), and 
chronic kidney disease (CKD), were responsible for 36% of all deaths. The economic burden of diabetes 
is estimated to be AU $1.7 billion in direct costs and over $14 billion including indirect costs [16]. 
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Individuals with diabetes are more likely to require hospital treatment and amongst those who were 
hospitalised, 30% had two or more hospital stays each year [17]. Hence, inpatient care is the biggest 
component of diabetes related-costs [18].  
 
In summary, diabetes is a chronic condition with both acute and chronic sequelae, and one of the biggest 
contributors to chronic disease morbidity and mortality.  The epidemic of diabetes is one of the greatest 
health priorities of the 21
st
 century, both in Australia and globally. 
 
1.2 The modern hospital in Australia 
Various examples of institutions to care for the ill can be found in ancient Greece, the Roman Empire, 
and in the Indian and Sri Lankan civilisations. During medieval times in Europe, infirmaries were 
established by religious orders with care provided by monks and nuns. In the 18
th
 century, ‘voluntary 
hospitals’ began to appear, evolving from basic places to care for the ill, to becoming complex institutions 
for provision of medicine, surgery, and conduct of research and education [19]. In the 19
th
 century, 
Florence Nightingale was instrumental in developing the modern nursing profession and reforming the 
hospitals by changing the image from places for the sick to go to die, to places for recuperation and 
healing. 
 
Today, modern hospitals are complex health care institutions providing patient treatment with medical, 
surgical, nursing care and specialised medical equipment. They are supported by various allied health 
professionals and ancillary departments such as radiology, pathology and pharmacy. Hospitals vary in 
size from rural and regional hospitals to tertiary and quaternary referral centres. Specialised hospitals, 
such as paediatric, obstetric, psychiatric, rehabilitation, aged care and palliative care hospitals may 
coexist in addition to the general hospitals. Although hospitals traditionally care for inpatients, 
ambulatory care departments provide treatment to patients who do not require inpatient treatment. Many 
hospitals are publicly funded; however, some are privately funded or supported by religious institutions.  
 
Hospital wards are generally classified as critical care or noncritical care and provide different levels of 
medical and physiological support, and different intensity of monitoring, depending on the acuity of 
patient illness. Operating theatres and procedure units provide equipment and staff for surgical or other 
interventional procedures. Some hospitals provide day procedure units, where an individual may be 
admitted for a procedure or minor surgery and discharged on the same day without the need for overnight 
admission. Many teaching hospitals are affiliated with a university and provide education and vocational 
training for undergraduate, postgraduate and specialist trainees in medicine, nursing and other disciplines. 
 
Treating doctors of various specialities provide specialised care for inpatients. In secondary and tertiary 
hospitals, treating medical teams generally comprise of specialist consultants, registrars (or fellows) who 
are specialists in training, and residents or house staff. Treating medical teams typically manage 
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inpatients admitted under their care, but additionally provide consultations and advice to inpatients 
admitted under other treating teams when requested.  
 
A hospital inpatient’s journey can commence in the emergency department for those with an emergency 
presentation, or in the day procedure or perioperative unit for those with an elective admission.  Patients 
are typically admitted under a treating general or specialist medical (or surgical) team depending on the 
reason for admission, and admitted in a ward where nursing care is provided by the nursing unit of the 
ward. During the hospital stay, medical care is mostly delivered by the treating team’s doctors, but other 
specialists may provide consultation advice if requested. As most clinicians work in shifts, patients are 
managed by different clinicians depending on the time: during business hours vs. after hours. In addition, 
many other health professionals, including pharmacists and allied health staff provide care. A patient may 
undergo investigations or procedures, some of which require interruption to nutrition (or fasting). With 
pressure on hospital bed occupancy, patients may be transferred between wards either due to clinical 
need, or due to nursing workload distribution. Upon convalescence, an inpatient may be discharged 
directly home, transferred to a subacute care hospital, or to a residential care facility. 
 
Compared to early Nightingale-era hospitals, modern hospitals have evolved to be dynamic institutions 
where there is a constant interplay between various clinicians, hospital wards and departments. Medical 
treatment, surgical techniques and nursing care have developed to improve patient comfort and safety. 
However, this is paralleled by a rise in the cost of health care and consequently there is pressure to 
improve efficiency, such as to decrease hospital length of stay (LOS). Although modern hospitals have 
improved patient care, they are often operating under financial constraints and constantly striving to 
improve efficiency, minimise cost, decrease LOS and utilise ambulatory treatment modalities.   
 
1.3 Diabetes in hospital 
1.3.1 Prevalence of diabetes in hospital 
Given the prevalence of diabetes, and its acute and chronic sequelae, it is not surprising that diabetes is a 
significant comorbidity in hospitals. The prevalence of diabetes in hospital varies depending on the 
methodology of measurement. Based on discharge diagnostic codes, 8.9% of all hospitalisations in 
Australia had diabetes as a diagnosis (principal or additional) [20]. However, this is probably a gross 
underestimate as diabetes is often omitted in discharge summaries [21]. More accurate estimates are 
obtained by point-prevalence studies using manual surveys, blood glucose (BG) screening, or 
glycosylated haemoglobin (HbA1c) measurements.  
 
In the United Kingdom (UK), the National Diabetes Inpatient Audit (NaDIA) is conducted annually. It 
includes over 200 hospitals in England and Wales, and uses a one-day ‘snap-shot’ survey. In 2016, 
NaDIA reported 17.3% of inpatients had diabetes, and this has progressively increased each year [22]. 
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There was wide variability between hospitals, with a quarter of hospitals reporting prevalence greater 
than 20%, and a few hospitals reporting prevalence greater than 33%.  Hospitals in continental Europe 
reported similar prevalence of diabetes (Table 1). 
 
In Australia, the prevalence of diabetes appears to be higher than in UK or Europe.  Point-prevalence 
surveys on 11 hospitals in Melbourne in 2011 reported that overall 25% of inpatients had diabetes, 
ranging from 16% to 35% across different hospitals [23]. At the Royal Melbourne Hospital (RMH), the 
prevalence was 30% in 2012, with the rate doubling in the preceding decade [24]. Other Australian 
hospitals have reported similar prevalence rates (Table 1). 
 
Within each hospital, the prevalence of diabetes varies between different medical and surgical units. 
Traditionally, medical units such as cardiology, nephrology, stroke, and general medicine, and surgical 
units such as vascular surgery and cardiothoracic surgery have higher prevalence rates of diabetes, 
reflecting the burden of diabetes-related cardiovascular and renal pathology. A study based on discharge 
codes at RMH, reported the prevalence of diabetes in nephrology, general medicine and cardiology units 
was 36%, 29% and 24%, respectively. In cardiothoracic and vascular surgery units, the prevalence was 
29% and 28%, respectively. In comparison, trauma, neurosurgery and orthopaedic surgery units had 
prevalence of 6%, 10% and 11% respectively [25]. 
 
Despite the significant prevalence of inpatients with diabetes, only a minority (3% to 8%) of individuals 
are admitted with diabetes as a primary diagnosis (such as DKA, HHS, or hypoglycaemia) [22, 26]. The 
majority are admitted with diabetes as a secondary diagnosis; most admissions are due to CVD, renal 
disease and infectious diseases [27]. Accordingly, the majority of inpatients with diabetes are admitted 
under different medical and surgical units and managed by treating teams who are not diabetes specialists.  
 
1.3.2 Prevalence of new hyperglycaemia in hospital 
Many individuals are discovered to have hyperglycaemia while in hospital, without previously recognised 
as having diabetes. New hyperglycaemia in hospital is generally defined as random BG >7.8 mmol/L in 
the absence of previously known diabetes [28].  Alternative thresholds such as fasting BG ≥7.0 mmol/L 
or random BG ≥11.1 mmol/L are occasionally used [29].  
 
New hyperglycaemia in hospital can occur as a first detection of hyperglycaemia in a patient with 
undiagnosed diabetes. It can also occur due to the physiological stress of acute illness in an individual 
with previously normal glucose tolerance, an entity called ‘stress hyperglycaemia’. To distinguish 
between these two scenarios, assessment of Glycosylated haemoglobin (HbA1c) may be helpful; HbA1c 
≥6.5% suggests pre-existing but undiagnosed diabetes. However, HbA1c does not reflect chronic 
hyperglycaemia in the setting of anaemia, acute blood loss or transfusion; therefore, the utility of HbA1c 
can be limited in the acute hospital setting. Hence, an oral glucose tolerance test after discharge from 
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hospital and resolution of acute physiological stress is recommended to distinguish between stress 
hyperglycaemia and undiagnosed diabetes [30]. Regardless of the aetiology, new hyperglycaemia in 
hospital is associated with adverse outcomes; therefore, this group of people should be identified and 
managed. 
 
The prevalence of new hyperglycaemia in hospital depends on the definition used and the method of case 
finding. Screening for new hyperglycaemia using plasma glucose testing detects new hyperglycaemia in 
10 to 15% of inpatients [31, 32]. Routine HbA1c testing reports 5% of all inpatients [33], and 11% of 
inpatients with BG ≥5.5 mmol/L have undiagnosed diabetes [34]. However, routine HbA1c screening is 
not able to detect individuals with stress hyperglycaemia, as it requires assessment of BG levels. Table 1 




Table 1: Point-prevalence of diabetes in hospitalised patients 
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1.3.3 The significance of diabetes and new hyperglycaemia in hospital  
It is well-established that diabetes is associated with poor outcomes in hospital. A wealth of observational 
studies consistently report that individuals with diabetes have increased risk of adverse hospital outcomes, 
including infection, poor wound healing, cardiac complications, renal failure, increased mortality and 
LOS. This association is consistent across various settings including critical care and noncritical care, as 
well as medical and surgical disciplines. In addition, regardless of the aetiology, new hyperglycaemia is 
also associated with poor outcomes, particularly with increased risk of mortality.  In this section, the 
association between diabetes and new hyperglycaemia with adverse outcomes is discussed. In the next 
section (Section 1.4) the mechanistic link between the severity of hyperglycaemia and adverse outcomes 
will be discussed. 
 
1.3.3.1 Mortality 
Diabetes is consistently associated with greater inpatient mortality across various patient populations 
(Table 2). In a UK study of 10 million admissions, patients with known diabetes had 6.5% higher risk of 
inpatient mortality compared to patients without diabetes, even after adjusting for comorbidities and 
severity of disease [39]. In individuals admitted with myocardial infarction (MI), diabetes increases the 
risk of inpatient and 180-day mortality [40-42], and is an important prognostic factor for poor outcomes 
[43]. It is of concern that the higher rates of diabetes-associated mortality in MI has not diminished over 
time [40]. In individuals hospitalised with respiratory illnesses (e.g. community acquired pneumonia, 
pulmonary embolism), neurological diseases (e.g. ischaemic and haemorrhagic stroke), and infectious 
diseases (e.g. pandemic influenza, infective endocarditis), diabetes is consistently associated with higher 
inpatient mortality (Table 2). Following cardiothoracic surgery, diabetes is a well-established prognostic 
factor for post-operative mortality [44, 45]. 
 
Although the majority of published research in cardiothoracic surgery demonstrated increased mortality 
with diabetes, two studies reported a lack of association [46, 47], but this may be related to perioperative 
intensive insulin infusion treatment that has been in routine practice since the early 2000s. Diabetes does 
not appear to be associated with inpatient mortality in individuals with hip fractures [48, 49]. Intriguingly, 





Table 2: Inpatient mortality in patients with pre-existing diabetes vs. no diabetes 
Study (Year) Country Population (n) 
Inpatient mortality: 
Diabetes vs. no diabetes. 
General Inpatients 
Umpierrez 2002 [31] USA All inpatients (n=2030) OR = 2.7 
Papazafiropoulou 
2010 [51] 
Greece All inpatients (n=16100) OR = 1.32 (1.14-1.53) 
Holman 2013 [39] UK All inpatients (n=10 million) Adjusted OR = 1.065 (1.052-1.079) 
Patients with cardiac illness 
Maier 2006 [52] Germany AMI females only (n=921) Adjusted OR = 2.92 (1.75-4.87) 
Canto 2012 [42] USA AMI (n=540,000) Adjusted OR = 1.23 (1.20-1.26) 
Parissis 2013 [53] Multinational Acute heart failure (n=4950) Adjusted OR = 1.9 (1.1-3.1) 
Ahmed 2014 [40] USA AMI (n=1.5 million) Adjusted OR = 1.069 (1.051-1.087) 
Patients with respiratory illness 
Lepper 2012 [54] Germany 
Community acquired 
pneumonia (n=6891) 
Hazard Ratio = 2.5 
Valent 2017 [55] Italy 
Community acquired 
pneumonia (n=458) 
OR = 1.94 
Fabbian 2013 [56] Italy 
Pulmonary embolism  
(n= 24690) 
Adjusted OR = 1.12 (1.001-1.253) 
Patients with neurological disease 
Arboix 2000 [57] Spain Haemorrhagic stroke (n=229) Adjusted OR = 6.1 (2.0-18.3) 
Koennecke 2011 [58] USA Stroke (n=16500) Adjusted OR = 1.37 (1.00-1.89) 
Patients with infectious disease 
Delahaye 2007 [59] France Infective endocarditis (n=560) Adjusted OR = 7.8 (2.7-23.1) 
Xi 2010 [60] China 
H1N1 Pandemic Influenza 
(n=155) 
Adjusted OR = 8.8 (2.0-38.2) 
Patients with surgical admissions 
Rosenthal 2003 [44] USA 
Coronary Artery Bypass Graft 
(n=19200) 
Adjusted OR = 1.29 (1.17-1.41) 
Nowicki 2004 [61] USA Mitral valve surgery (n=8900) Adjusted OR = 1.47 




New hyperglycaemia is also strongly associated with inpatient mortality (Table 3). A seminal study by 
Umpierrez et al., evaluated the hospital outcomes of over 2000 inpatients depending on their glycaemic 
status, and found inpatient mortality in patients with normoglycaemia, with pre-existing diabetes, and 
with new hyperglycaemia were 1.7%, 3.0% and 16.0% respectively. After adjustment for covariates, 
compared to the normoglycaemia group, patients with pre-existing diabetes had a 2.7 fold increase, and 
new hyperglycaemia had a 18.3 fold increase in mortality [31]. A similar Australian study of consecutive 
general medical inpatients, reported individuals with pre-existing diabetes had a modest (but non-
significant) increase in mortality compared to the normoglycaemic group, with odds ratio of 1.4 (95% CI 
0.6-3.2). However, individuals with new hyperglycaemia had a significantly higher risk of inpatient 
mortality compared to the normoglycaemic group: odds ratio 2.9 (1.2-7.0) [32].  
 
In summary, studies consistently report individuals with new hyperglycaemia have higher rates of 




Table 3: Inpatient mortality in patients with normoglycaemia vs. pre-existing diabetes vs. new 
hyperglycaemia 
Study (Year) Country Population (n) 
Inpatient mortality 
New hyperglycaemia vs. 
no diabetes. 
Pre-existing diabetes vs.  
no diabetes 
Umpierrez 2002 [31] USA 
All inpatients 
(n=2030) 
Adjusted OR = 18.3 Adjusted OR = 2.7 
Baker 2008 [32] Australia 
General medicine 
(n=903) 
Adjusted OR = 2.9 (1.2-7.0) Adjusted OR = 1.4 (0.6-3.2) 
Scheutz 2014 [62] Germany 
Community acquired 
pneumonia (n=880) 
Adjusted OR = 2.9 (0.8-9.9) Adjusted OR = 0.9 (0.1-9.9) 
Capes 2001 [63] 
Multi-
national 
Stroke (n=21 studies) Adjusted OR = 3.1 (2.5-3.8) NA 
Di Bonito 2003 [64] Italy 
Ischaemic stroke 
(n=286) 
OR = 5.9 (2.7-13.0) OR = 1.3 (0.6-2.8) 







Diabetes and new hyperglycaemia are well-established risk factors for hospital-acquired (also called 
nosocomial), or health-care associated infections. The strongest association is reported with post-
operative surgical site infections (SSI) and deep sternal wound infections (DSWI) after cardiothoracic 
surgery [65-69]. For example, in a prospective cohort of 1040 patients undergoing coronary artery graft 
surgery (CAGS), patients with diabetes had adjusted odds ratio of 2.7 (95% CI: 1.4-5.8) and patients with 
new hyperglycaemia (post-operative BG >11.1 mmol/L without known diabetes) had adjusted odds ratio 
of 2.2 (1.2-3.4) for developing SSI [70]. A similar association between diabetes and infection is found in 
non-cardiac surgery. In a prospective study of 3000 individuals undergoing non-cardiac surgery, those 
with diabetes had a 2.2 fold increase risk of pneumonia, 2.2 fold increase risk of SSI, and 3.2 fold 
increase risk of urinary tract infection compared to patients without diabetes [71]. In a meta-analysis of 
94 studies comprising over 860,000 surgical procedures, diabetes had an odds ratio of 1.5 (95% predictive 
interval 1.1-2.1) for SSI. The association was present across different types of surgery but was strongest 
in cardiac, spinal, orthopaedic and gynaecological surgeries [72]. 
 
Aside from SSI, other hospital-acquired infections are more common in individuals with diabetes. 
Diabetes is a risk factor for Staphylococcus aureus bloodstream infection: relative risk 10.6 (95% CI: 9.3-
11.9) in one study [73] and 4.4 times more prevalent in another study [74]. Diabetes is also associated 
with urinary tract infections [75], and peri-prosthetic joint infection [76]. In addition, diabetes is a risk 
factor for infections with more resistant or virulent microorganisms. Individuals with diabetes were 4 
times more likely to develop methicillin-resistant, rather than methicillin-sensitive, Staphylococcus 
aureus blood stream infection [77]; and more likely to develop Gram-negative rather than Gram-positive 
central line associated infections [78]. 
 
1.3.3.3 Length of stay and readmissions 
Patients with diabetes have longer hospital LOS than patients without diabetes. According to the 
Australian Institute of Health and Welfare data in 2012-2013, the mean LOS in public hospitals for all 
patients was 5.8 days, but 6.4 and 7.4 days for in patients with T1D and T2D, respectively [20, 79]. In the 
UK hospitals in 2011, median LOS was 6 nights for all inpatients, but 8 nights for patients with diabetes 
[80]. In the US, patients with diabetes had almost one day longer LOS (5.3 vs. 4.4 days) than patients 
without diabetes, based on 35 million admission episodes in 2008 [81]. In Japan, the difference in LOS 
was even greater: 14 vs. 10 days [82]. Locally at the Royal Melbourne Hospital, inpatients with diabetes 
had 1 day longer median LOS compared to patients without diabetes (6 days vs. 5 day) [25]. Inpatients 
with new hyperglycaemia have even longer LOS compared to individuals with normoglycaemia or pre-
existing diabetes. In the aforementioned seminal study by Umpierrez et al., LOS in new hyperglycaemia, 
known diabetes and normoglycaemia were 9.0, 5.5 and 4.5 days, respectively [31]. Patients with new 
hyperglycaemia have disproportionately higher LOS, possibly related to the severity of illness rather than 




LOS outcomes are generally based on hospital discharges data registries. Outcomes are often not adjusted 
for demographics or severity of illness. To overcome this limitation, one UK study analysed the mean 
‘excess bed days’ attributable to diabetes after matching for age and admission unit. This study reported 
patients with diabetes had 1.9 days in excess compared to patients without diabetes, which contributed to 
17.8% excess bed-day use [83]. Hence, inpatients with diabetes remains 1-2 days longer in hospital 
compared to patients without diabetes, even after adjusting for covariates. 
 
A small proportion of patients experience recurrent hospitalisations and this is a significant burden of 
inpatient care. Unplanned hospital readmission within 30 days of discharge is an important quality 
measure of hospital care. Similar to other chronic conditions, diabetes is associated with an increased risk 
of hospital readmissions. Compared to the 30-day readmission rate of between 9 to 14% in the overall 
hospital population, the readmission rate is between 15 to 23% in patients with diabetes [17, 84], which 
represents a 40% higher readmission rate [85]. The 3-month and 1-year readmission rates for diabetes 
patients are approximately 26% and 30%, respectively [86]. 
 
Identified risk factors for readmission in diabetes patients include medical factors (e.g. number of 
comorbidities, history of recent hospitalisations, low serum sodium, and high serum creatinine), and 
socioeconomic factors (e.g. socioeconomic status, ethnic minority, insurance status, and lack of carer or 
social supports) [84]. Prediction models for readmission have been developed [87] and approximately one 
quarter of readmissions were considered to be preventable [88]. The majority of readmissions were for 
reasons other than diabetes. In a cohort of older Australian veterans with diabetes, 25% were re-
hospitalised within 30 days of discharge, but only 24% were readmitted for diabetes-related reasons [89]. 
Another recent study evaluated readmission in people following an index admission with hypoglycaemia 
or hyperglycaemia. Following the index admission with hypoglycaemia, 10% were readmitted within 30 
days, comprising 1.2% for recurrent hypoglycaemia, 0.2% for hyperglycaemia, and 8.6% for non-diabetes 
reasons. Following the index admission for hyperglycaemia, 9.8% were readmitted within 30 days, 
comprising 4.0% for recurrent hyperglycaemia, 0.4% for hypoglycaemia, and 5.4% for non-diabetes 
related reasons [90]. Thus, although diabetes confers a 40% increased risk of early readmission; the 
majority of readmissions were not related to diabetes.  
 
1.3.4 Mechanisms for diabetes-related adverse outcomes in hospital  
Conceptually, there are three potential mechanism that link diabetes (and hyperglycaemia) with adverse 
outcomes (Figure 1). Firstly, long-term microvascular and macrovascular complications of diabetes may 
be responsible for adverse hospital outcomes. For example, patients with established CKD are more likely 
to experience acute kidney injury, and patients with established CVD are more likely to experience acute 
cardiac complications during acute illness in hospital. Secondly, chronic hyperglycaemia and its 
associated pathophysiology may be responsible for adverse hospital outcomes. Chronic hyperglycaemia 
causes endothelial and vascular dysfunction which impairs adaptive response to blood pressure changes 
of acute physiological stress. Chronic hyperglycaemia causes immune dysfunction and impaired wound 
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healing potentially accounting for increased risk of infection. Thirdly, the acute metabolic effects of 
dysglycaemia that occurs during hospitalisation may contribute to adverse hospital outcomes. Metabolic 
changes include acute hyperglycaemia, acute hypoglycaemia, and glycaemic variability, all of which are 




Figure 1: Potential mechanisms of diabetes leading to adverse outcomes in hospitalised patients 
 
The relative importance of each mechanistic link between diabetes and adverse outcomes are unclear; 
however, it is likely that all three mechanisms are involved. The finding that patients with stress 
hyperglycaemia have worse adverse outcomes implies the importance of the third mechanism, acute 
metabolic effects of dysglycaemia. Patients with stress hyperglycaemia have normal glucose tolerance 
prior to illness; therefore, would not be expected to have vascular complications or physiological changes 
of chronic hyperglycaemia. Furthermore, for the patient who is already admitted to hospital, only the third 
mechanism is modifiable. By improving glycaemic control in hospital, the negative effect of acute 
dysglycaemia may be mitigated. To explore this concept, the following section reviews the acute effects 




1.4 Adverse glycaemia in hospital 
Both acute hyperglycaemia and acute hypoglycaemia are associated with adverse pathophysiology and 
adverse clinical outcomes in hospital. The term adverse glycaemia is used to encompass both extremes of 
hyperglycaemia and hypoglycaemia in this thesis.  
 
1.4.1 Acute hyperglycaemia 
The definition of acute hyperglycaemia in hospital is understandably different across different studies and 
has varied over time. Most individuals with normal glucose tolerance maintain BG in a narrow range and 
rarely exceed 8.0 mmol/L. In hospital, BG >7.8 mmol/L is defined as inpatient hyperglycaemia, and BG 
>10.0 mmol/L is defined as a threshold to commence treatment [91]. BG is a continuous measure and 
adverse pathophysiological changes may occur at different thresholds in different individuals; thus, 
individualised targets may be necessary in specific situations.  
 
Many observational studies report a dose-dependent relationship between the severity of acute 
hyperglycaemia and adverse patient outcomes. The association is found in different clinical settings but 
has been most extensively studied in the following subgroups: coronary care, stroke care, critical care and 
noncritical care. The strength of the association between hyperglycaemia and adverse outcomes is 
modified by the presence of pre-existing diabetes. Therefore, there is debate whether hyperglycaemia 
causes adverse outcomes, or whether it is simply a marker of illness severity. To clarify this debate, 
intervention studies treating hyperglycaemia were performed aiming to decrease adverse clinical 
outcomes; however, results were mixed and differed between clinical settings. 
 
1.4.1.1 Pathophysiology 
The pathophysiological consequences of acute hyperglycaemia is summarised in a comprehensive review 
by Clement et al [1]. Acute hyperglycaemia affects the immune, cardiovascular and endothelial systems, 
which result in increased risk of infection, thrombosis, myocardial injury and renal failure.  
 
The effects of hyperglycaemia on immune function are well known. Prior to the discovery of insulin, 
infection was the major cause of death in people with diabetes. On the innate immune system, 
hyperglycaemia induces polymorphonuclear neutrophil and macrophage dysfunction [92]. 
Hyperglycaemia causes decreased mobilisation of neutrophils across the endothelial barrier, decreased 
chemotaxis, decreased superoxide radical production, and decreased neutrophil degranulation [93, 94] 
ultimately leading to decreased microbial killing. Hyperglycaemia impairs macrophage ability to secrete 
IL-1 and perform phagocytosis [95]. On the adaptive immune system, hyperglycaemia appears to cause 
increased glycosylation of B lymphocyte immunoglobulin, which may impair immunoglobulin-mediated 
immune response [1]. Hence, hyperglycaemia increases the risk of SSI and other hospital-acquired 




On the cardiovascular system, hyperglycaemia causes numerous changes in haemostasis favouring 
thrombosis. Hyperglycaemia has been shown to increase platelet hyperactivity, increase platelet 
activation, and elevate plasma fibrinogen levels, all of which may increase the risk of thrombotic events. 
Hyperglycaemia increases production of IL-6 and tumour necrosis factor-α; inflammatory responses that 
further contribute to vascular changes [1]. Hyperglycaemia at various thresholds between 8.0 and 16.7 
mmol/L causes endothelial dysfunction in human in vivo studies [96]. Endothelial dysfunction is linked 
to inflammation, thrombosis and decreased ability for maintenance of vascular homeostasis. 
Hyperglycaemia also induces reactive oxygen species causing oxidative stress [97], which leads to direct 
tissue injury and further inflammation. Ultimately hyperglycaemia increases the risk of cardiovascular 
complications including myocardial injury and renal complications [1]. Acute hyperglycaemia also causes 
osmotic diuresis which may lead to dehydration, metabolic disturbance, acute kidney injury and further 
cardiovascular stress.  
 
Pathophysiological changes of hyperglycaemia can occur even after exposure to a short duration 
(between 2 to 6 hours) of moderate levels of hyperglycaemia (BG 15.0 mmol/L) [98]. Reversal of 
hyperglycaemia leads to a rapid resolution of these changes [1]. Much of the evidence comes from animal 
studies, and human studies in both normoglycaemic individuals and those with diabetes. It is unclear if 
pathophysiological changes occur to the same extent in an individual with pre-existing chronic 
hyperglycaemia. It could be speculated in individuals with chronic hyperglycaemia, the adverse effects of 
acute hyperglycaemia may be somewhat blunted possibly due to adaptive changes. Conversely, 
individuals with stress hyperglycaemia may experience marked pathophysiological changes in response 
to acute hyperglycaemia.  
 
It is unclear whether the pathophysiological changes occur to the same extent in the hospitalised 
individuals who are already exposed to acute physiological stresses due to illness. Hospitalised patients 
have additional challenges from counter-regulatory hormones which cause increased insulin resistance 
leading to further hyperglycaemia and increased free fatty acid. Hyperglycaemia then causes 
glucotoxicity and β-cell dysfunction which further leads to a vicious cycle of hyperglycaemia and insulin 
deficiency [99]. Hyperglycaemia through immune, vascular and endothelial dysfunction further leads to 
tissue injury, inflammation and ischaemia which lead to increased stress response, perpetuating another 
vicious cycle. Ultimately, the combination of hyperglycaemia, insulin deficiency, tissue injury and stress 
response are postulated to be the mechanisms relating acute hyperglycaemia to organ dysfunction and 
poor hospital outcomes [1].  
 
1.4.1.2 Adverse outcomes in different hospital settings 
1.4.1.2.1 Acute myocardial infarction 
The prognostic importance of hyperglycaemia in MI has been recognised since the 1970s [100]. A meta-
analysis of 15 observational studies reported that in individuals without pre-existing diabetes, admission 
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glucose greater than the range of 6.1-8.0 mmol/L was associated with 3.9 fold (95% CI 2.9-5.4) greater 
risk of death compared to those with normoglycaemia [101]. In people with pre-existing diabetes, 
admission BG greater than the range of 10.0-11.0 mmol/L was associated with 1.7 fold (95% CI 1.2-2.4) 
increased risk of mortality. Admission hyperglycaemia is additionally associated with longer term 
adverse outcomes such as 30-day and 1-year mortality [102]. Fasting BG as a continuous measure is 
associated with poor outcomes including congestive cardiac failure, post-thrombolysis bleeding and 
mortality [103]. Persisting hyperglycaemia during the admission is reportedly a stronger predictor of poor 
outcomes than admission hyperglycaemia [104]. 
 
Intervention studies where insulin is utilised to manage hyperglycaemia following a MI demonstrated 
conflicting results. Two different approaches to insulin therapy in MI have been tried: the insulin-based 
approach and the glycaemic-based approach. The insulin-based approach used a glucose, insulin and 
potassium (GIK) infusion as a cardio-protective, therapeutic measure to potentially limit myocardial 
necrosis. Although several smaller studies in the 1990s showed some benefit, a large-scale definitive 
randomised controlled trial (RCT) reported no benefit of GIK infusion in patients with ST-elevation acute 
MI [105].  
 
The glycaemic-based approach focused on using intensive insulin therapy (IIT) to achieve BG targets. 
The DIGAMI RCT recruited 620 acute MI patients with admission hyperglycaemia (BG >11.0 mmol/L), 
regardless of underlying diabetes status [106]. Participants randomised to the IIT group were treated with 
glucose and insulin to maintain BG between 7 and 10 mmol/L for 24 hours, and then followed by a basal-
bolus subcutaneous insulin therapy for at least 3 months. The IIT group had lower mean BG at 24 hours 
(9.6 vs. 11.7 mmol/L), 29% lower 1-year mortality, and 11% lower mortality at 3.5 years; however, it was 
unclear if the benefit was due to the reduction in acute hyperglycaemia or due to the subsequent 
improvement in glycaemic control in the months following MI. The subsequent DIGAMI-2 [107] and Hi-
5 [108] studies failed to show the same benefits of IIT following MI. In the Hi-5 study, there was only a 
modest difference in mean 24-hour glucose (8.3 vs. 9.0 mmol/L) achieved between the two treatment 
groups. Furthermore, compared to the original DIGAMI study, participants in DIGAMI-2 and HI-5 had 
substantially better glycaemic control prior to admission, and less severe hyperglycaemia at admission; 
therefore, the possible benefits of improved glycaemic control could have been diminished [109, 110]. In 
a post-hoc analysis of the Hi-5 study, participants who achieved a mean BG ≤8 mmol/L in the first 24 
hours had a lower 6 month mortality rate than patients with mean BG >8 mmol/L, leading to the 
speculation that reducing acute hyperglycaemia could still be beneficial following an acute MI. 
 
1.4.1.2.2 Stroke 
In patients admitted with stroke, admission hyperglycaemia is associated with increased mortality and 
morbidity. A meta-analysis of 26 studies reported amongst patients without known diabetes with 
ischaemic stroke, admission hyperglycaemia greater than the range of 6.1–8.0 mmol/L had 3.3 (95% CI 
2.3-4.6) fold increase in mortality [63], and greater risk of poor functional outcomes. In contrast, amongst 
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patients with known diabetes, admission hyperglycaemia was not associated with increased mortality 
(odds ratio 2.0 [95%CI: 0.04-90.1]). Hyperglycaemia is common following stroke. Using continuous 
glucose monitoring technology, 50% of individuals without diabetes and 100% of individuals with 
diabetes were observed to develop hyperglycaemia following acute stroke [111]. Mean glucose levels 
post stroke was also independently associated with expansion of infarct size and worse clinical outcomes 
[112]. 
 
Intervention studies using insulin to treat hyperglycaemia following stroke reported conflicting results. A 
Cochrane meta-analysis reported a lack of benefit of IIT on mortality, disability or dependence following 
a stroke [113]. A more recent cluster randomised study named Quality in Acute Stroke Care (QASC), 
investigating a bundle of interventions including management of hyperglycaemia, fever, and swallowing 
dysfunction, reported a 15.7% absolute risk reduction in death or dependency at 3 months [114]. 
Although hyperglycaemia management was one component of the bundle of interventions, the QASC 
study suggested improving glycaemic control may contribute to improving outcomes following stroke.  
 
1.4.1.2.3 Cardiac Surgery 
An observational study in patients undergoing cardiac surgery demonstrated that pre-existing diabetes 
(OR 2.7) and peri-operative hyperglycaemia (OR 2.0) were both independently associated with SSI and 
Deep Sternal Wound Infection (DWSI) [70]. Interestingly, among patients with known diabetes, 
perioperative hyperglycaemia (but not admission HbA1c) was associated with SSI; suggesting that 
perioperative hyperglycaemia may be more detrimental than chronic hyperglycaemia [70].  
 
In the early to mid-1990s, there was a shift in cardiac surgery glycaemic management approach to more 
aggressively treat perioperative hyperglycaemia with continuous intravenous insulin infusion (CIII), 
rather than subcutaneous insulin injections [115]. CIII was commenced intraoperatively or immediately 
postoperatively to achieve BG target between 8.3 and 11.1 mmol/L. This approach resulted in a 
significant decrease in the rate of DSWI (from 2.0% down to 0.8%), to similar rates as normoglycaemic 
individuals [116], as well as decreased mortality [117]. A meta-analysis confirmed the improved 
outcomes with ‘tight glycaemic control’ in the perioperative setting in cardiac surgery [118]. It is now 
routine clinical practice to use CIII targeting a BG target of <11.1 mmol/L in cardiac surgery and 
following this approach, diabetes is no longer believed to be a risk factor for in-hospital mortality in this 
setting [47]. Hence, studies in cardiac surgery have provided some of the strongest evidence that treating 
hyperglycaemia decreases wound infection and mortality. 
 
1.4.1.2.4 Critical Care 
In patients admitted to the intensive care unit (ICU), there is a clear continuous relationship between 
severity of hyperglycaemia and mortality, across various conditions and severity of illness [119]. 
Falciglia et al., evaluated a retrospective cohort of 260,000 ICU admissions, reporting a dose-dependent 
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relationship between mean glucose and mortality, even after adjustment for age, diagnosis, comorbidities 
and severity of illness [120]. This association exists regardless of pre-admission diabetes status; however, 
it was strongest in patients without pre-existing diabetes (Figure 2). Several other ICU studies have 
reported similar findings [121-123] 
 
 
Figure 2: Mortality risk in patients with and without diabetes, depending on mean glucose in the 
intensive care. Odds ratios and 95% confidence intervals are presented compared to group with mean 
glucose ≤ 6.0mmol/L. Adapted from Falciglia, Crit Care Med 2009 [120] 
 
A number of large RCTs investigating intensive glycaemic control using IIT were performed in the 
critical care setting. The first study (Leuven-I), recruited patients admitted to a surgical ICU and 
randomised to IIT (target BG: 4.4 to 6.1 mmol/L) vs. conventional care (target BG: 10.0 to 11.1 mmol/L) 
[124]. The IIT group had 42% risk reduction in ICU mortality, 34% reduction in hospital mortality, and 
34% reduction in blood stream infections. The second study (Leuven-II) in a medical ICU, IIT did not 
show improvements in mortality, but there were reductions in secondary outcomes including kidney 
injury [125]. Although the Leuven studies sparked a worldwide interest in IIT, concerns were raised 
about the generalisability of these single-centre studies, with particular reference to a more aggressive 
provision of enteral and total parenteral nutrition, and high baseline mortality rate in this centre compared 
to many other ICUs worldwide. 
 
Subsequent multicentre trials on IIT in critical care did not reproduce the Leuven results [126-128]. In 
contrast, the multicentre NICE-SUGAR study involving more than 6000 patients reported increased 
mortality with IIT compared to conventional therapy (OR 1.14 [95% CI 1.02 to 1.28]) [129]. It has been 
speculated that excess mortality could be related to cardiovascular events associated with severe 
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hypoglycaemia, which were more prevalent with IIT (6.8% vs. 0.5%). A meta-analysis of intensive 
glycemic control (target BG 4.4 to 6.1 mmol/L) using IIT in critical care reported no difference in-
hospital mortality (pooled relative risk 0.98 [95% CI: 0.89 to 1.09] or long-term mortality (pooled relative 
risk 1.07 [CI: 1.00 to 1.14]), but caused more hypoglycaemia (pooled relative risk 6.00 [CI: 4.06 to 8.87]) 
[130]. This meta-analysis however, found that intensive glycaemic control was associated with a lower 
risk of hospital-acquired infection (pooled relative risk 0.78 [CI: 0.62 to 0.97]), suggesting lowering 
infection could be the standout benefit of intensive glycaemic control.  
 
1.4.1.2.5 Noncritical care 
Observational studies in noncritical care also report a dose-dependent relationship between 
hyperglycaemia and adverse outcomes, irrespective of the glycaemic measure (e.g. admission glucose, or 
mean glucose in hospital). The association exists regardless of diabetes status, although it is strongest in 
patients without pre-existing diabetes. For example, admission hyperglycaemia was reported as an 
independent marker of mortality with a threshold at ≥8.0 mmol/L, and each 1.0 mmol/L increase in BG 
conferred a hazard ratio of 1.04 [95% CI: 1.02-1.06] [131]. This association was strongest amongst 
patients with new hyperglycaemia, although a similar trend was observed (but did not reach statistical 
significance) in patients with pre-existing diabetes. In a more contemporary cohort, a similar relationship 
was reported between admission hyperglycaemia and in-hospital mortality after adjusting for covariates 
[132].  
 
In patients admitted with community acquired pneumonia, a continuous relationship exists between 
admission glucose and risk of complications and mortality [54, 133]; the severity of hyperglycaemia 
correlates with markers of inflammation [62]. In patients with exacerbation of chronic obstructive 
pulmonary disease, each 1 mmol/L increase in mean BG during hospital-stay is associated with 15% 
increased risk of adverse outcomes after adjustment for covariates [134]. In bone marrow transplant 
patients, mean laboratory glucose during admission correlates with LOS [135].  The mechanistic link 
between glucose levels and LOS is not entirely clear. Hyperglycaemia may reflect a greater severity of 
illness, affect clinical decision to discharge a patient, or delay discharge due patient education required 
for diabetes self-management. 
 
In non-cardiac surgery, hyperglycaemia during the pre-operative, intraoperative, and post-operative 
periods are all associated with adverse outcomes. Hyperglycaemia during the post-operative period is 
considered to be particularly detrimental due to the presence of a surgical wound which is vulnerable to 
infection and poor would healing. In a prospective cohort of 3100 individuals undergoing non-cardiac 
surgery, perioperative hyperglycaemia >10 mmol/L was associated with a higher risk of post-operative 
pneumonia, bacteraemia, urinary tract infection, acute renal failure, acute myocardial infarction and 
longer LOS [71]. In patients without pre-existing diabetes, 30-day mortality increased exponentially with 
degree of hyperglycaemia; however, in patients with pre-existing diabetes, this association was less 
strong. Table 4 summarises the association between perioperative hyperglycaemia and poor outcomes.   
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Table 4: Association between perioperative hyperglycaemia and adverse outcomes,  
non-cardiac surgery 








>12.2 mmol/L Infection 




>5.6 mmol/L Mortality, Cardiovascular mortality 
Ramos 2008 Boston, USA 
[137] 
General & vascular 
surgery (n=990) 
>6.1 mmol/L Infection 




>10.0 mmol/L Infection, AMI, AKI, Mortality 




>9.0 mmol/L SSI, Mortality 
Kwon 2013 Washington, 
USA [139] 
General & bariatric 
surgery (n=11600) 
> 10.0 mmol/L Infection, Reoperation, Mortality 
Kotagal 2015 Washington, 
US [140] 
General, bariatric, 
vascular & spinal surgery  
(n=40800) 
> 7.0 mmol/L 
Composite (AMI, stroke, Arrhythmia, 
unplanned ICU, fall w injury, 
infection, AKI, unplanned 
reoperation, mortality) 
Buehler 2015 Atlanta, 
USA[141] 
General surgery  
(n=2100) 
>7.8 mmol/L 
Composite (AMI, wound, respiratory 
infection, bacteraemia, AKI, 
mortality) 




A recent study analysed over 6600 non-cardiac surgeries at a large tertiary hospital network to investigate 
the relationship between pre-surgery glucose control (as determined by HbA1c), perioperative glucose 
control (as determined by median glucose from day 0 to day 3 following surgery) and 30-day mortality 
[142]. This analysis reported a linear relationship between perioperative glucose and mortality after 
adjustment for HbA1c. This relationship did not interact with the presence of pre-existing diabetes, 
suggesting perioperative hyperglycaemia is critically more important than chronic hyperglycaemia.  
 
Despite the wealth of observational studies, there have not been any RCTs of various glycaemic targets in 
noncritical care; therefore, the ideal BG target has not been subject to empirical research. However, the 
importance of glycaemic control in noncritical care was demonstrated by studies of different insulin 
regimens in hospital. In the RABBIT-2 Surgery study, surgical inpatients with hyperglycaemia were 
randomised to a basal-bolus regimen vs. sliding scale regimen [143]. The basal-bolus treated group 
achieved a lower mean glucose (8.1 mmol/L vs. 9.6 mmol/L), and had a lower rate of composite 
outcomes comprising: wound infection, pneumonia, acute respiratory failure, acute renal failure, 
bacteraemia and mortality (8.7% vs. 24.3% p=0.003). There were fewer wound infections, pneumonia 
and acute renal failure in the basal-bolus group. LOS in the intensive care unit was shorter but overall 
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hospital LOS was not different. This study was the first to demonstrate in noncritical care, basal-bolus 
insulin decreased hyperglycaemia and adverse clinical outcomes.  
 
Subsequent studies of intensive insulin treatment in noncritical care demonstrated improvements in 
glycaemic control but were not powered to investigate improvements in clinical outcomes [144-146]. A 
meta-analysis of 9 RCTs and 10 observational studies in noncritical care patients found intensive 
glycaemic control did not significantly affect risk of death, MI, or stroke. However, intensive glycaemic 
control demonstrated decreased risk of infection (relative risk 0.41 [95% CI 0.21-0.77]), mainly based on 
observational studies in surgical patients [147].  
 
1.4.1.3 Summary 
Acute hyperglycaemia results in altered pathophysiology including immunosuppression, endothelial 
dysfunction, and pro-thrombotic and pro-inflammatory changes. These changes lead to increased risk of 
infection, myocardial infarct, kidney injury, and ultimately higher mortality and longer LOS. These 
pathophysiological changes occur at moderate degrees of hyperglycaemia that is routinely encountered in 
hospital practice. Different thresholds may apply to individuals without diabetes vs. those with pre-
existing diabetes. There is a wealth of observational data in various clinical settings (including critical 
care and noncritical care) reporting associations between acute hyperglycaemia and adverse outcomes. 
Intervention studies in myocardial infarction and critical care have yielded mixed results on the 
effectiveness of intensive glycaemic control to improve outcomes. Current evidence suggests modest 
glycaemic control (aiming BG <10 mmol/L) is safer than tight glycaemic control (BG target 4.4 to 6.1 
mmol/L), at least in the critical care setting. In noncritical care, there is a lack of large prospective trials 
of glycaemic targets powered for clinical outcomes. Extrapolating the RABBIT-2 surgery study and the 
QASC study in stroke care, modest glycaemic control may improve outcomes in noncritical care, 





1.4.2 Acute hypoglycaemia 
The glycaemic threshold that defines hypoglycaemia of clinical and pathophysiological significance has 
been subject to debate. In ambulatory care, hypoglycaemia can be defined by the onset of 
sympathoadrenal or neuroglycopenic symptoms, and severity can be defined by whether third-party 
assistance is required for treatment. However, in the inpatient setting, it is inappropriate to define 
hypoglycaemia by symptoms because individuals may have counter-regulatory responses associated with 
illness; may have impaired conscious state; or may be treated with medications (such as beta adrenergic 
blockers) that interfere with symptoms. The individual may be unable to self-treat hypoglycaemia due to 
lack of mobility or access to carbohydrate supply. Hence, in the inpatient setting, absolute BG thresholds 
are used to define hypoglycaemia [148].  
 
There are minor differences in BG thresholds that define hypoglycaemia across different health systems. 
In the US, BG <70 mg/dL (<3.9 mmol/L) is commonly used to define hypoglycaemia. However, in the 
UK, Australia and European countries where mmol/L is the standard unit of glucose measurement, the 
whole number cut-off <4.0 mmol/L (<72 mg/dL) is commonly used. Furthermore, different BG 
thresholds have been proposed to define severe hypoglycaemia such as <3.0 mmol/L (<54 mg/dL), or 
<2.8 mmol/L (<50 mg/dL), or <2.2 mmol/L (<40 mg/dL) [148]. The American Diabetes Association 
(ADA) now recommends reporting inpatient hypoglycaemia at three different levels: Level 1, BG <3.9 
mmol/L (<70 mg/dL) but 3.0 mmol/L (54 mg/dL); Level 2, BG <3.0 mmol/L (<54 mg/dL); and Level 
3, a severe event characterised by altered mental and/or physical status requiring assistance [28]. 
 
1.4.2.1 Pathophysiology 
Hypoglycaemia can independently cause adverse pathophysiological changes in the immunological, 
cardiovascular and neurological systems. Hypoglycaemia causes a counter-regulatory response, 
comprising catecholamine release, inflammation and endothelial dysfunction. Hypoglycaemia causes 
expression of vascular adhesion molecules [149], leucocyte mobilisation [150], inflammation and platelet 
adhesion [151], which lead to a pro-inflammatory and pro-thrombotic state. These changes are observed 
in all individuals experiencing hypoglycaemia, regardless of whether the individual has pre-existing 
diabetes. 
 
Hypoglycaemia additionally causes ischaemic and arrhythmogenic changes. In rats, increasing duration 
of severe hypoglycaemia causes increasingly lethal changes on the electrocardiogram, including 
prolonged QT interval, heart block, atrioventricular dissociation, and finally malignant arrhythmia [152]. 
Blockade of the beta adrenergic receptor attenuates arrhythmias, supporting the critical importance of 
adrenergic system. In humans, similar ischaemic and QT interval changes have been observed on 
electrocardiograms during hypoglycaemia [153]. Hypoglycaemia-induced arrhythmia is the purported 
mechanism of the ‘dead in bed syndrome’, of unexplained sudden death in young individuals with type 1 
diabetes [154]. Most evidence is derived from ambulatory patients and it is unclear if pathophysiological 
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changes occur in hospitalised patients, who may have underlying adrenergic responses due to illness. On 
the other hand, hospitalised patients may be more vulnerable to hypoglycaemia as they are more likely to 
have CVD or electrolyte abnormalities. 
 
Severe hypoglycaemia causes neuroglycopenia which can result in temporary or permanent neurological 
deficit, seizure and coma, as well as indirect effects such as falls and injuries. As the human brain can 
utilise alternative fuels during hypoglycaemia, permanent neurological damage is thought to be rare 
[155], and the mechanisms of hypoglycaemia-related death is believed more likely to be secondary to 
cardiac arrhythmias. Furthermore, although an episode of hypoglycaemia may be transient with 
appropriate treatment, it could destabilise glycaemic control for many hours due to changes in counter-
regulatory hormone responses, resulting in hyperglycaemia or recurrent hypoglycaemia.  
 
1.4.2.2 Adverse outcomes 
Inpatient hypoglycaemia is associated with increased mortality, although a causal relationship has not 
been established. In critical care, a study including over 66000 admissions reported hypoglycaemia (<4.5 
mmol/L) due to any cause, within the first 24 hours of admission, was associated with increased mortality 
(adjusted OR 1.41 [95% CI, 1.31-1.54]) [156]. In noncritical care, amongst 4300 patients with diabetes, 
each additional day with hypoglycaemia (BG <2.8 mmol/L) increased the odds of inpatient mortality by 
83%; and increased LOS by 2.5 days [157]. Both studies demonstrated a correlation between severity of 
hypoglycaemia and subsequent risk of death.   
 
In hospital, spontaneous vs. treatment-related hypoglycaemia must be distinguished. Spontaneous 
hypoglycaemia occurs in the absence of diabetes or glucose-lowering agents, typically in the setting of 
severe organ failure. Hence, spontaneous hypoglycaemia is strongly associated with mortality; however, 
hypoglycaemia is usually not the cause of death. Treatment-related hypoglycaemia occurs in people 
treated with GLM and/or insulin; therefore, adverse outcomes could be caused by glycaemic management 
in hospital. Table 5 summarises studies evaluating the association between mortality and spontaneous vs. 
treatment-related hypoglycaemia. Two studies demonstrated mortality is associated with spontaneous 
hypoglycaemia only [158, 159], whilst two other studies reported mortality is associated with both 
spontaneous and treatment-related hypoglycaemia [160, 161].  
 
Studies evaluating mortality and morbidity associated with hypoglycaemia are summarised on Table 6 
and Table 7. Studies in Table 6 evaluated all patients (with and without diabetes), and did not 
differentiate between spontaneous vs. treatment-related hypoglycaemia. Studies in Table 7 included 
subsets of patients with pre-existing diabetes; hence, focussed on treatment-related hypoglycaemia. 
Studies consistently report increased risk of mortality, LOS, and other adverse outcomes with inpatient 
hypoglycaemia. Although cardiac complications of hypoglycaemia can occur, it is often difficult to 
attribute an episode of cardiac ischaemia solely to the hypoglycaemic event in patients who are subject to 
multiple sources of physiological stresses. In contrast, neurological sequelae, including transient altered 
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mental state, can often be attributed to inpatient hypoglycaemia. In a study of 500 episodes of 
hypoglycaemia, serious neurological sequelae, including seizures, occurred in 4% of individuals [162]. A 
survey of UK hospital endocrinology services compiled 12 serious hypoglycaemia-related adverse events 
including three deaths, two cases of permanent cerebral damage, two cardiac arrests and three seizures; a 
finding which is likely to be the ‘tip of the iceberg’ [163]. 
 
For treating clinicians, each episode of inpatient hypoglycaemia demands increased clinical resources for 
treatment of hypoglycaemia and increased frequency of BG monitoring. Occasionally a medical 
emergency team (MET) response may be required to treat a patient in a hypoglycaemia-induced 
depressed conscious state. Even in the absence of cardiac or neurological sequelae, an episode of 
symptomatic hypoglycaemia is an unpleasant event for the individual and could affect the physical and 
psychological wellbeing during hospitalisation. Hence, avoidance of hypoglycaemia is a major priority 
for safe hospital care.  
 
Table 5: Association between in-hospital hypoglycaemia and mortality risk, categorised between 














AMI patients with 
hyperglycaemia 
(n=7800) 
<3.3 mmol/L OR: 2.3 Nil association 
Boucai 2011  




<3.9 mmol/L HR: 2.6 Nil association 
Garg 2013 
Boston, USA [161] 
All hospital patients 
(n=2800) 
≤2.8 mmol/L OR 20 OR 7.0 











Table 6: In-hospital hypoglycaemia and adverse outcomes, diabetes and non-diabetes patients 





























Longer length of stay 
Gomez-Huelgas 
2013, Spain [167] 
All inpatients 
(n=154,000) 
Discharge code Mortality 





Composite (infection, acute renal failure, 
critical care admission) 
Merrill 2018, Ohio, 
USA [169] 
Patients with heart 
failure 
(n=13400) 
<3.9 mmol/L Mortality 
 
 






Associated Adverse Outcomes 
Turchin 2009, 
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1.4.3 Glycaemic variability 
Glycaemic variability (GV) refers to the glucose excursions from the mean value. In the short-term, GV is 
characterised by within-day glucose fluctuations (peaks to nadirs). As two individuals with diabetes with 
the same mean glucose and HbA1c can have different glucose profiles, GV can be significantly different 
between individuals. Various measures of GV have been developed particularly for reporting continuous 
glucose monitoring data, but in the hospital setting, standard deviation (SD) or coefficient of variation 
(CV) are most practical and commonly used [174].  
 
In addition to hyperglycaemia and hypoglycaemia, GV is postulated to contribute to adverse short-term 
and long-term complications. In vitro human and animal studies report intermittent exposure to high 
glucose stimulate greater production of reactive oxygen species than constant exposure to high glucose 
[174]. However, in-vivo studies in humans have not been consistent. One study in individuals with type 2 
reported a strong correlation between degree of GV and oxidative stress [175], whilst another study in 
individuals with type 1 diabetes reported no correlation [176]. 
 
In ambulatory care, long-term GV is emerging as an independent risk factor for mortality from 
cardiovascular disease and mortality from any cause in people with diabetes [177]. In hospital, short-term 
GV is associated with adverse outcomes in all inpatients, but the association is stronger in people without 
diabetes [178]. However, a recent study reported that GV remained a risk factor for longer hospital LOS 
and increased mortality in patients with and without diabetes, even after adjustment for several potential 
confounders [179]. As there are no intervention studies specifically targeting GV, it is unclear whether 
improving GV provides additional benefit than improving rates of hyperglycaemia and hypoglycaemia in 
hospital.  
 
1.4.4 Glycaemic targets 
As prospective studies of BG targets in noncritical care are not available, inpatient glucose targets are 
extrapolated from critical care. Based on RCTs in critical care, glycaemic control to avoid 
hyperglycaemia-related adverse effects is recommended. However, tight glycaemic control (BG 4.4-6.1 
mmol/L) may be deleterious and therefore is not recommended. As the comparator arms in critical care 
RCTs aimed for BG <10 mmol/L, this has become the recommended target for most critically ill patients 
[180]. In addition, observational data suggest thresholds of hyperglycaemia differ depending on the 
presence of diabetes. In individuals with pre-existing diabetes, adverse outcomes increase above a 
threshold of 10-11 mmol/L, whereas in those without diabetes, the threshold is around 6-8 mmol/L. 
Therefore, a more stringent glycaemic target may be more appropriate in individuals with new 
hyperglycaemia.  
 
Accordingly, the ADA and the US Endocrine Society recommend BG target of 7.8-10.0 mmol/L (140-
180mg/dL) in critical illness, and “a more stringent goal, such as 6.1-7.8 mmol/L (110-140 mg/dL) may 
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be appropriate for selected patients, if this can be achieved without significant hypoglycaemia” [28]. In 
some European ICUs, a more stringent target of 5.6-7.8 mmol/L is recommended [181], and following 
the Leuven studies, many Belgian ICUs target a BG range of 5.0-8.0 mmol/L [182].  
 
In noncritical care, the ADA and US Endocrine Society recommend a target of fasting BG <7.8 mmol/L 
and random BG <10.0 mmol/L [28, 183]. A lower limit of BG target was not specified, but guidelines 
recommend adjusting anti-diabetic therapy when BG falls <5.6 mmol/L (<100mg/dL) to avoid 
hypoglycaemia. The Australian Diabetes Society recommend similar targets stating “most patients in 
general hospital wards with hyperglycaemia should be treated to achieve and maintain glucose level less 
than 10 mmol/L”, and to “avoid treatment which lowers the glucose below 5.0 mmol/L” [30]. Of note, 
although hypoglycaemia is defined as <4.0 mmol/L, guidelines recommend avoiding BG <5.0 mmol/L to 
leave a buffer in place, and to de-intensify treatment appropriately to avoid hypoglycaemia. The Joint 
British Diabetes Societies for Inpatient Care has not recommended a specific BG target in critical or 
noncritical care, but in patients undergoing surgery, BG target of 6.0-10.0 mmol/L is recommended, but 
that BG 6.0-12.0 mmol/L “could be acceptable in most people” [184]. Conversely, patients with multiple 
comorbidities and frailty may not benefit from stringent control and hypoglycaemia could be more 
harmful; hence, all guidelines unanimously recommend higher BG targets with the main aims of avoiding 
symptomatic hyperglycaemia and hypoglycaemia.  
 
In summary, national and international guidelines recommended most individuals in critical and 
noncritical care should target BG <10 mmol/L. For some patients (with new hyperglycaemia), a more 
stringent target (such as <7.8 mmol/L) may be appropriate if this is able to be achieved without 
hypoglycaemia. Conversely, a less stringent and individualised target may be appropriate in individuals 
with severe comorbidities and life-limiting illness.  
 
1.4.5 Definition of adverse glycaemia 
Recommendations to target inpatient BG <10 mmol/L were not based on strong experimental data as 
there are no definitive studies comparing BG target <10 mmol/L vs. a higher cut-off, although a pilot 
study [185], and a phase 2 study comparing BG target <10 vs. <14 mmol/L for type 2 diabetes patients in 
critical care is currently underway (LUCID, ANZCTR 12616001135404). In people with severe 
comorbidities, a higher cut off is appropriate, although severe hyperglycaemia must be avoided to avoid 
symptoms such as thirst, polyuria and dehydration. In most people, adverse pathophysiological changes 
including immune and endothelial dysfunction, pro-inflammatory and pro-thrombotic changes occur after 
a few hours of exposure to glucose levels approximately 15 mmol/L (section 1.4.1.1). Therefore, the 
glucose level of 15 mmol/L was chosen as the upper cut-off for adverse glycaemia, a level of 




At the other extreme, any degree of hypoglycaemia in hospital is undesirable and should be avoided. 
Adverse outcomes occur with a threshold of BG <4.0 mmol/L (section 1.4.2.2); therefore, this threshold 
was chosen as the lower cut-off of adverse glycaemia.   
 
Hence, adverse glycaemia in this thesis is defined as BG <4.0 or >15.0 mmol/L, a composite of 
hypoglycaemic and hyperglycaemic extremes at which there are adverse changes in pathophysiology, and 
thresholds which are associated with adverse clinical outcomes. Adverse glycaemia describes unsafe 
glucose level that should be avoided in virtually all hospital patients regardless of clinical context or 
comorbidities.  
 
1.5 Diabetes management in critical care 
Diabetes management practice differs between critical care and noncritical care settings. In critical care, 
glucose-lowering treatment is often initiated when BG exceeds 10 mmol/L over two consecutive 
measurements [123]. Typically, most ICUs follow the ADA guidelines aiming for BG target of <10 
mmol/L. Intravenous insulin infusion is often used in preference to subcutaneous insulin as it allows for 
frequent dose titration in combination with intensive glucose monitoring. Central laboratory measurement 
or blood gas analysis on venous or arterial blood is often used in preference to capillary blood, which may 
be inaccurate in patients with hypotension and increased oxygen utilisation. Point-of-care (POC) glucose 
meters may have variable accuracy in the critically ill patient, particularly due to anaemia or drugs that 
interfere with enzymatic reactions of BG measurement [186]. However, improvements in technology 
have increased the accuracy of POC glucose meters. Recently, one POC glucose monitoring system was 
approved by the US Food and Drug Authority for capillary glucose measurements in critically ill patients 
[187], raising the possibility of less invasive methods of glucose monitoring.   
 
Most ICUs have established algorithms for initiation and titration of intravenous insulin infusion. In some 
centres, computerised alert systems and decision support tools assist insulin dosing and administration. 
Upon recovery from critical illness, insulin infusion is transitioned to subcutaneous insulin treatment at 
the time of transfer to noncritical care wards. Given the relatively confined environment and greater 
clinical resources available in ICUs, glucose management practice is often more protocolised and easier 





1.6 Diabetes management in noncritical care 
Given the lower acuity of illness and absence of evidence in noncritical care, diabetes management is 
more variable, less intensive and less protocol-driven than in critical care. There is also variation in 
glycaemic management practices between health systems in Australia and abroad. In general, most 
patients have capillary BG monitoring using POC glucose meters several times each day depending on 
clinical need. Adherence to glycaemic target guidelines is also more variable; therefore, there is generally 
a higher prevalence of adverse glycaemia in noncritical care wards than critical care wards [188, 189]. 
Although the ADA guidelines recommend subcutaneous insulin for treatment of hyperglycaemia in 
hospital, in practice, inpatients are treated with a variety of insulin regimens and GLM, especially in the 
UK, Europe and Australia.  As the focus of this thesis is diabetes care in the noncritical care setting, the 
remainder of the literature review focuses on the incidence of adverse glycaemia, barriers to glucose 
control and strategies to improve glycaemia in noncritical care. 
 
1.6.1 Traditional ‘reactive’ model of diabetes care 
Individuals admitted to hospital receive all aspects of medical care from the admitting (or parent) unit, 
which is determined by the primary reason for admission. In some countries, individuals are admitted 
under the care of ‘hospitalists’ who specialise in inpatient care. Therefore, comorbidities including 
diabetes are generally managed by the hospitalists or admitting team’s medical officers. Some larger 
hospitals have endocrinologists, diabetes specialists or physicians with an interest in diabetes who 
manage individuals admitted with diabetes-related illnesses (e.g. an individual presenting with DKA). As 
diabetes is seldom the primary reason for admission, the majority of inpatients with diabetes are admitted 
under the care of non-diabetes specialists. Diabetes specialists may provide a referrals service that can 
assist in management of patients admitted under other treating teams. Although various models of 
diabetes care exist, the majority consist of a diabetes or endocrinology advanced trainees (registrars) 
supervised by an endocrinologist or diabetologist, who provide a consultation service in response to a 
referral from the treating team.  
 
Many hospitals have also established a diabetes education service to assist inpatient and ambulatory 
diabetes care. These services are delivered by diabetes nurse educators who educate patients and assist in 
self-management of diabetes, including self-monitoring of glucose, self-administration of insulin, and 
insulin dose titration. Diabetes education services play an invaluable role in inpatient management, 
discharge planning, and follow up. Most diabetes education services provide a consultation service in 
response to referrals from the treating teams.  
 
The traditional model of diabetes care can be described as a ‘reactive’ service, which responds to formal 
referrals from the treating teams. However, in the absence of appropriate referrals, many patients do not 




1.6.2 Prevalence and incidence of adverse glycaemia in hospitals globally 
1.6.2.1 Hyperglycaemia  
Despite recommended glycaemic targets, hyperglycaemia remains common in hospital. A glycaemic 
survey of diabetes inpatients in 44 US hospitals reported 77% of patients had at least one episode of 
hyperglycaemia >11.1 mmol/L; 60% had at least one episode of hyperglycaemia >13.8 mmol/L; and 38% 
had persistent hyperglycaemia (three consecutive days with BG >11.1 mmol/L) [190]. Rates of 
hyperglycaemia were similar in two other cohorts. In one study, 76% of patients had at least one episode 
of BG >10 mmol/L [191]. In another study, 40% of patients had at least one episode of BG >16.5 mmol/L 
[192]. 
 
Networked BG meters, which automate collection of glucose measurements, facilitate hospital-wide 
assessment of inpatient glucose at many hospitals (see section 1.7.5). Cook et al., reported a glycaemic 
survey of 126 US hospitals which included over 9 million BG measurements from almost 1 million 
patient-admissions over a 1-year period [188]. Over 46% of noncritical care inpatients had 
hyperglycaemia >10 mmol/L. Of note, hospital-wide glucometric studies typically include all inpatients 
who had capillary glucose monitoring, including non-diabetes indications. This potentially explains a 
lower rate of hyperglycaemia compared to the aforementioned studies which included only individuals 
with pre-existing diabetes. 
 
Hyperglycaemia incidence can also be reported using standardised glucometric analyses and expressed as 
rates per patient-day (see section 1.7.6). In the study by Cook et al., patient-days with mean glucose >10.0 
mmol/L, >13.8 mmol/L, and >16.7 mmol/L occurred in 30%, 11% and 5% of patient-days respectively 
[188]. A subsequent larger hospital-wide glucometric study (involving 635 hospitals, 51 million BG 
measurements from 2.4 million patients), reported patient-days with mean glucose >10.0 mmol/L, >13.8 
mmol/L and >16.7 mmol/L occurred in 32%, 7% and 2% of patient-days respectively [189]. Outside the 
US, there is a paucity of published data on hyperglycaemia incidence. The annual NaDIA in the UK does 
not audit the incidence of hyperglycaemia. The available published data at other countries reported 
similar rates of hyperglycaemia (proportion of diabetes inpatients with at least one BG >10.0 mmol/L: 
57% in Puerto Rico [193], 90% in Brazil [194], and 81% in Singapore [195]).  
 
1.6.2.2 In-hospital diabetic ketoacidosis and hyperglycaemic hyperosmolar state 
DKA and HHS are life threatening hyperglycaemic emergencies that can occur due to lack of insulin 
treatment, failure to increase insulin dose to meet increased physiological demands, or in the presence of 
an SGLT-inhibitor therapy. Regardless of the precipitating cause, DKA and HHS occurring in hospital 
are severe adverse clinical outcomes that potentially reflect inappropriate diabetes management.  
 
NaDIA formally audits hyperglycaemic emergencies in hospital and in 2016 reported that 4.4% of 
inpatients with type 1 diabetes developed DKA during their inpatient stay [22]. Based on a survey of UK 
31 
 
diabetes services, 8% of DKAs developed in hospitalised patients [196]. NaDIA also reported that 0.2% 
of inpatients with type 2 diabetes developed HHS in hospital. Therefore, a significant number of patients 
experience life-threatening severe adverse clinical outcomes related to hyperglycaemia.  
 
1.6.2.3 Hypoglycaemia 
The reported prevalence of hypoglycaemia depends on the glucose definition and method of data 
collection. Using hospital discharge codes may underestimate the prevalence of hypoglycaemia because 
of inconsistencies in coding. For example, in a study of all diabetes inpatients admitted to internal 
medicine wards in Spain, 5% had documented hypoglycaemia on discharge code [167]. More accurate 
incidence of hypoglycaemia may be obtained using manual or automated glycaemic surveys. In 2016, 
NaDIA reported 20% and 8.4% of patients had at least one episode of hypoglycaemia <4 mmol/L, and 
severe hypoglycaemia <3 mmol/L respectively, in the preceding 7 days [22]. This finding is comparable 
to the glycaemic survey in US hospitals where 16% of patients had hypoglycaemia <3.3 mmol/L and 10% 
had severe hypoglycaemia <2.8 mmol/L [190]. In other countries, glycaemic surveys report the 
proportion of patients with hypoglycaemia (<3.9 mmol/L) varies between 10% in Spain [27], 19% in 
Singapore [195], and up to 30% in Brazil [194]. In the networked glucose meter assisted large glycaemic 
survey of US hospitals, hypoglycaemia <3.9 mmol/L occurred in 21% of patients [188]. Analysis by 
patient-day reported glucose <3.9 mmol/L and <2.8 mmol/L occurred in 6.1% and 1.7% of patient-days 
respectively.   
 
1.6.2.4 ‘Good diabetes day’ 
Thus far, the prevalence of hyperglycaemia and hypoglycaemia has been reported as two separate figures, 
but a metric that combines both glycaemic extremes can be useful. NaDIA uses the metric ‘good diabetes 
day’, defined as a patient-day with no BG in the hypoglycaemic range (<4.0 mmol/L), and no more than 
one BG >11.0 mmol/L. Therefore, a ‘good diabetes day’ represents a patient-day with relatively stable 
glucose. In 2017, amongst all inpatients with diabetes, 4.6 out of 7.0 (66%) of patient-days were ‘good 
diabetes days’, therefore 34% of patient-days had glucose in the ‘unstable’ range. As would be expected, 
inpatients with T1D and insulin-requiring T2D had a lower proportions of ‘good diabetes days’; 2.6 out 
of 7.0 (37%), and 3.5 out of 7.0 (50%) respectively [22].  
 
1.6.3 Prevalence and incidence of adverse glycaemia in Australian hospitals 
In Australia, there is scarcity of inpatient glycaemic data or benchmarking, largely due to a lack of 
automated technologies to capture inpatient glucose data. Glycaemic assessment typically required 
resource-intensive manual chart reviews of inpatient glucose measurements from paper-based clinical 
records or scanned electronic clinical records. Only one Australia study included glucometric data. 
Cheung at al., evaluated the impact of a standardised glucose observation and insulin prescription chart at 
Westmead hospital in Western Sydney [197]. In a cohort of 205 inpatients with pre-existing diabetes, 
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patient-days with mean BG >10 mmol/L and >16 mmol/L occurred in 40% and 4% respectively; both of 
which were higher than the US hospital cohort [189]. Hypoglycaemia (<4.0 mmol/L) occurred in 44% of 
inpatients during their admission. On patient-day analysis, 14% of patient-days had hypoglycaemia. 
Although both hyperglycaemia and hypoglycaemia rates were higher than the US glucometric studies, the 
Australian cohort included only patients with pre-existing diabetes.  
 
In summary, adverse glycaemia remains common in noncritical care. Globally, hyperglycaemia occurs in 
approximately 50 to 80% of patients, or 30 to 40% of patient-days. Hypoglycaemia occurs in 20% of 
inpatients or 6 to 10% of patient-days. There is a lack of hospital glycaemic data in Australia. As auditing 
and benchmarking is important to improve clinical care, there is a pressing need to audit and report 
glycaemic control in Australian hospitals.   
 
1.6.4 Barriers to optimal glucose control in hospital 
Multiple factors contribute to the ongoing high incidence of adverse glycaemia in hospital. Blood glucose 
concentrations are highly dynamic and affected by many factors: patient and illness-related, treatment-
related, health professional-related, and hospital systems-related factors.  
 
1.6.4.1 Patient and illness factors 
An individual’s diabetes and glucose control prior to admission influences glycaemic control in hospital. 
An individual with chronic hyperglycaemia prior to admission may experience ongoing hyperglycaemia 
in hospital. Conversely, an individual with stable glucose prior to admission can become hyperglycaemic 
in hospital due increased insulin resistance related to counter-regulatory response of illness or surgery. 
The severity of hyperglycaemia reflects the interplay between the intensity of counter-regulatory 
responses and β-cell reserve; however, anecdotally there is wide inter-individual variability. 
Hyperglycaemia may also be exacerbated by deceased skeletal muscle glucose uptake due to decreased 
physical activity when an individual is confined to bed rest.  
 
Conversely, in individuals treated with GLM or insulin, decreased carbohydrate intake due to illness can 
cause hypoglycaemia. Hypoglycaemia can also occur with impaired renal gluconeogenesis and insulin-
clearance due to kidney injury, and with impaired hepatic gluconeogenesis due to liver failure. Both 
kidney and liver dysfunction cause altered metabolism and clearance of diabetes medications which can 
promote hypoglycaemia. Patients with multiple comorbidities, multi-organ dysfunction, frailty, and 
polypharmacy are particularly at risk. Therefore, the severity of illness, burden of comorbidities, and 




1.6.4.2 Nutrition and medication treatment  
Treatments in hospital, including nutrition and medications can contribute to adverse glycaemia. 
Nutritional interruption due to the requirement for fasting prior to procedures or surgery, can predispose 
an individual to hypoglycaemia. Conversely, the provision of nutritional supports, such as oral 
carbohydrate-containing supplements, often exacerbates hyperglycaemia. Enteral nutrition (which 
delivers carbohydrate and nutrient rich liquid into the gastrointestinal system) and total parenteral 
nutrition (which delivers carbohydrate, protein and lipids directly into the systemic circulation) can cause 
hyperglycaemia and other metabolic disturbances. Many inpatients can develop adverse glycaemia due to 
a loss of self-management routine due to altered meal times, delays in medication administration and a 
lack of direction from treating clinicians. 
 
Medications administered or altered in hospital contribute to glycaemic instability. GLMs are often 
withheld in periods of altered nutritional intake. Some GLMs including metformin, become 
contraindicated due to sepsis, impaired renal function or liver failure. Without appropriate substitution 
with alternative treatments, hyperglycaemia could ensue. Glucocorticoid medications, calcineurin 
inhibitors and tyrosine kinase inhibitors are potent inducers of hyperglycaemia [198] and adverse 
glycaemia can develop during treatment with these medications in the absence of an appropriate 
escalation in glucose-lowering therapy. 
 
1.6.4.3 Health professional factors 
Adverse glycaemia in hospital can occur as a result of decisions and actions performed by the treating 
health professionals. Firstly, health professionals may not recognise that the individual has diabetes and 
therefore may not commence appropriate glucose observation or GLM treatment. The clinician may 
misclassify the type of diabetes (e.g. attribute an individual with pancreatogenic diabetes as type 2 
diabetes), an error which can result in inappropriate withholding or cessation of insulin. The clinician 
may not perform BG monitoring at the appropriate timing or frequency for clinical need. For example, 
infrequent BG monitoring during fasting can lead to a failure to detect falling glucose levels prior to 
developing hypoglycaemia.  
  
Medication errors (which include recommendation, prescription and administration errors) are common 
causes of adverse glycaemia. Medication recommendation errors include inappropriate treatment or 
withholding of GLM or insulin. Prescription errors include prescription of an incorrect medication, dose, 
timing, or ambiguous handwriting (including the practice of writing ‘U’ instead of ‘unit’, which could be 
mistaken with a zero, potentially causing a ten-fold increased dosing error). Administration errors include 
inappropriate withholding, or incorrect timing of administration (such as administering prandial insulin 
separated in time from a meal).  
 
A significant clinician-related barrier is the ongoing widespread use of sliding-scale insulin (SSI) alone. 
SSI refers to boluses of short acting insulin dose dependent on BG at the time of administration. Multiple 
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studies reported SSI is ineffective at controlling hyperglycaemia, causes excessive hypoglycaemia, and 
could potentially cause DKA [199]. RCTs demonstrate the superiority of scheduled insulin over SSI in 
controlling hyperglycaemia (section 1.7.2). However, there is continued widespread practice of SSI 
treatment which may contribute to the ongoing high incidence of adverse glycaemia [27, 191, 192, 194] 
An underpinning contributor is the lack of knowledge and confidence in initiating or titrating insulin 
treatment contributing to clinical inertia (section 1.6.4.5).  
 
Collectively, audits demonstrate health professional factors remain significant barriers. NaDIA reported 
38% of patients have at least one diabetes-related medication error; half of which were due to prescription 
or administration error and the remaining half were due to a lack of escalation or de-escalation of diabetes 
medication despite hyperglycaemia or hypoglycaemia [22].  
 
1.6.4.4 Hospital system factors 
As discussed in section 1.2, modern hospitals are dynamic institutions where a patient’s clinical care may 
be managed by multiple health professionals, even during a relatively short hospital stay. As treating 
medical and nursing teams work in rotating shifts, a patient’s clinical care is ‘handed over’ between 
clinicians multiple times per day resulting in a lack of continuity of care. At each handover, many clinical 
observations and clinical tasks are communicated between clinicians, and during each interaction there is 
a potential for error or omission. As most treating team doctors work business hours (8 am to 5 pm 
Monday to Friday), after business hours and on weekends (which comprises 123 hours or 73% of the 
week), an individual’s management is the responsibility of doctors that are not part of the treating team. 
An audit of barriers contributing to hyperglycaemia reported that being the weekend was the 4
th
 most 
common reason for suboptimal glycaemic control [200].  
 
Due to the pressure on bed occupancy in modern hospitals, the patients’ journey through the hospital 
admission can involve multiple ward and bed changes. With pressures on expediting discharge, there are 
pressures to focus only on the presenting problem with a less focus or scope to manage comorbidities 
including diabetes. A large study in the Veteran’s association hospitals in the US demonstrated in a 
cohort of inpatients with pre-existing poor glycaemic control (average HbA1c 9.6%), only 22% had 
intensification of therapy at discharge [201].  
 
The structure of medical teams is also a barrier, because the most junior medical staff (intern or resident 
staff) are often tasked with inpatient diabetes management, so clinicians experienced in managing 
diabetes are seldom involved in patient care. Although the doctors’ clinical skills, knowledge and 
experience improve over time, due to rotating medical officer training system, several new groups of 
junior staff rotate through treating teams several times each year, necessitating retraining and relearning 
of clinical skills. Lastly, clinical systems to streamline diabetes care, such as dedicated glucose 
observation and insulin prescription charts, insulin order sets or protocols, are not universally available. 
Electronic medical records, alerts or glycaemic auditing systems which can facilitate inpatient glucose 
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control are not yet universally available especially outside the US. Hence, a lack of infrastructure and 
resources contribute to ongoing high prevalence of adverse glycaemia. 
 
1.6.4.5 Clinical inertia 
A common overarching theme that contributes to adverse glycaemia is clinical inertia. Defined as a 
failure to optimise therapy when indicated, the term clinical inertia was first used in ambulatory care 
[202]. In acute inpatient care, clinical inertia describes a lack of health professional action in response to 
adverse glycaemia.  This was first demonstrated in a cohort of inpatients with diabetes where only 34% of 
those with hyperglycaemia had any change in therapy [203]. In a subsequent large cohort of 2900 
inpatients, despite persistent hyperglycaemia, 42% had no change in insulin therapy and more than 50% 
remained on SSI insulin therapy alone [204]. Clinical inertia is demonstrated in various settings, 
including perioperative care, and surgical and medical noncritical care wards [205-207]. Without 
appropriate intensification of therapy, individuals may experience persistent hyperglycaemia.  Without 
treatment de-escalation in response to hypoglycaemia, individuals may experience recurrent episodes of 
hypoglycaemia. 
 
Clinical inertia was also demonstrated at RMH in during a prospective audit of 200 inpatients with 
diabetes. This audit surveyed capillary BG measurements in the first 72 hours of admission and found 
150 episodes of acute hyperglycaemia (BG >10 mmol/L on two occasions over 24 hours) and 65 episodes 
of acute hypoglycaemia (BG <4.0 mmol/L). In 43% of acute hyperglycaemic and 58% of acute 
hypoglycaemic events, there was no clinical escalation from nursing staff to medical officers and there 
was no change in diabetes therapy [208]. 
 
Clinical inertia is the result of multiple barriers discussed above. Most diabetes inpatients are managed by 
admitting units who are focussed on delivering optimal care in their respective specialist fields, but may 
not be well-equipped to deal with the complex issues of diabetes. Often diabetes management is the 
responsibility of the junior medical staff who may lack the knowledge, clinical experience or confidence 
to adjust therapy to achieve optimal glycaemia. Adverse glycaemia often occurs after hours and the 
covering medical officer (who is not part of the treating team) may not feel empowered to make 
appropriate adjustment to treatment; instead temporary (or ‘Band-Aid’) solutions are often prescribed. 
Due to frequent ward and staff changes, diabetes treatment plans may not be appropriately or completely 
handed over between clinicians. With the pressures of expediting discharge, adverse glycaemia may be 
overlooked, in fear of slowing down the patient’s journey through the hospital system. Although diabetes 
specialists and diabetes education services are available, the majority rely on referrals from the treating 
team. With the competing clinical tasks and increasing prevalence of inpatients with diabetes, treating 
teams often do not refer or delay referring to the diabetes specialists for assistance. Ultimately, the 
diabetes specialist expertise is not utilised effectively resulting in ongoing clinical inertia and adverse 
glycaemia. Hence, multifaceted interventions are likely to be required to address clinical inertia and 
improve clinical outcomes. 
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1.7 Strategies to improve hospital diabetes care 
From the early 2000s, with accumulating evidence on the adverse effects of hyperglycaemia in hospital, 
various strategies to optimise glucose control have been investigated. In noncritical care, strategies for 
improving glucose can be categorised into methods to promote medication treatment (e.g. more intensive 
insulin regimens, insulin order sets, non-insulin GLMs); methods for glucose surveillance (e.g. 
glucometrics and benchmarking); and methods to increase diabetes specialist management (e.g. inpatient 
diabetes teams).  
 
1.7.1 Insulin regimens 
Sliding scale insulin (SSI) was the predominant hospital insulin regimen in the 1990s. SSI therapy 
consisted of a variable dose of insulin administered according to the BG measurement at the time of 
administration. However, due to the reactive nature of insulin dosing, SSI resulted in wide BG variability, 
was ineffective at controlling hyperglycaemia [199, 209], and was associated with worse clinical 
outcomes. There was a risk of DKA in insulin-dependent patients because insulin was not consistently 
administered.  
 
The superiority of basal-bolus insulin (BBI) regimen over SSI regimen was demonstrated in the 
RABBIT-2 RCTs. In the first study, a BBI regimen was compared against SSI regimen in a cohort of 
insulin-naïve general medical patients with type 2 diabetes. BBI was initiated at a weight-based 
calculated dose (0.5 units/kg), half administered as basal and half administered as bolus (or prandial) 
insulin in separate doses with each meal. Both treatment arms had daily insulin titration according to a 
pre-specified protocol. The group treated with BBI had a significantly lower mean BG compared to the 
group receiving SSI (9.2 vs 10.7 mmol/L), and resulted in a higher proportion of patients at target mean 
BG of <7.8 mmol/l (65% vs 14%) [210]. In a subsequent RABBIT-2 surgery study, BBI treated surgical 
patients had a lower inpatient mean glucose, but additionally had a significantly lower rate of composite 
adverse clinical outcome (see also section 1.4.1.2.5) [143]. However, BBI-treated patients had a higher 
proportion of hypoglycaemia (BG <3.9 mmol/L: 23% vs. 5%), but no difference in severe hypoglycaemia 
(BG <2.2 mmol/L). 
 
Other studies investigated optimal initial insulin doses for BBI. A case-control study reported insulin 
doses exceeding 0.6 units/kg/day was associated with an increased risk of inpatient hypoglycaemia [211], 
and an RCT reported initiating dose of 0.25 units/kg caused fewer episodes of hypoglycaemia than 0.50 





Subsequent studies compared BBI with basal-plus insulin (BPI) therapy. In contrast to BBI regimen 
where prandial insulin is administered with each meal, in BPI regimen, prandial insulin is administered 
with meals only if pre-meal BG was above a certain threshold (>7.8 mmol/L in the study). A RCT 
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reported BPI was equally efficacious as BBI in controlling hyperglycaemia, but hypoglycaemia rates 
were lower [143], therefore was safer. A post-hoc analysis concluded outcomes were consistent between 
medical and surgical patients [213]. Based on these RCTs, the ADA guidelines recommend treating 
inpatients with an insulin regimen that contained basal insulin: specifically, BPI for patients with poor 
nutritional intake or nil by mouth; BBI for patients with adequate nutritional intake; and SSI monotherapy 
was strongly discouraged [28].  
 
In ambulatory care setting, people with type 2 diabetes may be treated with a variety of insulin regimens. 
BBI treatment is common in the US, but pre-mixed insulin (fixed combination of rapid and intermediate 
acting insulin) treatment is more common in Europe, Asia and Australia. The efficacy and safety of pre-
mixed insulin in hospital was evaluated in several studies. In one RCT, an insulin regimen consisting of 
30% human insulin and 70% neutral protamine Hagedorn (NPH) given twice daily, was comparable to 
BBI regimen in efficacy and safety [214]. Another RCT compared pre-mixed insulin (Mixtard 30/70 ®) 
twice daily vs. BBI. Both regimens achieved similar glycaemic control, but the trial was terminated early 
due to excess hypoglycaemia with pre-mixed regimen compared to SSI (64% vs. 24%) [215]. Excess 
hypoglycaemia occurred pre-lunch and pre-dinner in the context of an aggressive insulin titration protocol 
aiming for BG target of 4.4-7.8 mmol/L. Resultantly, the ADA guidelines recommend against the routine 
use of pre-mixed insulin in hospital [28]. In contrast, another similarly designed, albeit smaller, RCT 
comparing pre-mixed analogue insulin (lispro mix 25/75 ®) vs. BBI reported similar efficacy in glucose 
control and incidence of hypoglycaemia [216]. Anecdotal clinical experience suggests pre-mixed insulin 
may be efficacious and safe in certain scenarios. For example, hyperglycaemia exacerbated by 
glucocorticoid mediations, or in patients with significant renal impairment, a higher dose of premixed 
insulin in the morning can be efficacious and minimise hypoglycaemia. Therefore, although discouraged 
by the ADA guidelines, pre-mixed insulin regimens in hospital may be appropriate in selected clinical 
scenarios.  
 
1.7.2 Insulin protocols and order sets 
Given the importance of insulin treatment in controlling hyperglycaemia in hospital, various strategies 
have been developed to facilitate appropriate insulin prescription and administration. One such strategy is 
a chart that combined documentation of glucose observations and insulin prescription. In an Australian 
hospital, the implementation of a dedicated hospital insulin prescription chart decreased the rate of 
hypoglycaemia and increased the proportion of BG measurements within the ideal range [197]. A more 
recent and updated chart improved clarity of insulin prescription and increased the number of BG 
measurements within the target range [217]. 
 
Insulin order sets and protocols that facilitate insulin prescription were evaluated in many studies. Order 
sets involve pre-printed prescription forms, often incorporating insulin protocols and dosing guidelines 
[218-221]. Implementation of order sets were usually accompanied by educational campaigns. Electronic 
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insulin order sets were evaluated in hospitals with an electronic medical record (EMR). Such systems 
have the advantage of electronically incorporating patient’s weight and patient’s eGFR to aid calculation 
of insulin doses [218, 222, 223].  
 
Most studies investigating insulin order sets utilised a pre- and post-implementation observational study 
design, and most reported improved rates of BBI prescription, and decreased rates of hyperglycaemia 
(Table 8 and Table 9). However, rates of hypoglycaemia largely remained unchanged, although several 
studies reported higher rates of hypoglycaemia. There is one cluster randomised study comparing a 
computerised order set vs. a paper order set in a cohort of general medical inpatients. This study 
demonstrated the superiority of computerised order set over paper-based order set in increasing the 
proportion of patients treated with scheduled insulin (42% vs 75%), decreasing patient-day mean glucose 
(8.8 mmol/L vs. 8.2 mmol/L), and increasing proportion of BG measurements within ideal range (71% 
vs. 75%) [224]. Although significant improvements in glycaemic control were reported, these studies did 
not (and were not powered to) evaluate differences in clinical outcomes. Furthermore, pre- and post- 
intervention observational studies are subject to unmeasured confounders and a Hawthorne effect. None-
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1.7.3 Glucose-lowering medications 
GLM treatment in hospitalised patients is somewhat controversial and is an active area of research. 
Metformin is contraindicated in renal failure, sepsis or shock due to the risk of lactic acidosis. 
Sulphonylureas can cause hypoglycaemia in individuals with decreased carbohydrate intake. SGLT-
inhibitors can cause dehydration, electrolyte imbalance, ketone production and increases the risk of DKA 
and should be withheld in ill patients or those undergoing surgery [230]. Glucagon-like peptide-1 (GLP-
1) agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors can cause gastrointestinal symptoms and can 
interfere with nutritional intake. The ADA guidelines recommend that all GLM be withheld and 
subcutaneous insulin therapy initiated in all individuals with diabetes admitted to hospital [183]. As a 
result, US hospital cohort studies report low rates of GLM treatment in hospital (10 to 30% of inpatients) 
[191, 193]. Outside the US, GLMs continue to be used in hospital with rates varying between 38% in 
Brazil [194], 45% in UK [22], 50% in Australia [197] and 80% in Singapore [195]. 
 
A recent RCT randomised inpatients with type 2 diabetes to sitagliptin plus basal insulin vs BBI in order 
to formally evaluate the safety and efficacy of DPP-4 inhibitors in hospital [146]. Sitagliptin-plus-basal 
insulin had similar efficacy in glucose control to BBI with no difference in hypoglycaemia or clinical 
complications. Another recent pilot study evaluated the efficacy and safety of a GLP-1 agonist in an RCT 
comparing exenatide vs. exenatide plus basal insulin vs. BBI. This study reported exenatide plus basal 
insulin and BBI had comparable efficacy in glucose control and both were superior to exenatide alone. 
Hypoglycaemia rates were similar but exenatide-containing treatment regimens caused more nausea and 
vomiting with 6% of participants discontinuing treatment due to adverse events [231].  
 
Hence, recent studies suggest inpatient treatment regimens containing DPP-4 inhibitors and/or GLP1 
agonists may decrease the necessity of more intense subcutaneous insulin regimens, and can provide 
alternative methods to achieve optimal glucose control. However, these agents were used in addition to 
basal insulin, further strengthening the importance of basal insulin treatment in hospital.  
 
1.7.4 Staff education programs 
Educating and upskilling treating team clinicians is an obvious strategy to improve glucose control. 
Various staff education programs have been implemented ranging from short duration (e.g. 1 hour) [232] 
to more comprehensive (e.g. 8 hour) education sessions [233]. Some interventions consisted of face-to-
face small group sessions [233-236], whilst others involved computerised learning packages [237]. 
Training programs mostly aimed at upskilling medical officers and hospitalists. These interventions 
generally reported increased clinician knowledge and confidence [232, 235], increased use of BBI [226, 
237-239], and reduction in medication errors [232-234]. In the subset of studies that evaluated glycaemic 
outcomes, results were heterogeneous with some interventions decreasing hyperglycaemia [226, 236, 
239, 240], some did not change glucose control [235, 241], and of concern, some interventions increased 
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hypoglycaemia [236, 238, 239]. Studies of education programs have not evaluated patient or economic 
outcomes.  
 
The main disadvantage of education interventions is the frequent rotations of resident medical staff 
between clinical services, necessitating programs to be repeated regularly. It is not surprising some 
studies reported initial improvements in clinical care that were not sustained upon reassessment at a later 
time [242, 243]. Hence, a successful education program should provide repeated or ‘refresher’ education 
sessions [236, 240]. With improving information technology, online education resources are more likely 
to be sustainable and may be incorporated as regular mandatory training requirements to achieve long-
term improvements in clinical care. 
 
Anecdotally, some inpatients with diabetes are highly complex and optimising their glucose challenges 
even the most experienced diabetes specialists. For these individuals, general education of treating staff 
may not be sufficient to ensure optimal management and diabetes specialist management remains 
essential. Thus, an effective educating program and upskilling resident medical officers may improve 
general diabetes management but will not completely replace expert management by diabetes specialists 
altogether.  
 
1.7.5 Networked glucose meter technology 
Point-of-care capillary glucose meters are essential for inpatient diabetes care. Using a small volume of 
blood, capillary BG testing allows immediate determination of glucose levels facilitating rapid treatment 
decisions. The alternative methods of determining BG (formal laboratory glucose or blood gas analysers 
testing) are slower, more complex, and require more invasive procedures to acquire a larger blood volume 
[244]. However, POC technology has disadvantages, including the potential for assay interference in the 
presence of non-glucose sugars (such as maltose and xylose), and with extremes of low or high 
haematocrit or blood oxygen levels [244-246]. New advances in POC glucose meter chemistry can 
overcome some of these limitations [187]. 
 
An important new development in POC glucose testing is the connectivity or networked technology. Prior 
to this technology, hospital BG monitoring practice involved a health professional (most often a nurse) 
who performed a capillary BG measurement using a non-connected BG meter and manually recording the 
result on a glucose observation chart into an EMR. In contrast, networked BG meters are connected to the 
hospital information system via docking stations and cables, or using wireless fidelity (WIFI) network. 
With each BG measurement, the patient unique identifier is also recorded so that each measurement is 
linked to an individual patient and the time of measurement. This data is then electronically transferred 
into a database, clinical result system or EMR, eliminating transcription errors and administrative time 




A major advantage of networked BG meter technology is automated capture of hospital-wide capillary 
BG data which allows institution-wide analysis of glucose and benchmarking against other hospitals. It 
also enables evaluation of glycaemic management programs by analysing glycaemic outcomes for groups 
of patients or time periods of interest. In addition, remote surveillance of glucose is now possible, 
whereby diabetes specialist teams can monitor glucose measurements and identify individuals with 
adverse glycaemia, allowing targeted management strategies. Hence, networked BG meters are becoming 
an essential component of glycaemic improvement programs [248].  
 
Although networked BG technology has been available in the US since the early 2000s, and in the UK 
and Europe since mid-late 2000s, it has not been available in Australia until recently. Accordingly, 
Australian hospitals were limited in auditing and benchmarking inpatient glucometric data. In 2015, two 
different networked BG meter systems, (Statstrip ®, Australasian Medical and Scientific Limited and 
Freestyle Precision Pro ®, Abbott Diabetes Care) gained approval from the Australian Therapeutic Goods 
Administration to be used for capillary BG measurement in hospital.  
 
1.7.6 Glucometric reporting and benchmarking 
Hospital ‘glucometrics’ was developed to systematically analyse and report inpatient glucose control 
from the large amount of capillary glucose data captured by networked BG meters. The fundamental 
issues in reporting inpatient glucose data are: 1) the variability in frequency and timing of BG 
measurements between patients; 2) the variability in LOS between patients. As a routine, an inpatient 
with diabetes may have four BG measurements performed each day in hospital. However, another patient 
with unstable glucose may have BG measurements performed every 2 hours (e.g. 12 measurements each 
day), and a patient on an intravenous insulin infusion routinely have BG measurements performed every 
hour.  Furthermore, while one patient may be admitted for 2 days (e.g. 8 measurements performed), 
another patient may be admitted for 30 days (e.g. 120 measurements performed) during hospital-stay. 
Traditional analytical methods of determining mean and variance of all BG measurements do not reflect 
the variability in number of tests per day and the number of tests per patient during hospital-stay. 
Glucometric reporting techniques overcome these issues. 
 
Although various glucometric reporting techniques are described, the most widely used was first 
described by Goldberg et al., [249]. Briefly, inpatient glucose data can be presented in three separate 
models: 
1) Per-population model, where all BG measurements for the entire cohort are considered and 
weighted equally. 
2) Per-patient-stay model, where BG measurements for the entire hospital-stay for each patient 
are aggregated, and weighted equally irrespective of their length of stay.  





Although each model can be useful in certain situations, the per-patient-day model is the most balanced 
and useful model to analyse and present glucometric data. As glucose outcomes are aggregated by each 
calendar day for each patient, an individual with a longer LOS is given more weight than an individual 
with a shorter LOS. The key glucometric measure is the patient-day mean glucose obtained by calculating 
the mean of glucose measurements per-patient, per-calendar day. Other key glucometric outcomes 
include the proportion of patient-days with various thresholds of hypoglycaemia or hyperglycaemia.  
 
Additional glucometric techniques have been developed to account for multiple repeated BG 
measurements following a clinical episode of hypoglycaemia or hyperglycaemia. For example, if a 
patient’s BG measurement is abnormal, a clinician may perform another measurement immediately to 
confirm the result. Similarly, after treating an episode of hypoglycaemia, repeated measurements are 
usually performed in close succession to ensure resolution. Repeated measurements unequally weigh the 
glucose aggregates towards the extremes. Therefore, glucometric reports are recommended to exclude 
repeated BG measurements from a single clinical episode of hypo- or hyperglycaemia [250]. Other 
recommendations have been developed pertaining to accurate selection, analysis and presentation of 
glucometric outcomes to ensure standardised reporting [251]. 
 
With widespread use of networked BG meters, health systems in the US have developed central 
repositories of capillary BG data from multiple hospitals and developed benchmarking of glycaemic 
control [188, 189, 252]. Hospitals can submit local glucometric data and receive feedback on their 
performance compared to similar hospitals. As benchmarking is essential to improve the quality of care 
and patient safety, further development of inpatient glucose benchmarking in other countries, including in 
Australia, can lead to improvements in diabetes care. 
 
1.7.7 Glycaemic alert systems 
Alert systems are designed to elicit an appropriate action from users to prevent an adverse event. In 
ambulatory care, continuous glucose monitors often function as alert systems to warn the individual of 
impending hypoglycaemia. Similarly, alerts systems have been used to improve clinicians’ awareness of 
adverse glycaemia in the inpatient care setting. In critical care, computerised alert systems can notify 
bedside nurses about glucose abnormalities and aid treatment with insulin infusion. In Leuven, Belgium 
(where tight glycaemic control is routinely practiced), a computerised alert system which aid adjustment 
of insulin infusion decreased mean glucose and decreased hypoglycaemia [253]. A similar alert system at 
another Belgian ICU which generated an audio-visual alert when BG was out of target range, resulted in 
increased BG in target range whilst decreasing hyperglycaemia and hypoglycaemia [254].  
 
In perioperative care, two studies of glycaemic alert systems have been reported. In a study by 
Satishkumar et al., a computerised alert system incorporated patient information, laboratory results and 
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physiological data into standardised display and generated an audio-visual alert when intraoperative BG 
measurement exceeded 11.1 mmol/L [255]. The alert was ‘silenced’ when insulin prescription was 
initiated, but a subsequent alert was then generated 90 minutes later if a follow up BG measurement was 
not performed. This system was associated with 55% increased insulin treatment in patients with 
intraoperative hyperglycaemia. A similar intraoperative glucose alert system was studied by Ehrenfeld et 
al., demonstrating increased intraoperative glucose monitoring, decreased post-operative hyperglycaemia, 
and decreased rate of surgical site infections [256]. 
 
In noncritical care, alert systems vary widely in function and complexity. A manual alert system was 
studied by Roman et al., [257] consisting of colour-coded BG observation charts which provided a visual 
alert when BG measurements were out of range, coupled with a management algorithm. Use of this 
system was associated with 41% decrease in the frequency of prolonged hyperglycaemia (three 
consecutive BG measurements >13.9 mmol/L). Electronic alert systems can monitor POC BG 
measurement and generate alerts on EMR. Electronic alert systems can be classified as retrospective or 
real-time. A retrospective alert system generates alerts when clinicians interact with the system (e.g. when 
a clinician ‘logs on’ to computer system or generates a report). A real-time alert system generates alerts 
without input from the clinician (e.g. a pop-up alert is generated on a computer as soon as a glucose 
trigger is reached). Some electronic alert systems use an algorithm to integrate other available clinical 
information such as age, weight, laboratory results (e.g. GFR), and current treatment (e.g. insulin 
treatment) to generate alerts [258]. Such alert systems require fully-integrated hospital electronic clinical 
information systems. 
 
Most alert systems target treating medical and nursing staff at the point-of-care, but some systems directly 
target a specialist diabetes team. Donihi et al., studied a glucose alert system that alerted an inpatient 
diabetes team (IDT) when an inpatient had severe hyperglycaemia (BG >16.7 mmol/L). The IDT then 
provided a consultation and advice to the treating team to intensify glycaemic management. In a 3-month 
pre- and post- intervention study, this service improved the treating team’s response to hyperglycaemia 
by 50% and decreased occurrence of subsequent severe hyperglycaemia by 55% [243]. Two subsequent 
observational studies evaluated electronic systems that generated an automated referral to IDTs [259, 
260]. These alert systems facilitated more IDT consultations and decreased mean glucose by 0.7 mmol/L 
in one study [259] and achieved a 20% reduction in proportion of patient-days with mean BG >15mmol/L 
in another study [260]. Both alert systems required complex integrated hospital EMRs and demanded 
greater resources.  
 
In summary, glycaemic alert systems improve health professional response to adverse glycaemia. 
However, in noncritical care glycaemic alert systems are heterogeneous in design and complexity. A few 
observational studies of complex electronic alert systems which alert IDTs report improvement in glucose 
control. There are few studies of simple alert systems aiming to improve clinician response at the point-
of-care, and there are no studies evaluating clinical outcomes. 
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1.7.8 Specialist Inpatient Diabetes Teams 
Although endocrinologists and diabetes specialist physicians practice at many hospitals, the traditional 
model of inpatient diabetes care is a referral-based consultative service (section 1.6.1). With this model, 
inpatient diabetes management is primarily performed by the treating team’s medical staff and at their 
discretion, diabetes specialists are invited to assist with management. However, due to rising prevalence 
of diabetes, the majority of diabetes inpatients do not receive diabetes specialist management. In addition, 
referrals to the diabetes specialists typically occur after the occurrence of adverse glycaemia and often 
after many days of persistent adverse glycaemia. Therefore, new approaches to inpatient diabetes care 
have been developed. 
 
Inpatient Diabetes Teams (IDTs) (also known as Glycaemic Management Teams) were introduced in 
some hospitals particularly in the UK and US since the early 2000s. The roles of IDTs are to improve 
diabetes management expertise throughout the hospital. IDTs develop and implement diabetes 
management protocols, deliver education programs, perform clinical audits, and directly assist in diabetes 
management of patients admitted under various treating medical and surgical teams. Various models of 
IDTs have been described (Table 10 and Table 11). Although models of IDT vary, the essential features 
can be summarised into the following four components. 
 
1. Team composition: Members of IDT generally include nursing and medical staff but can also 
include other members such as pharmacist and dietitians. The IDTs in the UK generally consist 
of Diabetes Inpatient Specialist Nurse, with oversight by a consultant diabetes physician. The 
IDTs in US generally consist of diabetes nurse consultants, diabetes nurse practitioner (DNP) 
and diabetes fellow (i.e. registrar), led by a diabetologist. DNPs with prescribing rights are 
particularly suited for this role.  
 
2. Patient identification: IDTs require an efficient method of identifying inpatients with diabetes 
or adverse glycaemia. Patient identification can be performed manually (e.g. physical ward 
rounds), or remotely (e.g. using electronic referrals or alerts). Some IDTs identify patients using 
protocolised referrals from treating medical or nursing staff. For example, hospitals in the UK 
use a clinical triage tool (‘Think Glucose’ program) to identify diabetes inpatients who should be 
referred to the IDT. In some UK hospitals this triage tool is incorporated into an EMR to 
generate an automated referral to the IDT [261]. A subsequent improved referral tool (Diabetes 
Patient At Risk score), incorporating the clinical indication and urgency of referral further 
refined referrals to the IDT [262]. At hospitals with networked glucose meter systems and 
EMRs, IDT can perform remote surveillance of POC BG measurements to identify inpatients for 
management. Remote surveillance has the advantage of bypassing referrals from the ward staff; 




3. Model of care: IDT models of care can be classified as reactive or proactive. A reactive IDT 
provides care in response to referrals from the treating teams. A reactive model is less resource 
intensive and care can be delivered to individuals who were identified by the treating teams to 
require care. However, the reactive model can miss patients who may benefit from care due to 
inappropriate recognition or assessment by the treating teams. Consultations may occur later in 
the admission course, often after multiple episodes of adverse glycaemia. A proactive IDT 
provides management autonomously, without referral from the treating teams. As proactive care 
bypasses the need for referrals, more patients can receive specialist care. However, proactive 
models are resource-intensive. Additionally, from clinical experience, some treating teams may 
not prefer IDT involvement due to potential loss of autonomy. 
 
4. Model of management: IDT can provide consultative or direct management. In a consultative 
management model, the IDT provides management advice (e.g. suggesting commencing or 
titrating insulin) to the treating teams. The treating team clinicians can then consider the 
recommendations (e.g. prescribing insulin or adjusting doses). In a direct management model, 
the IDT directly prescribes the medication treatment (e.g. directly prescribing insulin or 
adjusting doses). The direct management model ensures treatment is administered promptly; 
however, this approach may not be acceptable to some treating teams due to the potential for 
confusion and loss of clinician autonomy.  
 
There are twenty-nine studies on various models of IDTs. Twelve studies evaluated an IDT with a 
reactive model of care (Table 10), and seventeen studies evaluated an IDT with a proactive model of care 
(Table 11). Only two were prospective randomised studies whist the remainder were observational 
studies. The first RCT conducted in 1997 aimed to evaluate the impact of a proactive IDT, but the study 
was inconclusive and was stopped early due to poor recruitment [263]. In 2001, in a Welsh hospital, a 
diabetes nurse educator (DNE) service was studied in a prospective RCT. The DNE service operated on a 
reactive model of care in response to referrals from the treating nurses. Inpatients randomised to receive 
DNE care had 3 day shorter median LOS than patients who did not receive DNE care (8 vs. 11 days) 
[264]. This study provided the first prospective RCT evidence that inpatient care delivered by a DNE 
service improved hospital LOS, possibly related to provision of diabetes self-management which 
facilitated earlier discharge from hospital. Glycaemic or clinical outcomes were not evaluated. Of note, 
baseline LOS was 11 days in this study, much longer than the median LOS in UK hospitals in 
contemporary years (8 days in NaDIA 2013) [265]. 
 
The remaining twenty-seven studies all employed an observational design consisting of a pre- and post- 
intervention analyses, retrospective cohort analyses, or time-series analyses. In pre- and post- intervention 
studies, outcomes before and after implementation of an IDT intervention were compared; some studies 
used a retrospective pre-intervention group as a comparator. The primary outcomes usually consisted of 
glycaemic outcomes (i.e. various indices of hyperglycaemia and hypoglycaemia) or LOS. Only four 
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studies reported both glycaemic and LOS outcomes concurrently [266-269], whereas the remainder 
reported either outcome. Studies in the UK mainly focussed on LOS, whilst studies from the US 
generally focused on glucometric outcomes captured by networked BG meter systems.  
 
Several studies reported time-series analyses of hospital LOS data or glucometric data to evaluate trends 
in outcomes after implementation of an IDT. Flanagan et al, published two a proactive IDT intervention 
studies. The first study was in general inpatients, and a subsequent study was in elective surgical patients 
[270, 271]. The primary outcomes in these studies were the difference in LOS between diabetes and non-
diabetes inpatients. The time-series analyses reported: 1) diabetes patients had longer LOS than non-
diabetes patients; 2) there were gradual reductions in LOS in both groups of patients; but 3) the LOS 
reductions in diabetes patients were greater than in non-diabetes patients, concluding that proactive IDT 
was associated with a reduction in excess LOS experienced by diabetes patients. Other studies using LOS 
as primary outcome reported reductions in LOS between 0.3 and 3 days, depending on cohorts studied.  
 
In the seventeen IDT studies reporting glycaemic outcomes, reduction in hyperglycaemia was a consistent 
finding. Although various glucometric parameters were reported, IDT interventions were generally 
associated with a 0.5 to 2.0 mmol/L decrease in population, or patient-day mean glucose. Hypoglycaemia 
outcomes were variable, with 8 studies reporting improvement, 8 studies reporting no significant change, 
and one study reported increase in hypoglycaemia [238].   
 
Several studies evaluated multifaceted hospital-wide glycaemic management interventions in addition to 
an IDT [267, 272-275]. The various interventions included a combination of insulin protocols, electronic 
order sets, glycaemic alerts, and education campaigns in addition to implementation of an IDT. These 
studies reported improvement in glycaemic outcomes but it is difficult to ascertain the proportion of 
improvement attributable to the IDT amongst the bundle of interventions.  
 
From the available literature it is difficult to compare the efficacy of reactive vs. proactive models of IDT. 
Most studies reported similar magnitude of hyperglycaemia or LOS reduction. Given the heterogeneity of 
IDT models and study designs, a pooled analysis was not possible and there were no head-to-head 
studies.  
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Table 10: Inpatient Diabetes Teams operating with a reactive model of care 
Study, Location, 
Year 
Design n  




























Reactive Consultative NA NA ↓ 
Patients who received IDT consultation had 
56% shorter mean LOS than patients who did 
not receive IDT. (3.6 vs 8.2 days) 
Davies,  
Wales, UK, 2001 
[264] 
RCT 300 DNE 
Consecutive 
patients 
Reactive Consultative NA NA ↓ 
Randomised Controlled Trial of DNE vs. no 
DNE. 
Median LOS 11 vs. 8 days 
Cavan,  
Bournemouth, 
UK 2001 [279] 
Pre-Post 1611 DNE 
Nursing 
Referral 
Reactive Consultative NA NA ↓ Median LOS decreased: 11 to 8 days   
DeSantis,  
Chicago, USA 






Reactive Consultative ↓ ↔ NA 
Multi-faceted hospital-wide glycaemic 
management program including IDT. 










Reactive Consultative NA NA ↓ 
Time series analysis. LOS (excess bed days for 









Reactive Consultative NA NA ↓ 
Mean LOS in diabetes patients decreased: 5.5 














Reactive Consultative ↓ ↔ ↓ 
Multi-faceted hospital-wide glycaemic 
management program (insulin protocol, 
electronic order sets, education) and reactive 
IDT. Population BG decreased 9.4 to 8.6 
mmol/L. LOS reduction in diabetes patients 
40% greater than in non-diabetes patients.  
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Bar-Dayan,  
Israel 2014 [272] 
Pre-Post NA DNE Unclear Reactive Consultative ↓ ↓ NA 
Multi-faceted hospital-wide glycaemic 
management program. Pop mean BG 
decreased: 10.8 to 9.7 mmol/l; Hypoglycaemic 














Reactive Direct ↓ ↔ ↓ 
Patients who had treatment with enteral 
nutrition (EN).  
Mean BG during EN lower 11.1 vs. 8.6 mmol/L 
LOS shorter: 37 vs 27days.  




Pre-Post 3848 DNE 
Diabetes 
Patient at Risk 
Score (DPAR) 
Reactive Consultative NA ↓ NA 
Comprehensive diabetes assessment by treating 
nurse at admission. Risk score dictated referral 
to diabetes nurse. Patients with hypoglycaemia 
decreased: 15% to 10%. Medication errors 














Reactive Consultative ↓ ↓ NA 
Patient-day mean glucose decreased 10.0 to 9.4 
mmol/L 
Patient-day with hypoglycaemia decreased 4.8 










Reactive Unclear NA NA NA 
Retrospective RV of patients with ‘cardiac’ or 
‘infection’ discharge code.  
Clinical: In patients with mean BG >10 during 
admission, those seen by IDT had 50% fewer 
complications than those not seen by IDT (26% 
vs 48%) 
Abbreviations: IDT: Inpatient diabetes team; DNP: Diabetes Nurse Practitioner; DNE: Diabetes Nurse Educator; Consultant: endocrinologist or diabetologist; Fellow: diabetes fellow or 
endocrinology registrar; NA: not assessed; LOS: length of stay; BG: blood glucose. ↓: decreased; ↑: increased; ↔: no change.  See text for explanation on model of care and management  
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Table 11: Inpatient Diabetes Teams operating with a proactive model of care 
Study, Location, 
Year 
Design n  

























Pre-Post 186 Consultant Ward Round Proactive Direct ↓ ↑ NA 
Population mean BG decreased: 11.1 to  8.3 mmol/l 
Hypoglycaemia increased 1.4 to 3.6% 
Newton,  
North Carolina, 
USA, 2006 [266] 
Pre-Post NA DNP Ward Round Proactive Consultative ↓ ↔ ↓ 
Population mean BG decreased: 9.8 to 8.9 mmol/l 
LOS decreased 0.1 day more with intervention. 





Pre-Post 452 DNP Unclear Proactive Direct NA NA ↓ 
Medication errors decreased by 50% 









Ward Round Proactive Consultative NA NA ↓ 
LOS decreased by 0.3 days more for diabetes 












Proactive Consultative NA NA ↓ 
LOS decreased by 0.26 days more for diabetes 











Proactive Consultative ↓ ↓ NA 
Proportion of patients with glucose in range 







Ward Round Proactive Unclear NA NA ↓ 
LOS for diabetes patients decreased from 9 to 4 









Proactive Direct ↓ ↔ NA 
Proportion of patients with hyperglycaemia (BG 
>15 mmol/L) during admission decreased from 









Proactive Consultative ↓ ↔ NA 





Pre-Post NA Consultant 
Glycaemic 
surveillance 
Proactive Direct ↓ ↔ NA Pop mean glucose decreased: 8.9 to 7.9 mmol/l 
Maynard,  








Proactive Consultative ↓ ↓ NA 
Multi-faceted glycaemic management program 
Patients with hypoglycaemia decreased 13.7 to 
9.8% 
Patient-day with hyperglycaemia decreased: 37 to 
35% 
Mendez,  












↓ ↓ NA 
Patient-day mean BG decreased 9.9 to 9.6 mmol/L 










Proactive Consultative ↓ ↔ NA 
Patient-days with mean BG >15 mmol/L decreased: 
5.3 to 4.1% 
Swee, 









Proactive Consultative ↓ ↓ ↓ 
Patient-day mean BG decreased: 11.2 to 10.0 
mmol/L 
LOS mean decreased 15 to 12 days. 
Rushakoff, 
San Francisco, 












↓ ↓ NA 
Patient-days with hyperglycaemia (2 or more BG 
≥12.5 mmol/L) decreased 6.6 to 4.0% 













Reactive Unclear NA NA ↓ 
Amongst surgical patients, those seen by IDT had 
lower LOS. 
Amongst medical patients those seen by IDT had 
lower 30 day readmission. 
Abbreviations: IDT: Inpatient diabetes team; DNP: Diabetes Nurse Practitioner; DNE: Diabetes Nurse Educator; Consultant: endocrinologist or diabetologist; Fellow: diabetes fellow or 






In addition to glycaemic and LOS outcomes, three studies also reported clinical outcomes. Newton et al., 
reported the impact of a proactive IDT service in a community hospital in a pre- and post- 
implementation comparison. A reduction in population mean glucose of 0.9 mmol/L, and a 33% 
reduction in central line associated blood stream infections was reported suggesting improvements in 
glucose control contributed to decreased infections [266]. Wong et al., analysed a retrospective cohort of 
74 individuals who had enteral nutrition treatment, and compared those that received IDT intervention vs. 
those that did not [269]. The group that received IDT intervention had a lower mean glucose (11.1 vs. 8.6 
mmol/L), shorter mean LOS (37 vs 27 days), but also lower proportion with in-hospital mortality (32% vs 
11%). Lastly, Wang et al., retrospectively analysed 440 patients with diabetes discharged with a ‘cardiac’ 
or ‘infection’ diagnostic codes and compared patients who had IDT treatment vs. those who were 
managed by the treating team alone. In the analysis of the entire cohort, there were no differences in 
clinical outcomes. However, in a subgroup of people who had a mean BG >10 mmol/L during admission, 
the group managed by an IDT had a 50% reduction in complications (a composite outcome comprising 
nine items including mortality, infection, renal failure, ICU admission and readmission) [276]. Therefore, 
there is published data suggesting that IDT intervention improved clinical outcomes in addition to 
glucose control; however, evidence is based on observational and retrospective studies only and 
generalisability may be limited. 
 
A major limitation in this area of research is the abundance of observational, rather than prospective 
randomised studies, reflecting the difficulty in performing prospective trials of clinical care in hospitals. 
With a lack of a parallel control group, these observational studies are subject to confounding such as 
variation in hospital processes and outcomes over time. For example, many aspects of hospital care are 
becoming more efficient, and outcomes such as LOS are decreasing year on year. Therefore, reduction in 
LOS associated with IDT intervention maybe partially related to these measured and unmeasured 
confounders. In addition, some studies used retrospective ‘pre-intervention’ cohorts as the control group, 
which are subject to selection biases. Hence, changes in glycaemic and LOS outcomes are associated with 
an IDT intervention, rather than proving a definitive causal link. Lack of prospective randomised trials of 
IDTs is a significant gap in research evidence, prompting the ADA’s ‘Planning Research in Inpatient 






1.7.9 Risk stratification and prediction models 
With the rising number of inpatients with diabetes, there is an increasing need for efficient allocation of 
management resources. Specialist IDTs improve glucose control but providing management to every 
diabetes inpatients is resource intensive, as it can be up to 25 to 30% of the hospital population. There are 
efforts to develop risk stratification or prediction models to identify inpatients who are more likely to 
require IDT management. Studies on risk stratification either focus on those who develop adverse 
outcomes, or who develop adverse glycaemia.  
 
Nirantharakumar et al., reported a prediction model for adverse outcomes in inpatients with diabetes 
[289]. Adverse outcomes in this study were defined as inpatient mortality or LOS that was above the 75
th
 
centile of LOS for patients with diabetes. Analysis of 25,000 inpatient episodes from a UK hospital 
database found multiple clinical factors (including age, gender, admission type, foot disease, insulin use, 
critical care admission), and biochemical factors (low albumin, low GFR, low haemoglobin, low 
potassium, high inflammatory markers, and either low or high sodium) were associated with adverse 
outcomes. A regression model based on these variables was accurate at predicting adverse outcome, with 
receiver-operating characteristic, area under curve (ROC-AUC) of 0.802. A subsequent external 
validation study reported a similar accuracy of this prediction model in other UK cohorts, supporting its 
clinically utility [290]. However, this model did not include glycaemic variables as it was not reliably 
available in the discharge databases; therefore, it is unclear if adverse outcomes were linked to adverse 
glycaemia or whether targeted intervention by an IDT can improve outcomes.  
 
Several studies developed risk stratification strategies for adverse glycaemia; however, these only 
focussed on hypoglycaemia. Known risk factors for inpatient hypoglycaemia include greater 
comorbidities, greater duration of diabetes, lower HbA1c, insulin or sulphonylurea treatment, kidney and 
liver impairment and longer LOS [162, 291-293]. Four prediction models for hypoglycaemia have been 
described (Table 12). 
 
Despite hyperglycaemia being significantly more common, there are relatively few studies formally 
addressing risk factors. From clinical experience, many variables are known to cause exacerbation of 
hyperglycaemia including patient variables (pre-existing hyperglycaemia, counter-regulatory stress 
response, severity of illness), and hospital treatment factors (glucocorticoid treatment, provision of enteral 
and parenteral nutrition and withheld glucose-lowering treatment). There are two studies reporting that 
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Insulin dose 
Type 1 diabetes 
Type 2 diabetes 
Mean BG 
Nadir BG 







Abbreviations: BG: blood glucose; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease; CV: 







1.7.10 Continuous glucose monitoring and automated insulin delivery systems 
Diabetes technology in ambulatory care has rapidly evolved and many individuals (especially those with 
type 1 diabetes) now use subcutaneous insulin infusion (CSII) pumps with or without continuous glucose 
monitoring (CGM) systems to optimise diabetes management. Some individuals use stand-alone CMG 
systems with multi-dose insulin injections (i.e. not insulin pump) to closely monitor glucose and make 
treatment decisions. Strategies and protocols have been developed to deal with such technology when 
individuals using these systems are admitted to hospital. In addition, the possibilities of using these new 
technologies de novo in hospital to optimise inpatient diabetes management have been explored. 
 
Current guidelines recommend individuals using an insulin pump prior to hospitalisation should remain 
on the pump in hospital, when safe to do so [30, 300]. This requires the individual to self- monitor BG 
and self-manage the insulin pump. There are also established contraindications to insulin pump therapy in 
hospital including critical illness, psychiatric or cognitive conditions and hyperglycaemic emergencies.  
 
Real-time CGM in the hospital has potential advantages due to the ability to rapidly detect increasing or 
decreasing BG and enable rapid treatment decisions aiming to prevent adverse glycaemia. CGM systems 
in hospital can be invasive and intravascular (used in the intensive care) or less invasive and subcutaneous 
(similar to systems used in ambulatory care). However, the limitation of subcutaneous interstitial CGM in 
the inpatient setting include: 1) the need for regular calibration; 2) the time-lag for capillary glucose 
measure to be reflected in interstitial glucose measure; 3) interference with substances such as mannitol, 
maltose ,and paracetamol; and 4) a lack of evidence of accuracy during hypotension, hypothermia and 
hypoxia. Use of CGM in hospital remains experimental at present although a number of small studies 
evaluating device accuracy have been performed in critical care and noncritical care [300]. Currently 
there is only one subcutaneous CGM system approved for inpatient use in Europe, but there are no 
approved systems in US or Australia. There are no studies to date evaluating if CGM improves inpatient 
glycaemia in the noncritical care arena. 
 
Another new technology that has the potential to revolutionise diabetes management in ambulatory care is 
automated insulin delivery systems (or a closed-loop pumps). Utilising a CGM and a computer algorithm, 
a closed-loop pump constantly adjusts insulin infusion rate to achieve optimal glycaemic control. This 
technology has been tested in the hospital in a RCT of 136 inpatients with type 2 diabetes, who were 
randomised to a closed-loop system or a conventional subcutaneous BBI regimen [301]. The group 
randomised to closed-loop had a significantly higher percentage of time in target range (66% vs. 42%), 
lower proportion of patients with BG above target range (23% vs. 50%), and lower mean glucose (8.5 vs. 
10.4 mmol/L). Automated insulin delivery systems have the potential to significantly improve BG control 







The prevalence of diabetes in hospital has increased rapidly in the last few decades and diabetes now 
affects one in four inpatients. Most diabetes inpatients are admitted under the care of non-diabetes 
specialists. Individuals with diabetes and those who are discovered to have hyperglycaemia in hospital 
have worse outcomes, including increased risk of hospital-acquired infections, longer LOS, greater 
readmissions and higher inpatient mortality. Adverse outcomes are (at least partially) attributable to 
metabolic and physiological changes resulting from acute hyperglycaemia and hypoglycaemia; 
collectively termed adverse glycaemia.  
 
There are well-established cellular and pathophysiological mechanisms linking adverse glycaemia with 
adverse clinical outcomes. Acute hyperglycaemia causes immune dysfunction, pro-inflammatory and pro-
thrombotic changes, and endothelial dysfunction. These changes occur even after a short duration of 
exposure to moderate levels of hyperglycaemia, situations that are routinely encountered in hospitalised 
patients. Treatment of hyperglycaemia improves outcomes, especially decreasing the risk of hospital-
acquired infections, but aggressive ‘tight glycaemic control’ is not warranted and may be harmful, 
possibly due to increased incidence of hypoglycaemia. Acute hypoglycaemia is linked to cardiac 
arrhythmia, cardiac ischaemia, endothelial dysfunction, neurological sequelae and injuries. Therefore, 
adverse glycaemia (defined as blood glucose <4.0 or >15.0 mmol/L in this thesis) should be avoided in 
hospitalised patients. Despite the importance of glucose control, adverse glycaemia remains common in 
noncritical care, with more than 50% of inpatients with diabetes experiencing hyperglycaemia and 20% 
experiencing hypoglycaemia. There are multiple barriers interfering with optimal glucose control 
including patient-related, illness-related, treatment-related, health professional-related, and hospital-
system-related factors all contributing to clinical inertia.  
 
Various strategies to improve hospital diabetes care have been studied. Several RCTs demonstrated the 
superiority of basal-insulin containing insulin regimens over sliding-scale insulin. Insulin protocols and 
order sets improve appropriate insulin prescription in hospital. Although staff education programs 
improve clinician knowledge and glucose control in the short term, improvements are  often unsustained. 
Glucometric reporting and benchmarking are essential aspects of auditing and improving inpatient 
glucose control; however, due to the lack of automated technologies to capture glucose data, there is a 
lack of glucometric data or benchmarking in Australian hospitals. Glycaemic alert systems may improve 
clinician response to adverse glycaemia; however, many alert systems require integrated electronic 
medical records and information systems. 
 
Ultimately, the significant barrier in current diabetes management practice is a lack of diabetes clinical 
expertise for the majority of inpatients with diabetes. Specialist IDTs have been implemented to provide 
specialist diabetes management aimed at improving glycaemic control and clinical outcomes. However, 





lacking. Furthermore, studies have focused on glycaemic or LOS outcomes; very few studies evaluated 
clinical outcomes.  
 
Alert systems and IDTs that foster a more proactive model of diabetes care can theoretically be more 
effective at decreasing clinical inertia. A proactive IDT would also benefit from a system to risk-stratify 
and identify subgroups of inpatients who are most at risk of developing adverse glycaemia to enable 
targeted management. Above all, a successful inpatient diabetes management approach should increase 
insulin use, decrease adverse glycaemia, and improve clinical outcomes for individuals with diabetes and 
hyperglycaemia in hospital. The term ‘proactive’ originates from a Greek word ‘Pro’ (meaning ‘before’ 
or ‘early’), and the Latin word ‘Activus’ (meaning ‘to act’). Hence, to be proactive is to provide an ‘early 
action’ or an ‘early intervention’ for people with diabetes. 
 
1.9 Research aims 
The aims of this thesis are to develop and evaluate early intervention models of inpatient diabetes care to 
address adverse glycaemia in hospital. The specific aims are: 
 
 To develop and evaluate a glucose alert system designed to improve health professional responses to 
adverse glycaemia 
 To implement networked glucose meter technology and describe baseline glucometric outcomes at 
Royal Melbourne Hospital compared to international benchmarks.  
 To develop a comprehensive early intervention model of inpatient diabetes care and investigate its 
effects on glycaemic and clinical outcomes, in a prospective randomised controlled trial 
 To develop a prediction tool for early identification of inpatients at high-risk for adverse glycaemia.  
 
1.10 Hypotheses 
 A glucose alert system, comprising of a clinical escalation pathway and alert-capable networked 
glucose meters, will improve health professional responses to adverse glycaemia and improve 
inpatient glycaemia 
 Inpatients with diabetes at the Royal Melbourne Hospital have similar glucose control as hospitals in 
the United States and United Kingdom. 
 A comprehensive early intervention model of inpatient diabetes care will increase insulin treatment, 
as well as improve glycaemia and clinical outcomes.  
 Clinical factors available early in admission can predict the development of adverse glycaemia 





2. CHAPTER TWO: MATERIAL AND METHODS 
General materials and methods are outlined in this chapter. Specific details of methods for each study are 
outlined in the respective chapters. 
2.1 Study design overview 
Two separate clinical studies were conducted at the Royal Melbourne Hospital (RMH), a tertiary teaching 
hospital affiliated with the University of Melbourne. Study 1 was a prospective, pre- and post- 
implementation, observational study on two wards over 16 weeks investigating the efficacy of a glucose 
alert system (Chapter 3). This study also provided invaluable insights into the performance of networked 
glucose meters at our hospital. Following this, networked glucose meters were implemented on eight 
noncritical care wards for the subsequent study. Study 2, was the Randomised study of a Proactive 
Inpatient Diabetes Service (RAPIDS) which was prospectively registered with the Australia New Zealand 
Clinical Trials registry (ANZCTR.org.au: number: 12616000265471). RAPIDS was a cluster randomised 
trial with a baseline period, conducted on eight wards over 24 weeks and formed the basis of Chapters 4, 
5 and 6. Both studies were approved by the Melbourne Health Humans Research and Ethics committee 
(QA2013.189 and HREC 2015.127) with a waiver of the need for individual consent. 
 
2.2 Setting 
Located in Parkville, 2 kilometres from Melbourne’s central business district, the RMH comprises a 480-
bed acute care campus, and a 100-bed subacute care campus. The studies were conducted at the acute 
care campus. The RMH is co-located with the Peter MacCallum Cancer Institute and the Royal Women’s 
Hospital, in addition to a number of medical and scientific research facilities comprising the Parkville 
medical and research precinct. The RMH provides acute medical and surgical care for adult patients in 
most disciplines, as well as serving as one of two dedicated trauma centres for the State of Victoria. It 
does not provide paediatric, maternity or gynaecology services as these are provided by co-located 
specialist hospitals. As a university teaching hospital, the RMH has a full array of students including 
medical, nursing and allied health, across a range of education including undergraduate, postgraduate and 
specialist training.  
 
The wards included in the studies are acute, noncritical care, general and specialist medical and surgical 
wards. In study 1, a specialty surgical ward (vascular and urology surgery) and a specialty medical ward 
(rheumatology and infectious diseases) were included. In study 2 (RAPIDS), eight wards (half medical 





were two general medical, two general surgical, and one each of cardiology, neurology, neurosurgery and 
orthopaedic/trauma surgery wards. These wards were chosen to be representative of patients admitted to 
the hospital. The wards range from 20 to 32 beds and with the exception of two general medical wards 
which are considered symmetrical wards, the remaining wards are considered specialist wards with 
unique medical or surgical services. 
 
The RMH does not have a fully-integrated EMR for inpatient care. Therefore, documentation of patient 
observations, clinical progress notes and medication prescription are performed on paper charts at the 
patient bedside. Pathology, radiology, patient administration, scanned medical records and various other 
clinical systems are available in separate electronic programs. 
 
Inpatient diabetes care is generally provided by the treating team’s medical officers but the Department of 
Diabetes and Endocrinology provides a referral-based diabetes consultation service. The inpatient 
diabetes referrals service consists of an advanced endocrinology trainee and a diabetes nurse practitioner 
who are supervised by the ward service endocrinologist. Various inpatient diabetes guidelines, including 
hypoglycaemia management and perioperative diabetes management, are available to assist with clinical 
care. Twice yearly education sessions are conducted for junior medical staff and nursing staff. The 
diabetes education department also provides a referral-based service in response to requests from ward 
nursing staff and treating medical teams.  
 
2.3 Networked glucose meter implementation 
In study 1, two different networked glucose and ketone meter systems (Precision Pro ®, Abbott Diabetes; 
and Statstrip ®, Nova Biomedical – distributed by Australasian Medical and Scientific Limited [AMSL]) 
were used as part of the glucose alert system. Subsequently, Statstrip ® glucose meter system was 
implemented for the RAPIDS study. The Statstrip was chosen as the preferred system for the RAPIDS 
study after an evaluation of both systems by a multidisciplinary team, as it was found to be superior in 
functionality and connectivity, in addition to superior accuracy in the setting of critical illness and 
extremes of haemoglobin. Both systems comply with the International Organisation for Standardisation 
(ISO) 15197 and Clinical and Laboratory Standards Institute standards for accuracy [186] and both are 
approved by the Therapeutics Goods Administration for use in Australian hospitals. 
 
Networked glucose meter systems were installed on participating wards using a Local Area Network 
(LAN) cable which connected the meter docking stations to the hospital’s information technology (IT) 
network. Each meter was configured and administered using associated data management software 
(POCcelerator ®, Siemens Healthineers for Precision Pro; and Novanet ®, Nova Biomedicals for 
Statstrip). Meters communicated to the hospital IT system using Health Level-7: Admission, Discharge 





glucose measurement results. During the studies, electronic glucose measurement data was not available 
for routine clinical care, but available only to the research team for delivery of proactive interventions and 
data collection. BioViewer (© Bio-Asia Diagnostics) data manager was used to extract capillary glucose 
data from the database. 
 
Implementation of networked glucose meters was accompanied by an extensive staff training program, 
consisting of small group 30-minute nursing ‘in-service’ sessions. At least five sessions were provided for 
each participating ward with more than 90% of staff receiving face-to-face training. In addition, train-the-
trainer sessions were held for nursing educators who continued to educate new staff members. For study 
1, implementation of networked BG meters (which was a component of the glucose alert pathway) was 
completed during the two-week implementation phase. For study 2, implementation of networked BG 
meters was completed one month prior to the beginning of the study to ensure adequate staff familiarity 
with this technology. Quality control testing of the meters was performed as per hospital policy (daily for 
glucose strips and weekly for ketone strips) The pre-existing simple glucose meters (Freestyle Optium ®, 
Abbott Diabetes) were removed from the wards to ensure all BG measurements were performed using the 
networked meters in the participating wards.  
 
2.4 Participants 
For both studies, consecutive inpatients who were admitted to a study ward, during the study period, were 
included. Study 1 included inpatients with pre-existing diabetes. Study 2 included inpatients with pre-
existing diabetes and new hyperglycaemia (random capillary BG >11.1 mmol/L). Exclusion criteria 
comprised of inpatients admitted under the care of the diabetes and endocrinology unit, those admitted 
with hyperglycaemic crises (DKA or HHS), and those admitted for palliative care. Inpatients admitted for 
day procedures and those with hospital LOS less than 1 day were also excluded.  
 
To ensure inclusion of all consecutive eligible inpatients, the ward patient list was generated each 
calendar day and screened for the presence of patients with diabetes or new hyperglycaemia. All 
inpatients meeting inclusion criteria were identified and included prospectively, without the need for 
individual patient consent for recruitment based on the waiver approved by the ethics committee. For 








2.5 Data collection 
Patient clinical information was collected from the inpatient clinical notes from the time of admission. 
Data collection was subsequently completed after patient discharge from hospital, to ensure accurate 
collection of clinical outcome data. To determine patient outcomes, clinical progress notes, discharge 
summaries, pathology and radiology result systems were assessed. Patient identification and initial data 
collection was performed on a paper data collection forms, but later the information was entered into a 
Microsoft Access ® database. In study 2, patient clinical outcomes were adjudicated by an independent 
clinician who was blinded to the treatment allocation. 
 
Glycaemic data collection was performed by manual audit of glucose observation charts for study 1. In 
study 2, glycaemic data collection was performed by extracting electronically captured glucose 
measurements, and additionally verified by cross-referencing all glucose measurements with the paper 
glucose observation charts. In the event of discordance between electronic data and paper observation 
chart data (estimated to be present in less than 5% of measurements), the BG measurements documented 
on the observation charts were used. 
 
For each included patient an HbA1c measurement was requested if it was not already requested by the 
treating teams. HbA1c results were available to all clinicians regardless of whether it was ordered by the 
treating clinical team or the research team. HbA1c was performed using high performance liquid 
chromatography. Creatinine and eGFR results were requested at the discretion of treating teams and were 
performed in the hospital pathology department using Abbott Architect analyser.  
 
2.6 Data analysis 
Data analysis was performed using a variety of statistical software. Minitab Version 17.2.1 (Minitab Inc., 
State College, PA, USA) was used to perform glucometric analyses and comparative analyses for 
Chapters 3 and 4. STATA version 15 (StataCorp LLC, College station, TX, USA) was used to perform 
complex analyses including logistic and Poissons regression (including mixed-level regression), and 
creation of ROC curves in Chapters 5 and 6. GraphPad Prism version 7.00 for Windows, (La Jolla 
California USA) was used to create charts and figures. For continuous variables, parametric or non-
parametric tests were used to compare between groups as appropriate. Categorical variables were 




3. CHAPTER THREE:  
GLUCOSE ALERT SYSTEM TO IMPROVE HEALTH PROFESSIONAL RESPONSES TO 
ADVERSE GLYCAEMIA 
3.1 Introduction 
Clinical inertia is a common barrier to attaining optimal glycaemia in hospital. Clinical inertia in inpatient diabetes care 
describes a lack of health professional action in response to adverse glycaemia. A lack of appropriate treatment 
adjustment often leads to persistent adverse glycaemia. Alert systems to notify the occurrence of adverse glycaemia can 
prompt health professionals to make appropriate remedial actions. Studies of glucose alert systems in noncritical care 
have been heterogeneous and mostly required complex integrated electronic systems.  
 
We sought to develop a simple glucose alert system that incorporated a novel clinical escalation pathway coupled with 
alert-capable networked glucose meters. The alert system provided a visual alert when BG was out of range, and 
prompted clinicians to respond according to the ‘Melbourne glucose alert pathway’. The alert system was aimed at both 
nursing and medical staff at the point of care. It is an example of a proactive intervention, as it aims to increase early 
treatment. The efficacy of the alert system was investigated in a pre- and post- implementation observational study. 
Additionally, this study provided invaluable experience with the two available networked glucose meter systems, as 
well as generating pilot data on the incidence of adverse glycaemic days at our institution. The design and conduct of 
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Abstract
Aim To investigate the effect of a novel glucose alert system, comprising the Melbourne Glucose Alert Pathway and
glucose-alert-capable networked blood glucose meters, on nursing and hospital medical officer responses to adverse
glycaemia.
Methods A prospective, pre- and post-observational study was undertaken in non-critical care wards of a tertiary
hospital over 4 months (n=148 or 660 patient-days). The intervention consisted of two components designed to promote
a consistent staff response to blood glucose measurements: (1) a clinical escalation pathway, the Melbourne Glucose
Alert Pathway, and (2) networked blood glucose meters, which provide a visual alert for out-of-range blood glucose
measurement. All consecutive inpatients with diabetes were assessed for diabetes management and capillary blood
glucose. The primary outcome was documented nursing and medical staff action in response to episodes of adverse
glycaemia (blood glucose >15 mmol/l or <4 mmol/l). Secondary outcomes consisted of glycaemic measures.
Results In response to episodes of adverse glycaemia, nursing action increased (proportion with nursing action: 45% to
73%; P<0.001), and medical action increased (proportion with medical action: 49% to 67%; P=0.011) with the glucose
alert system in place. Patient-days with hyperglycaemia (any blood glucose value >15 mmol/l: 24% vs 16%; P=0.012)
and patient-days with mean blood glucose >15 mmol/l (7.4% vs 2.6%; P=0.005) decreased. There was no difference in
hypoglycaemia incidence.
Conclusions Use of a novel glucose alert system improved health professional responses to adverse glycaemia and
decreased hyperglycaemia in the hospital setting.
Diabet. Med. 00: 1–8 (2018)
Introduction
In hospitalized individuals, both hyper- and hypoglycaemia
are associated with worse outcomes [1–4]. The term ‘adverse
glycaemia’ can be used to describe both extremes of
hyperglycaemia and hypoglycaemia, which should be
avoided. Despite established glycaemic targets in the non-
critical care setting [5,6], glycaemic control remains subop-
timal with hyperglycaemia occurring in up to 80% of
inpatient diabetes admissions [7,8], and hypoglycaemia
occurring in 20% of admissions [7,9].
Clinical inertia in acute diabetes care can be defined as a
lack of health professional action in response to adverse
glycaemia and is a significant barrier to optimizing glycaemia
in hospital. Despite hyperglycaemia being common in
diabetes inpatients, capillary blood glucose (BG) measure-
ments are often overlooked and appropriate intensification of
therapy does not occur [10]. Persistent hyperglycaemia or
recurrent hypoglycaemia on multiple consecutive days may
occur without appropriate adjustment in therapy [11].
Clinical inertia is evident in both nursing and hospital
medical officer practice. Nursing staff who perform point-of-
care BG observations may not escalate a case to medical staff
for assistance with managing out-of-range BG measure-
ments, and hospital medical officers may not review BG
observation charts daily, make appropriate therapy adjust-
ment, or refer to specialist diabetes services for assistance.
Glucose alert systems have been shown to improve staff
action in response to adverse glycaemia. In the intensive care
setting, real-time computer-generated glucose alert systems
(which provide audio-visual alerts when BG measurements
are out of range) have been used to facilitate insulin infusionCorrespondence to: Mervyn Kyi E-mail: mervyn.kyi@mh.org.au
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adjustment by the treating nurse, and can improve glucose
control [12,13]. In the non-critical care setting, structured
glucose observation charts (with a coloured background to
indicate when BG measurements are out of range), accom-
panied by hyperglycaemia and hypoglycaemia management
guidelines have been used to encourage staff response to
adverse glycaemia [14]. The efficacy of this approach to
address clinical inertia has not been studied in detail,
although one study observed a decrease in hyperglycaemia
after the introduction of a structured BG observation chart
[15].
Networked BG meters are point-of-care devices that link
BG measurements to patient identifiers and store this
information in a central database. Hospital-wide implemen-
tation of networked BG meters enables collection of
electronic point-of-care BG data for research, quality
improvement and benchmarking of glycaemic control
between hospitals [16,17]. In addition, networked BG meters
can be programmed to display visual cues when BG
measurements are outside a predefined range and therefore
could function as an alert device for adverse glycaemia.
Experts have suggested that system-based solutions are
required to overcome obstacles for glycaemic control in
hospital [18]. In an attempt to decrease clinical inertia and
improve glycaemic control, we developed a glucose alert
system designed to escalate health professional responses to
adverse glycaemia. The glucose alert system comprised the
Melbourne Glucose Alert Pathway (GAP), along with
glucose-alert-capable networked BG meters. We hypothe-
sized that this glucose alert system would increase nursing
and hospital medical officer responses to adverse glycaemia.
Methods
This was a prospective observational study conducted over a
4-month period in 2015. It was performed on two wards at
the Royal Melbourne Hospital, a tertiary teaching hospital
affiliated with the University of Melbourne, and approved by
the local Human Research Ethics Committee.
Population
Consecutive inpatients with diabetes who were admitted to
one of two study wards were recruited. One surgical ward
(predominantly vascular and urology surgery) and one
medical ward (predominantly general medicine) were
included in the present study because of the relatively high
prevalence of diabetes in these wards. We excluded people
with hyperglycaemia without a history of diabetes, and those
admitted under endocrinology or palliative care units, or
admitted for <1 day. Participant information, capillary BG
measurements and diabetes management during hospitaliza-
tion were collected prospectively from progress notes and
bedside charts. For people with a prolonged hospital stay,
only the first 14 days of admission were collected and
analysed.
Baseline: routine care
At our hospital, diabetes management is primarily the
responsibility of the hospital medical officers of the admitting
unit. The specialist diabetes referral team (diabetes nurse and
endocrinologist) is available for assistance on a formal
referral basis. Documentation and management of acute
inpatient care is performed via written medication orders,
glucose observation charts and progress notes at the bedside.
In accordance with local practices, there is no standardized
algorithm of routinely withholding all antidiabetic medica-
tions and commencing regular and/or supplemental subcu-
taneous insulin on all patients admitted to hospital. A
hypoglycaemia management algorithm has been in routine
use, but a hyperglycaemia management algorithm has not
been used.
During the baseline period, there was no formal glucose-
based alert system and non-networked (and not alert-
capable) point-of-care capillary BG meters (Freestyle
optium; Abbott Diabetes, Alameda, CA, USA) were in
use. Baseline 2-month data collection was performed prior to
implementation of the glucose alert system.
Intervention
The glucose alert system consisted of two components: (1)
the GAP and (2) glucose-alert-capable networked BG meters.
The first component, the GAP, was a structured clinical
escalation pathway to be used by nursing and medical staff in
response to BG measurements (Fig. 1). The GAP was
developed by a multidisciplinary team of nursing and
medical staff in conjunction with the Department of Diabetes
and Endocrinology at the Royal Melbourne Hospital. The
GAP is a colour-coded guide attached to the bedside glucose
observation charts consisting of four different BG ranges
What’s new?
• Lack of health professional response (clinical inertia) to
adverse glycaemia is a major barrier to improving
diabetes care in the hospital setting.
• To improve health professional responses, a novel
glucose alert system, comprising the Melbourne Glu-
cose Alert Pathway (a clinical escalation and manage-
ment guide) and glucose alert-capable networked blood
glucose meters, was implemented and evaluated.
• The glucose alert system improved health professional
responses and decreased the number of hyperglycaemic
episodes and could be a component of various strategies
to improve the care of hospitalized people with
diabetes.
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with corresponding action responses for nursing and medical
staff. The four BG ranges are hypoglycaemia (BG <4.0 mmol/
l, red), safe glycaemia (BG 4.0–10.0 mmol/l, green), acute
hyperglycaemia (one BG 15.1–20.0 mmol/l or two consec-
utive BG 10.1–15.0 mmol/l, yellow) or critical hypergly-
caemia (BG >20.0 mmol/l, red). Within each range,
recommended nursing actions are summarized as follows:
manage the situation, monitor BG more intensively and
notify medical officer. The recommended medical officer
actions are summarized as follows: review BG, revise
diabetes treatment and refer to diabetes team for assistance.
In addition to glucose measurements, the GAP also provided
recommendations in response to clinical changes that may
affect BG (such as fasting, provision of enteral nutrition, or
glucocorticoid treatment).
The second component was the glucose-alert-capable
networked BG meters, which enabled a visual alert for out-
of-range BG measurements and facilitated electronic transfer
and storage of BG data linked to a unique identifier. Two
networked BG meter systems [Nova StatStrip (Australasian
Medical and Scientific Ltd, Chatswood, NSW, Australia) and
Freestyle Precision Pro (Abbott Diabetes)] were introduced
to our hospital and used in the present study. Networked BG
meters were programmed to display visual alerts when BG
was outside the optimal range defined in the GAP. The visual
alerts consisted of a yellow highlight or single arrow for
moderately out-of-range measurements (BG 3.1–3.9 mmol/l
or 10.1–20.0 mmol/l) and a red highlight or double arrows
for critically out-of-range measurements (BG <3.0 mmol/l or
>20.0 mmol/l). Nursing staff continued to record BG
measurements manually on the bedside glucose observation
charts, as per routine clinical care.
All nursing staff and medical officers underwent group
education sessions on both components of the glucose alert
system. A 2-month intervention period and data collection
was undertaken with the glucose alert system in place.
Outcomes
The primary outcome was staff response to adverse gly-
caemia. An episode of adverse glycaemia was defined as a
patient-day with capillary BG in the severe hyperglycaemia
range (BG >15 mmol/l) or hypoglycaemia range (BG <4
mmol/l). These thresholds were chosen because severe
hyperglycaemia is associated with adverse physiology (neu-
trophil dysfunction, osmotic diuresis) [19] and hypogly-
caemia <4 mmol/l is associated with counter-regulatory
hormone responses and adverse events [20]. Adverse gly-
caemia indicated unsafe glycaemic extremes that should be
avoided and should prompt a review of diabetes management
and adjustment of therapy [9].
Nursing and medical staff responses (<24 hours after an
episode of adverse glycaemia) were assessed. Nursing
response was defined as documented evidence of notifying
FIG. 1 Melbourne Glucose Alert Pathway (GAP). BG, blood glucose.
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(or escalating to) medical officers about adverse glycaemia.
Medical officer response was defined as documented evidence
of one or more of the following: reviewing BG observations;
revising diabetes treatment (adjustment of diabetes medica-
tion or insulin, including prescription of correctional dose of
insulin, as per the medication prescription chart); or escalat-
ing by referral to the specialist diabetes team. To account for
potential confounders that may affect staff action, a logistic
regression analysis was also performed to evaluate staff
response to hyperglycaemia, adjusting for the peak BG
(severity of hyperglycaemia), insulin treatment, admission
unit and day of occurrence (weekday vs weekend).
Secondary outcomes were measures of glycaemic control
(patient-days with hyperglycaemia or hypoglycaemia and
patient-day mean glucose). To ensure BG measurement
assessment was consistent across the entire study, capillary
BG measurements that were documented in writing by the
nursing staff in the BG observation charts were used, rather
than electronically extracting data from networked BG
meters. In addition, we excluded repeated BG measurements
from a single episode of hypo- or hyperglycaemia as
previously described [21]. Despite differences in chemical
methods, all the BG meters in the study comply with the
2013 ISO: 15197:2013 standards and therefore we
anticipated minimal difference in BG measurements in this
non-critically ill population. Outcomes were compared
between the baseline and intervention periods using Fish-
er’s exact test, a t-test or a rank-sum test, as appropriate,
using Minitab version 17.2.1 (Minitab Inc., State College,
PA, USA). At the conclusion of the study, nursing staff were
asked to complete a survey evaluating satisfaction with both
components of the glucose alert system.
Results
In the present study, we observed a total of 148 inpatients
(660 patient-days), including 70 patients (349 patient-days)
in the baseline period and 78 patients (311 patient-days) in
the intervention period. The groups were well matched
between baseline and intervention periods (Table 1). The
majority had Type 2 diabetes, a third were receiving insulin
treatment prior to admission and the mean HbA1c was 57
mmol/mol (7.4%). This cohort consisted of largely surgical
admissions (80%), with half admitted for elective proce-
dures. The median length of stay was 4 days per person.
During the study there were 168 episodes of adverse
glycaemia, with severe hyperglycaemia (>15 mmol/l) and
hypoglycaemia (<4 mmol/l) occurring in 24% and 7% of




(n = 78) P
Mean  SD age, years 7014 6814 0.90
Men, n (%) 48 (69) 52 (68) 0.99
Mean  SD BMI 29  7 30  7 0.58
Median (IQR) modified* Charlson comorbidity index 2 (0, 4) 2 (1, 4) 0.89
Diabetes type, n (%) 0.40
Type 2 diabetes 60 (86) 72 (92)
Type 1 diabetes 4 (6) 3 (4)
Other (e.g. steroid-induced, pancreatic) 6 (8) 3 (4)
Diabetes treatment prior to admission, n (%) 0.33
Diet only 16 (23) 11 (14)
Oral and glucagon-like peptide-1 31 (44) 42 (54)
Insulin-requiring 23 (33) 25 (32)
Mean  SD HbA1c, mmol/mol 54  15 60 17 0.06
Mean  SD HbA1c, % 7.1  1.4 7.6  1.6
Mean  SD admission eGFR, ml/min/1.73m2 71  19 69  22 0.53
Elective admission, n (%) 34 (49) 36 (46) 0.87
Admission unit, n (%) 0.35
Surgical 52 (74) 64 (82)
Vascular surgery 21 (30) 21 (27)
Urology surgery 20 (29) 26 (33)
Other surgery 11 (16) 17 (22)
Medical 18 (26) 14 (18)
Median (IQR) observed patient-days per patient 3.8 (2.1, 7.8) 3.2 (1.8, 6.3) 0.18
Median (IQR) BG measurements per patient-day 4 (2, 5) 4 (2, 5) 0.10
Insulin regimen on admission to ward, n (%) 0.99
No insulin treatment 43 (61) 48 (62)
Insulin treatment: basal  bolus 10 (14) 11 (14)
Insulin treatment: pre-mixed 11 (16) 12 (15)
Insulin treatment: supplemental only 6 (9) 7 (9)
BG, blood glucose; eGFR, estimated GFR; IQR, interquartile range.
*Excludes items related to diabetes.
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patient-days, respectively. In the baseline period there were
101 episodes of adverse glycaemia compared with 67
episodes in the intervention period. In response to adverse
glycaemia, nursing responses increased from 45% during the
baseline period to 73% during the intervention period
(P<0.001). Medical responses increased from 49% during
the baseline period to 67% during the intervention periods
(P=0.011). The medical responses consisted mostly of
reviewing BG measurements and revision of diabetes treat-
ment (Table 2). After multivariable adjustment, staff
response to hyperglycaemia was much more likely during
the intervention than the baseline period [nursing action:
adjusted odds ratio 6.7 (95% CI 2.5, 18.1); medical action
4.9 (95% CI 1.9, 12.7); Appendix S1].
On glucometric analyses, 1331 and 1077 BG measure-
ments were observed in the baseline and intervention
periods, respectively. Frequency of BG monitoring was as
per local guidelines (median 4 measurements per person-day)
and was consistent throughout the entire study. Patient-days
with severe hyperglycaemia (>15 mmol/l) decreased (24% vs
16%; P=0.012), and patient-days with critical hypergly-
caemia (>20 mmol/l) decreased (9% vs 2%; P<0.001).
Patient-days with mean BG >15 mmol/l decreased [7.4% vs
2.6%; P=0.005 (Fig. 2)]. There was no difference in patient-
days with hypoglycaemia (BG <4 mmol/l; 7% vs 6%; P=0.9)
or severe hypoglycaemia (BG <3 mmol/l; 3.4% vs 2.8%;
P=0.8). The proportion of patients with severe hypogly-
caemia during hospitalization was not different (11% vs 5%;
P=0.2). Patient-day mean glucose was not different
(although showed a trend to decrease) between baseline
and intervention periods (9.53.2 vs 9.12.5 mmol/l;
P=0.082).
Satisfaction surveys were returned by 24 nurses (40% of
eligible nurses). Twenty respondents (83%) were satisfied
with the GAP, and 18 respondents (75%) were satisfied with
networked BG meters; however, 25% indicated that the alert
system placed increased demands on their time. The majority
responded that both components improved patient safety
(Appendix S2).
Discussion
In keeping with previous literature, the present study
identified frequent episodes of adverse glycaemia in non-
critical care inpatients with diabetes. In the baseline period of
this study, more than half of adverse glycaemic episodes did
not lead to documented action by nursing or medical staff,
highlighting significant clinical inertia. Adjustment of dia-
betes treatment occurred in only one-third of episodes,
similar to findings in a previous study in which only 22% of
patient-days with hyperglycaemia led to treatment intensifi-
cation [22].
Intervention with an instructive visual glucose alert system
aiming to escalate health professional responses resulted in
significant improvement in responses to adverse glycaemia.
Increased staff responses were most evident in nursing staff,
where a 62% increase in notification of adverse glycaemia to
hospital medical officers was observed. Similarly, medical
staff reviewed BG measurements and made adjustment to
diabetes treatment more often. The two components of the
glucose alert system were designed to work in concert, as
networked BG meters provided a visual alert for an out-of-
range BG measurement, prompting staff to refer to the GAP,
which then provided the clinical escalation and management
guideline. In addition, treating staff were aware that patient-
identifiable BG data were electronically recorded with the
theoretical potential for remote electronic surveillance
(which was not performed in this study), which may have
encouraged a greater sense of accountability for BG man-
agement. Improved accountability is an important aspect of
improving inpatient diabetes management, which can be
facilitated by networked BG meters [23]. In the present study
Table 2 Staff response to adverse glycaemia episodes
Baseline Intervention P *
1.1.1 Number of episodes of adverse glycaemia (BG >15 or <4 mmol/l) 101 67
Nursing response, % (n) 45 (45) 73 (49) <0.001
Medical response, % (n) 49 (49) 67 (46) 0.011
Types of medical responses, % (n)
Review of BG measurements 41 (41) 63 (42)
Revision of diabetes treatment (adjustment of medications or
insulin and prescription of correctional insulin)
32 (32) 45 (30)
Referral to specialist inpatient diabetes team 19 (19) 16 (11)
1.1.2 Number of episodes of severe hyperglycaemia (BG> 15.0 mmol/l) 85 51
Nursing response, % (n) 47 (40) 75 (38) 0.002
Medical response, % (n) 49 (42) 69 (35) 0.032
1.1.3 Number of episodes of hypoglycaemia (BG <4.0 mmol/l) 24 20
Nursing response, % (n) 50 (12) 70 (14) 0.227
Medical response, % (n) 46 (11) 70 (14) 0.135
BG, blood glucose.
*Fisher’s exact test.
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it was not possible to determine the relative contributions of
the two components to modification of staff action.
Increase in the proportion of adverse glycaemic episodes
with staff action resulted in significant improvements in
glycaemia. A 33% decrease in patient-days with severe
hyperglycaemia (BG >15 mmol/l), and a 65% decrease in
patient-days with mean glucose levels >15 mmol/l were
observed. Other studies have shown similar improvements in
glycaemic control using alternative glucose alert interven-
tions aimed at increasing staff responses. Roman et al. [15]
devised a colour-coded BG monitoring chart that provided
visual alerts for out-of-range BG trends, coupled with a
management algorithm. This intervention resulted in a 41%
decrease in the frequency of prolonged hyperglycaemia (three
consecutive BG measurements >13.9 mmol/l) [15]. Donihi
et al. [24] studied a glycaemic management team who
remotely monitored BG measurements and alerted treating
teams of the occurrence of severe hyperglycaemia (BG >16.7
mmol/l). This approach improved treating team staff
response by 50%, and decreased the occurrence of subse-
quent severe hyperglycaemia by 55% [24]. Our study
supports the evidence that increasing health professional
action (and decreasing clinical inertia) in response to adverse
glycaemia may improve glycaemic control in hospital.
Glucose alert systems in the non-critical care setting can vary
greatly in function and complexity, as evident in a relatively
small number of heterogeneous studies [15,24–28]. A manual
alert system may be a simple colour-coded BG monitoring
chart, whilst an electronic alert system uses point-of-care BG
data and generates computerized alerts when predefined BG
criteria are met. An alert may be generated electively by a user
(e.g. when the user logs on to a computer system or generates a
report) or in real time (e.g. when an alert is generated without
input from the user). The alerts may be based on BG
measurements alone or on integration of various clinical
variables such as age, weight, laboratory results and current
treatment [25], but such systems necessitate fully integrated
hospital electronic clinical information systems. Although
most systems alert the treating staff at the point of care, some
electronic alert systems directly alert a specialist diabetes team.
Two studies have evaluated an electronic alert system that
generated an automated referral and subsequent consultation
by a specialist diabetes team. There was a modest decrease in
meanBG (0.7mmol/l) in one study [26], and a20%decrease in
the proportion of patient-days with mean BG >15 mmol/l in
another [27]. These alert systems require complex integrated
hospital electronic systems, and demand greater resources and
staffing. In contrast, the simple glucose alert system investi-
gated in the present study provides real-time electronic visual
alerts and structured recommendations to the treating staff at
the point of care. This is an example of a less resource-intensive
alert system, which is more likely to be applicable in a wider
variety of hospital settings.
Our glucose alert system did not decrease the incidence of
hypoglycaemia, similar to other systems which alerted the
treating team [15,24]. Hypoglycaemia is less common than
hyperglycaemia; therefore a longer duration of study may be
required to detect improvements in hypoglycaemia. Never-
theless, it is reassuring that this intervention, which intensi-
fied staff responses to hyperglycaemia, did not concomitantly
increase hypoglycaemia. A larger study by Rajendran et al.
[29] showed that a comprehensive diabetes care pathway,
significantly decreased the proportion of patients with severe
hypoglycaemia (BG <3 mmol/l) from 15.4% to 9.7%, but
that intervention was multi-faceted; it included an extensive
education campaign, new subcutaneous insulin prescription
and BG observation charts, as well as increased staffing levels
[29]. Similarly, Rushakoff et al. [28] implemented a com-
prehensive glycaemic management service where a specialist
inpatient diabetes team remotely identified patients with
adverse glycaemia, and provided a consultation note, effec-
tively acting as a glucose alert system. This service was
associated with a 36% decrease in patient-days with hypo-
glycaemia, along with a decrease in hyperglycaemia. These
studies suggest more resources and staffing may be required
to decrease hypoglycaemia [28].
FIG. 2 (a) Patient-days with any blood glucose (BG) value in the severe hyperglycaemia (>15 mmol/l), or critical hyperglycaemia (>20 mmol/l) range.
(b) Patient-days with mean BG >10 or >15 mmol/l. Baseline period represented with filled bars and intervention period represented as open bars.
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A limitation of the present study is its observational
format, which may be more susceptible to a ‘Hawthorne
effect’ on clinical practice because staff were more likely to
take action whilst aware that a clinical study was being
undertaken. Nevertheless the changes in staff responses
observed were associated with a decrease in the number of
hyperglycaemic episodes. This study was of relatively short
duration and thus less susceptible to any influence from
hospital-wide changes in staff or hospital processes.
To fully address the problem of managing diabetes in the
hospital it is important to appreciate and address each step
required to identify and treat adverse glycaemia. Recognizing
clinical inertia and alerting adverse glycaemia to health
professionals is the first step and cornerstone for improving
diabetes care in the hospital. Implementing a practical and
novel glucose alert system, the GAP with glucose-alert-
capable networked BG meters, can address clinical inertia in
the management of inpatients with diabetes in the non-
critical care setting. The glucose alert system improved both
nursing and medical staff responses to adverse glycaemia and
decreased number of episodes of hyperglycaemia. Glucose
alert systems could become important components of larger
hospital-wide intensive management strategies required to
improve the care of persons with diabetes admitted to
hospital.
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3.3 Supplemental material 
Appendix 1: Staff action in response to episodes of hyperglycaemia (BG > 15 mmol/L) 
 
Nursing staff action 
Clinical factor Adjusted OR 95% CI p-value 
Intervention period (vs. baseline) 6.7 2.5, 18.1 <0.001 
Peak BG: (each mmol/L increase) 1.4 1.2, 1.7 <0.001 
Insulin treatment 0.7 0.3, 1.6 0.360 
Surgical admission (vs. medical) 2.6 1.0, 5.7 0.061 
Weekend (vs. weekday) 1.0 0.4, 2.6 0.928 
 
 
Medical staff action 
Clinical factor Adjusted OR 95% CI p-value 
Intervention period (vs. baseline) 4.9 1.9, 12.7 0.001 
Peak BG: (each mmol/L increase) 1.4 1.2, 1.6 <0.001 
Insulin treatment 1.8 0.8, 4.1 0.171 
Surgical unit (vs. medical) 1.5 0.6, 3.4 0.370 
Weekend (vs. weekday) 0.4 0.2, 0.9 0.035 
 
 
Logistic regression models were constructed to determine if improvement in nursing and medical staff action 
were independent of potential confounders. The potential confounders used were selected due its association 
with staff action on statistical analysis and consisted of: 
1) Peak BG (severity of hyperglycaemia) 
2) Insulin treatment (whether insulin treatment was in place at the time of hyperglycaemia) 
3) Admission unit (surgical vs. medical) 






Appendix 2: Staff Survey 
Regarding the Glucose Alert Pathway (GAP)  
1) To what extent do you agree or disagree with the following statements? 
 Strongly 
Disagree 
Disagree Neutral Agree 
Strongly 
Agree 
The GAP was easy to follow. ⃝ ⃝ ⃝ ⃝ ⃝ 
The GAP was helpful. ⃝ ⃝ ⃝ ⃝ ⃝ 
The GAP placed excessive demands on my time.  ⃝ ⃝ ⃝ ⃝ ⃝ 
The GAP improved patient safety. ⃝ ⃝ ⃝ ⃝ ⃝ 
Overall, I am happy with the GAP. ⃝ ⃝ ⃝ ⃝ ⃝ 
 




Regarding the Networked Blood Glucose Meters (NGBM) 
1) To what extent do you agree or disagree with the following statements? 
 Strongly 
Disagree 
Disagree Neutral Agree 
Strongly 
Agree 
The NBGM were easy to use. ⃝ ⃝ ⃝ ⃝ ⃝ 
Out-of-range indicators were helpful. ⃝ ⃝ ⃝ ⃝ ⃝ 
The NBGM placed excessive demands on my time. ⃝ ⃝ ⃝ ⃝ ⃝ 
The NGBM improved patient safety. ⃝ ⃝ ⃝ ⃝ ⃝ 
Overall, I am happy to continue using the NBGM. ⃝ ⃝ ⃝ ⃝ ⃝ 
 













Disagree or Strongly 
Disagree 
Neutral 
Agree or Strongly 
Agree 
The GAP was easy to follow. 1 (4%) 1 (4%) 22 (92%) 
The GAP was helpful. 0 4 (17%) 20 (83%) 
The GAP placed excessive demands on my time.  11 (50%) 6 (27%) 5 (23%) 
The GAP improved patient safety. 0  4 (17%) 20 (83%) 
Overall, I am happy with the GAP. 0 4 (17%) 19 (83%) 
The NBGM were easy to use. 2 (8%) 2 (8%) 20 (83%) 
Out-of-range indicators were helpful. 0 6 (25%) 18 (75%) 
The NBGM placed excessive demands on my time. 12 (50%) 6 (17%) 6 (24%) 
The NGBM improved patient safety. 4 (17%) 6 (25%) 14 (58%) 






4. CHAPTER FOUR:  
GLUCOMETRIC BENCHMARKING IN AN AUSTRALIAN HOSPITAL ENABLED BY 
NETWORKED GLUCOSE METER TECHNOLOGY 
4.1 Introduction 
Glucometric assessment, reporting and benchmarking are important strategies in improving inpatient glucose control 
but this approach has been deficient in Australian hospitals due to a lack of automated technologies to capture glucose 
data. As part of the RAPIDS cluster randomised trial, we implemented networked glucose meters on eight medical and 
surgical wards, representative of patients admitted to the Royal Melbourne Hospital. Applying well-established 
glucometric reporting techniques, we provided first ever detailed glucometric analysis in noncritical care wards at an 
Australian hospital. This study enabled assessment of baseline glycaemia for the RAPIDS study. 
 
4.2 Manuscript 
The work described in this chapter has been published in the peer-reviewed journal, Medical Journal of Australia. The 
citation is: 
 
M. Kyi, P.G. Colman, K.A. Marley, L.M. Rowan, P.R. Wraight, S. Fourlanos, Glucometric benchmarking in an 
Australian hospital enabled by networked glucose meter technology, Medical Journal of Australia, 2019;211(4):175-
180.  DOI: 10.5694/mja2.50247 
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Glucometric benchmarking in an Australian hospital 
enabled by networked glucose meter technology
Mervyn Kyi1,2 , Peter G Colman1, Lois M Rowan1, Katie A Marley1, Paul R Wraight1, Spiros Fourlanos1,2
Diabetes is emerging as one of the greatest health care chal-lenges of the 21st century. In 2014, more than 1.2 million Australians had been diagnosed with diabetes,1 and the 
number was expected to double during the following decade.2 
Diabetes increases the likelihood of needing hospital care;3 25–
30% of inpatients have diabetes,4 and a further 5–10% have un-
diagnosed diabetes.5,6 The direct and indirect costs of diabetes 
in Australian adults were nearly $11 billion in 2005;7 inpatient 
care is a major contributor to the overall costs of diabetes in the 
United States.8
Although the importance of long term glycaemic control is rec-
ognised, that of acute glycaemic control during a hospital stay 
is often underappreciated. Acute hyperglycaemia in hospital is 
linked with hospital- acquired infections because of the associ-
ated neutrophil and macrophage dysfunction, as well as with 
cardiovascular and renal disease secondary to pro- thrombotic 
changes, osmotic diuresis, and endothelial dysfunction.9,10 
Similarly, acute hypoglycaemia in hospital can lead to neuro-
glycopenia, causing seizures, falls, and neurological injury, as 
well as cardiac ischaemia and arrhythmia.11 Adverse glycaemia 
is a term used to describe both hyperglycaemia and hypogly-
caemia; both are associated with pathophysiology and adverse 
clinical outcomes,12 and optimising glycaemic control in hospital 
patients is essential.13 Glucometric reporting and benchmarking 
standards for optimal diabetes care, however, have not been 
standardised in Australian hospitals.
The National Safety and Quality Health Service (NSQHS) has 
published standards for Australian hospitals for reporting and 
benchmarking important adverse outcomes in hospital, includ-
ing staphylococcal blood stream infections, falls, and pressure 
injuries.14 A key recommendation in the Australian National 
Diabetes Strategy 2016–202015 was that the NSQHS standards 
be expanded to encompass diabetes care for hospital patients. 
Auditing and benchmarking of glucose control in inpatients is 
receiving increasing attention around the world,16 and hospital 
glucometrics have been developed for systematically analysing 
and reporting inpatient glucose data17 and assessing diabetes 
management programs.18
Efficient acquisition of point- of- care blood glucose (BG) mea-
surements is essential for glucometric assessment, but has been 
limited in Australia by the lack of automated technologies for 
capturing patient- level glucose data. Glucose monitoring in 
Australian hospitals typically involves nurses performing bed-
side capillary glucose measurements with point- of- care glucose 
meters and manually recording the results on paper observation 
charts or in electronic clinical records. Although data from glu-
cose meters can be downloaded manually, BG measurements are 
not linked with unique patient identifiers, making patient- level 
analysis impossible. Investigations of inpatient glucose control 
have therefore required labour- intensive manual auditing of 
clinical records.19
Networked glucose meters have recently become available in 
Australia, enabling electronic capture of patient BG measure-
ments, with the data readily available in searchable databases. 
Networked meters have facilitated hospital- wide glycaemic 
management programs18 and inter- hospital benchmarking of 
glucose control in the US.20 As this approach will be important 
1 Royal Melbourne Hospital, Melbourne, VIC. 2 University of Melbourne, Melbourne, VIC. mervyn.kyi@mh.org.au ▪ doi: 10.5694/mja2.50247  
Abstract
Objective: To assess glucometric outcomes and to estimate the 
incidence of hypo- and hyperglycaemia among non- critical care 
inpatients in a major Australian hospital.
Design, setting and participants: A prospective 10- week 
observational study (7 March – 22 May 2016) of consecutive 
inpatients with diabetes or newly detected hyperglycaemia 
admitted to eight medical and surgical wards at the Royal 
Melbourne Hospital. Point- of- care blood glucose (BG) data were 
collected with networked glucose meters.
Main outcome measures: Glycaemic control, as assessed with 
three glucometric models (by population, by patient, by patient- 
day); incidence of adverse glycaemic days (AGDs; patient- days with 
BG levels below 4 mmol/L or above 15 mmol/L).
Results: During the study period, there were 465 consecutive 
admissions of 441 patients with diabetes or newly detected 
hyperglycaemia, and 9817 BG measurements over 2953 patient- 
days. The mean patient- day BG level was 9.5 mmol/L  
(SD, 3.3 mmol/L). The incidence of hyperglycaemia was higher than 
for a United States hospital benchmark (patient- days with mean BG 
level above 10 mmol/L, 37% v 32), and that of hypoglycaemia lower 
(proportion of patient- days with mean BG level below 3.9 mmol/L, 
4.1% v 6.1%). There were 260 (95% CI, 245–277) AGDs per 1000 
patient- days; the incidence was higher in medical than surgical 
ward patients (290 [CI, 270–310] v 206 [CI, 181–230] per 1000 
patient- days). 604 AGDs (79%) were linked with 116 patients (25%). 
Episodes of hyperglycaemia (BG above 15 mmol/L) were more 
frequent before lunch, dinner, and bedtime; 94 of 187 episodes of 
hypoglycaemia (BG below 4 mmol/L) occurred between 11 pm and 
8 am.
Discussion: Glucometric analysis supported by networked glucose 
meter technology provides detailed inpatient data that could enable 
local benchmarking for promoting safe diabetes care in Australian 
hospitals.
The known: Despite the importance of glucose control for people 
admitted to hospital, inpatient glucose levels have not been 
systematically audited or benchmarked in Australia.
The new: We report the first detailed glucometric analysis for 
inpatients in a major Australian hospital, an analysis facilitated by 
networked glucose meter technology. For 260 of every 1000 
patient- days, blood glucose levels were outside the safe range for 
hospital patients. The incidence of hyperglycaemia was higher and 
that of hypoglycaemia lower than in an American hospital benchmark.
The implications: Glucometric benchmarking in Australian 

















for establishing standards of diabetes care in Australian hospi-
tals, we undertook detailed glucometric assessments of consecu-
tive inpatients at a major metropolitan hospital, with the aim of 
reporting glucometric outcomes and the incidence of hypo- and 
hyperglycaemia.
Methods
We undertook an observational study in the non- critical care 
wards of a tertiary referral hospital, the Royal Melbourne 
Hospital. We installed thirty networked blood glucose meters 
(StatStrip, Australasian Medical and Scientific [AMSL]) in eight 
wards during January 2016; the installation was accompanied by 
a comprehensive staff education program. The meters were con-
nected to the hospital information system and the Health Level 
7: Admission, Discharge and Transfer (HL7- ADT) messaging 
system for instant transfer of patient information and glucose 
data. The patient unique record number and time of measure-
ment were recorded with each point- of- care BG measurement, 
allowing analysis of patient- level glucose data.
Inpatient diabetes care in our hospital is primarily the respon-
sibility of the medical officers of the admitting unit; a diabetes 
referrals team is available for consultations on a formal referral 
basis. Patients are treated with various combinations of glucose- 
lowering medications and insulin as appropriate. At the time of 
the study, the hospital had guidelines for inpatient diabetes man-
agement, but no dedicated insulin prescription charts or order 
sets. Patients with diabetes routinely had four capillary BG meas-
urements each day (before each meal and before going to bed).
Participants
We included consecutive inpatients with pre- existing diabetes 
or newly detected hyperglycaemia (patients with random capil-
lary BG levels exceeding 11.1 mmol/L but without a history of 
diabetes) admitted to a study ward during the 10- week study 
period (7 March – 22 May 2016). The eight study wards included 
two general medical, two general surgical, and single cardiol-
ogy, neurology, neurosurgery, and orthopaedic surgery wards (a 
total of 220 beds, or 50% of all acute non- critical care beds); the 
patients were thus representative of the non- critical care hospital 
population. We excluded patients hospitalised for less than 24 
hours and those receiving palliative care. Patients were identi-
fied and included prospectively at admission, and patient- and 
admission- related data were extracted from progress notes, dis-
charge summaries, and pathology systems after their discharge.
Glucometric outcomes
We analysed point- of- care BG measurements for each patient 
from ward admission until discharge. We excluded BG measure-
ments after admission day 14 (to avoid skewing by data from the 
few patients with prolonged hospital stays), BG measurements 
during intensive care admissions or intravenous insulin infu-
sions, and closely repeated measurements following episodes 
of hypoglycaemia or hyperglycaemia, as previously described.21
We assessed glycaemic control with the glucometric models de-
scribed by Goldberg and colleagues:17
• by population: all BG measurements for all patients were in-
cluded and equally weighted;
• by patient stay: all BG measurements during the hospital stay 
of a patient were aggregated and weighted equally, irrespec-
tive of length of stay;
1 Characteristics of the 441 patients with pre- existing diabetes 
or newly detected hyperglycaemia admitted to the eight 
study wards
Characteristics: patients
Total number of patients 441
Age (years), mean (SD) 70 (15)
Sex (men) 247 (56%)
Modified Charlson comorbidity score,* median (IQR) 2 (0–3)
Diabetes type
Type 2 diabetes 383 (87%)
Type 1 diabetes 19 (4%)
Other (including pancreatogenic and steroid- induced) 15 (3%)
Newly detected hyperglycaemia 24 (5%)
Diabetes treatment prior to admission
Diet only 99 (23%)
Glucose- lowering medications only† 212 (48%)
Insulin 130 (29%)
Glycated haemoglobin (HbA1c) (mmol/mol), median (IQR) 54 (45–65)





Missing data 10 (2%)
Characteristics: admissions
Total number of admissions 465
Admission to medical unit 293 (63%)
General medicine 117 (25%)
Cardiology 71 (15%)
Neurology and stroke 49 (11%)
Respiratory 21 (4%)
Gastroenterology 22 (5%)
Other medical 13 (3%)
Surgical unit 172 (37%)
General surgery 70 (15%)
Neurosurgery 49 (11%)
Orthopaedic and trauma 47 (10%)
Other surgical 6 (1%)
Elective admission 59 (13%)
Length of stay (days), median (IQR) 5 (3–9)
Insulin treatment during hospital admission
No insulin 216 (46%)
Basal (with or without prandial insulin) 105 (23%)
Pre- mixed insulin 59 (13%)
Supplemental insulin only 85 (18%)
Glucocorticoid treatment‡ 74 (16%)
Managed by inpatient diabetes team 48 (10%)
IQR = interquartile range; SD = standard deviation. * Items related to diabetes excluded. 
† Including glucagon- like peptide- 1 agonists. ‡ Treatment with glucocorticoid medications 
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• by patient-day: BG measurements were grouped by each cal-
endar day for each patient, and the key glucometric measure 
is the patient-day mean glucose level (mean glucose measure-
ment per patient per calendar day).
We compared the glucometric outcomes with a US benchmark 
based on all BG measurements for the more than 2.4 million peo-
ple admitted to 635 hospitals during the 2012 calendar year,20 
and with United Kingdom National Diabetes Inpatient Audit 
(NaDIA) data for 15 774 people with diabetes admitted to 209 
hospitals during a single day in 2016.16
In addition, we evaluated a novel measure of inpatient glu-
cose control: the adverse glycaemic day (AGD), defined as a 
patient- day for which the BG level was below 4.0 mmol/L or 
above 15.0 mmol/L, extremes that should be avoided in hospi-
tal patients.22 The incidence of AGDs (per 1000 patient- days) is 
reported, and is the converse of the “good diabetes day” (patient- 
day without hypoglycaemia and no more than one measurement 
exceeding 11 mmol/L) used by NaDIA.16 We compared AGD 
incidence for medical and surgical patients, and evaluated the 
temporal distribution of hypoglycaemia or severe hyperglycae-
mia across the day. Differences between groups were assessed in 
non- parametric tests, Fisher exact tests, or χ2 tests, conducted in 
Minitab 17.2.1 (Minitab).
Ethics approval
The investigation was approved by the Melbourne Health 
Human Research Ethics Committee (reference, 2015.126), with a 
waiver of the requirement for individual patient consent.
Results
During the 10- week study period, there were 465 consecutive 
admissions of 441 patients with diabetes or newly detected hy-
perglycaemia; 22 people were admitted twice, one person was 
admitted three times. Most patients had type 2 diabetes (383, 
87%); 130 (29%) had been treated with insulin prior to admis-
sion. Patients were treated with insulin during 249 admissions 
(54%) and with glucocorticoid medications during 74 admissions 
(16%). The median length of hospital stay was 5 days (interquar-
tile range, 3–9 days) (Box 1).
Primary glucometric outcomes
A total of 9817 BG measurements were made over 2953 patient- 
days; the mean number of BG observations was 21 (standard 
deviation [SD], 16) per patient stay, and 3.3 (SD, 1.7) per patient- 
day. A total of 394 patients (85%) had at least one measurement 
exceeding 10 mmol/L and 206 (44%) had at least one exceeding 
15 mmol/L during their stay; 75 people (16%) had at least one 
episode of hypoglycaemia (BG < 4 mmol/L) and 27 (5.8%) epi-
sodes of severe hypoglycaemia (BG < 3 mmol/L). The mean BG 
level by patient stay was 9.5 mmol/L (SD, 2.8 mmol/L) (Box 2).
In the patient- day analysis, the mean patient- day glucose level 
was 9.5 mmol/L (SD, 3.3 mmol/L). The mean BG level exceeded 
10 mmol/L for 1083 (37%) and 15 mmol/L for 216 patient- days 
(7.3%); hypoglycaemia and severe hypoglycaemia were respec-
tively recorded for 136 (4.6%) and 38 (1.3%) patient- days (Box 2).
Adverse glucometric days
The overall incidence of AGDs was 260 per 1000 patient- days 
(95% confidence interval [CI], 245–277 per 1000 patient- days); 
of the 769 AGDs, 633 (82%) were related to hyperglycaemia, 113 
(15%) to hypoglycaemia, and 23 (3%) to both. There were no 
AGDs for half the patient admissions (228 of 465); the 121 pa-
tients (26%) with one or two AGDs accounted for 165 (21%) of all 
AGDs, while the 116 patients (25%) who had three or more AGDs 
accounted for 604 (79%). AGDs were more frequent among medi-
cal than surgical ward patients (290 [95% CI, 270–310] v 205 [95% 
CI, 181–230] AGDs per 1000 patient- days) (Box 3, A).
The patient- day mean BG level was also higher for medical than 
surgical patients (9.7 mmol/L [SD, 3.5 mmol/L] v. 9.2 mmol/L 
[SD, 3.0 mmol/L] (Box 3, B). The median number of comorbid 
conditions was higher for medical than surgical patients, and 
the distribution of estimated glomerular filtration rates at ad-
mission was shifted to lower values; glucocorticoid treatment 
during admission was more frequent among medical ward pa-
tients (20% v 9%) (Box 4).
Diurnal distribution of episodes of hypo- and 
hyperglycaemia
Hyperglycaemia was most frequent during the day, with three 
peaks before lunch, dinner, and bedtime, coinciding with three 
2 Glucometric data for 441 patients (465 admissions) with pre- existing diabetes or newly detected hyperglycaemia admitted to the 
eight study wards
Model
By population By patient stay By patient- day
Number of samples 9817 465 2953
Blood glucose observations per unit, mean (SD) 9817 21 (16) 3.3 (1.7)
Blood glucose level (mmol/L), mean (SD) 9.9 (4.3) 9.5 (2.8) 9.5 (3.3)
Mean blood glucose level > 10 mmol/L NA 171 (37%) 1083 (37%)
Mean blood glucose level > 15 mmol/L NA 27 (5.8%) 216 (7.3%)
Any measurement < 4 mmol/L 187 (1.9%) 75 (16%) 136 (4.6%)
Any measurement < 3 mmol/L 47 (0.5%) 27 (5.8%) 38 (1.3%)
Any measurement > 10 mmol/L 3945 (40%) 394 (85%) 1672 (57%)
Any measurement > 15 mmol/L 1254 (13%) 206 (44%) 656 (22%)
Adverse glycaemia (< 4 mmol/L or > 15 mmol/L) 1441 (15%) 237 (51%) 769 (26%)
















of the peak times for BG measurements. Hypoglycaemia was 
most frequent overnight, before breakfast, and before dinner 
(Box 5). BG measurements were performed between 11 pm and 
8 am on 2217 (75%) of patient- days; 94 of 187 hypoglycaemic epi-
sodes (50%) were during this period.
Discussion
Benchmarking of key hospital clinical outcomes is essential for 
improving the quality of care and patient safety. We anticipate 
that our detailed study of glucometric outcomes in an Australian 
hospital will initiate a systematic approach to auditing and 
benchmarking glycaemic control in Australia.
Our patient- day mean glucose level was marginally higher than 
for the US hospital benchmark20 (9.5 mmol/L v 9.3 mmol/L); the in-
cidence of hyperglycaemia was higher (37% v 32%), but that of hy-
poglycaemia lower (4.1% v 6.1%) in our sample (Box 6). The patients 
in the British NaDIA had similar characteristics to our patients 
(90% with type 2 diabetes, 29% treated with insulin prior to ad-
mission);16 the incidence of hypoglycaemia was, however, lower in 
our group: BG level under 4 mmol/L, 16% v 20%; BG level 
below 3 mmol/L, 5.8% v 8.4%. As NaDIA does not collect 
detailed glucometric data, comparing the incidence of hy-
perglycaemia with our findings was not possible.
Comparisons with the American benchmark may be 
limited by differences in patient selection and hospital 
management practices. The US benchmarking study, 
despite comprehensive glucose data, did not include 
patient- level clinical information,20 so it was not possible 
to ascertain whether the characteristics of the Australian 
and American cohorts were similar. We included pa-
tients with diabetes or newly detected hyperglycaemia, 
whereas the US benchmarking study included all pa-
tients whose blood glucose levels were monitored, in-
cluding for reasons unrelated to diabetes. Further, we 
did not include all patients with diabetes in our study, 
excluding, for example, those admitted as nephrology 
or cardiothoracic surgery patients. These differences 
may restrict the direct comparison of glucose outcomes. 
Further, like most Australian hospitals, our hospital 
has not adopted basal–bolus insulin treatment for all 
inpatients with diabetes, an approach that is widely 
promoted in the US. The incidence of hyperglycaemia 
among our patients was similar to that found by a study 
in western Sydney,19 but the glucometric outcomes in 
Australian hospitals that regularly employ basal–bolus 
insulin treatment23,24 may be more comparable with 
those of American hospitals. In the absence of stan-
dardised glucometric analyses by Australian hospitals, 
this question remains open, but we have shown that 
glucometric analysis and benchmarking is possible in an 
Australian hospital.
3 Glycaemic control in patients admitted to medical and surgical units. A. Patient- days with any blood glucose measurement below 
4 mmol/L or above 15 mmol/L), with 95% confidence intervals. B. Distribution of patient- day mean blood glucose level 
measurements
A B






Number of patients 282 159
Age (years), mean (SD) 72 (15) 68 (14) 0.008
Sex (men) 155 (55%) 92 (58%) 0.62
Modified Charlson comorbidity score,† 
median (IQR)
2 (1–4) 1 (0–2) < 0.001
Patients with type 2 diabetes 246 (87%) 137 (86%) 0.77
Insulin treatment prior to admission 89 (32%) 41 (26%) 0.23
Glycated haemoglobin (HbA1c) level  
(mmol/mol), median (IQR)
54 (45–67) 52 (44–61) 0.12
Estimated glomerular filtration rate  
(mL/min/1.73 m2) (admission)
< 0.001
≤ 30 39 (14%) 9 (6%)
31–59 98 (36%) 41 (26%)
60–89 88 (32%) 51 (33%)
≥ 90 49 (18%) 55 (35%)
Glucocorticoid treatment‡ 55 (20%) 14 (9%) 0.002
Managed by inpatient diabetes team 26 (9%) 20 (13%) 0.33
IQR = interquartile range; SD = standard deviation. * Kruskal–Wallis test for continuous variables, 
Fisher exact or χ2 tests for categorical variables. † Items related to diabetes excluded. ‡ Treatment 
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Optimal glycaemic management requires a balance between 
reducing hyperglycaemia and avoiding hypoglycaemia, and 
a complete glucometric analysis therefore concurrently as-
sesses and reports both conditions. The traditional glucometric 
outcome of patient- day mean BG level does not reflect the two ex-
tremes; further, a lower mean BG level may not reflect safer gly-
caemic control if the hospital rate of hypoglycaemia is also high. 
Accordingly, the AGD, encompassing both hyperglycaemia and 
hypoglycaemia, could become an important index of glycaemic 
control and a useful concept for educating health professionals 
about unsafe glycaemia in hospital patients. Guidelines for inpa-
tients recommend avoiding BG levels below 4 mmol/L or above 
10 mmol/L, but the level of the upper threshold depends on the 
clinical context.13 We chose 15 mmol/L because it pragmatically 
defined an unsafe hyperglycaemic extreme that should gen-
erally be avoided, regardless of clinical context, but does not 
require aggressive treatment that could increase the risk of hy-
poglycaemia. The impact of hospital diabetes care quality im-
provement programs can be assessed with the AGD concept; a 
recent cluster randomised trial found that AGD incidence, as a 
primary outcome measure, was reduced by an early intervention 
model of inpatient diabetes care.25
The incidence rate of 260 AGDs per 1000 patient- days indicates 
excursions of BG levels into the unsafe extreme ranges for a sub-
stantial proportion of patient- days. The incidence was higher for 
medical than surgical patients, perhaps reflecting greater com-
plexity of their diabetes and hospital treatment. The peak peri-
ods for hyperglycaemia were before lunch, dinner and bedtime, 
suggesting that the prandial insulin regimen was inadequate; 
more standardised insulin treatment at meal times could re-
duce the incidence of hyperglycaemia. In contrast, hypoglycae-
mia was more frequent overnight, as also reported by another 
study.26 This suggests that insulin and sulphonylurea treatment 
should be employed at night with caution, and that carbohydrate 
snacks at bedtime might be helpful, especially for people with 
risk factors for hypoglycaemia. Further, as one- quarter of pa-
tients contributed 81% of AGDs, management strategies should 
5 The diurnal distribution of blood glucose measurements (A), 
blood glucose measurements exceeding 15 mmol/L (B), and 




* Meals are routinely provided at 8 am (breakfast), noon (lunch), and 5 pm (dinner); bed-
time is usually at 9 pm. ◆
6 Glucometric data (patient- day model) for our sample of 






Number of patient admissions 465 2.4 million
Number of patient- days 2953 about 
17 million
Blood glucose (mmol/L),  
mean (SD)
9.5 (3.3) 9.3 (0.8) 0.001
Hyperglycaemia
Mean glucose > 10.0 mmol/L 
(> 180 mg/dL), patient- days
1083 (37%) 32.3% < 0.001
Mean glucose > 13.9 mmol/L 
(> 250 mg/dL), patient- days
314 (11%) 7.4% < 0.001
Mean glucose > 16.7 mmol/L 
(> 300 mg/dL), patient- days
110 (3.7%) 2.3% < 0.001
Hypoglycaemia
Glucose < 3.9 mmol/L  
(< 70 mg/dL), patient- days
120 (4.1%) 6.1% < 0.001
Glucose < 2.8 mmol/L 
(< 50 mg/dL), patient- days
26 (0.9%) 1.7% < 0.001
SD = standard deviation. * Consecutive patients with diabetes admitted to non- critical 
care wards over 10 weeks. † Consecutive patients admitted to non- critical care wards 
(635 hospitals) over one calendar year. ‡ Kruskal–Wallis test for continuous variables, 
















 1 Australian Institute of Health and Welfare. 
Australia’s health 2016 (Cat. No. AUS 199; 
Australia’s Health series no. 15). Canberra: AIHW, 
2016.
 2 Magliano DJ, Peeters A, Vos T, et al. Projecting 
the burden of diabetes in Australia: what is 
the size of the matter? Aust N Z J Public Health 
2009; 33: 540–543.
 3 Jiang HJ, Stryer D, Friedman B, et al. Multiple 
hospitalizations for patients with diabetes. 
Diabetes Care 2003; 26: 1421–1426.
 4 Bach LA, Ekinci EI, Engler D, et al. The high 
burden of inpatient diabetes mellitus: the 
Melbourne Public Hospitals Diabetes Inpatient 
Audit. Med J Aust 2014; 201: 334–338. https :// 
www.mja.com.au/journ al/2014/201/6/high-
burden-inpat ient-diabe tes-melli tus-melbo 
urne-public-hospi tals-diabetes.
 5 Nanayakkara N, Nguyen H, Churilov L, et 
al. Inpatient HbA1c testing: a prospective 
observational study. BMJ Open Diabetes Res 
Care 2015; 3: e000113.
 6 Valentine NA, Alhawassi TM, Roberts GW, 
et al. Detecting undiagnosed diabetes using 
glycated haemoglobin: an automated screening 
test in hospitalised patients. Med J Aust 2011; 
194: 160–164. https ://www.mja.com.au/journ 
al/2011/194/4/detec ting-undia gnosed-diabe tes-
using-glyca ted-haemo globin-autom ated-scree 
ning.
 7 Lee CM, Colagiuri R, Magliano DJ, et al. The cost 
of diabetes in adults in Australia. Diabetes Res 
Clin Pract 2013; 99: 385–390.
 8 American Diabetes Association. Economic costs 
of diabetes in the US in 2017. Diabetes Care 2018; 
41: 917–928.
 9 Clement S, Braithwaite SS, Magee MF, et al. 
Management of diabetes and hyperglycemia in 
hospitals. Diabetes Care 2004; 27: 553–591.
 10 Umpierrez GE, Isaacs SD, Bazargan N, et al. 
Hyperglycemia: an independent marker 
of in- hospital mortality in patients with 
undiagnosed diabetes. J Clin Endocrinol Metab 
2002; 87: 978–982.
 11 Brutsaert E, Carey M, Zonszein J. The clinical 
impact of inpatient hypoglycemia. J Diabetes 
Complications 2014; 28: 565–572.
 12 Kyi M, Wraight PR, Rowan LM, et al. Glucose alert 
system improves health professional responses 
to adverse glycaemia and reduces the number 
of hyperglycaemic episodes in non- critical care 
inpatients. Diabet Med 2018; 35: 816–823.
 13 Australian Diabetes Society. Guidelines for 
routine glucose control in hospitals. 2012. http://
diabe tesso ciety.com.au/docum ents/ADSGu ideli 
nesfo rRout ineGl ucose Contr olinH ospit alFin 
al2012_000.pdf (viewed Dec 2018).
 14 Australian Commission on Safety and Quality in 
Health Care. National safety and quality health 
service standards: guide for hospitals. Second 
edition. Sydney: ASCQHC, 2017. https ://www.
safet yandq uality.gov.au/wp-conte nt/uploa 
ds/2017/12/Natio nal-Safety-and-Quali ty-Health-
Servi ce-Stand ards-Guide-for-Hospi tals.pdf 
(viewed Dec 2018).
 15 Australian Department of Health. Australian 
National Diabetes Strategy 2016–2020. Updated 
12 Jan 2018. http://www.health.gov.au/inter net/
main/publi shing.nsf/conte nt/nds-2016-2020 
(viewed Dec 2018).
 16 NHS Digital. National Diabetes Inpatient Audit 
(NaDIA) 2016. Mar 2017. http://www.digit al.nhs.
uk/pubs/nadia 2016 (viewed Dec 2018).
 17 Goldberg PA, Bozzo JE, Thomas PG, et al. 
“Glucometrics”: assessing the quality of 
inpatient glucose management. Diabetes 
Technol Ther 2006; 8: 560–569.
 18 Mendez CE, Ata A, Rourke JM, et al. Daily 
Inpatient Glycemic Survey (DINGS): a process to 
remotely identify and assist in the management 
of hospitalized patients with diabetes and 
hyperglycemia. Endocr Pract 2015; 21: 927–935.
 19 Cheung NW, Cinnadaio N, O’Neill A, et al. 
Implementation of a dedicated hospital 
subcutaneous insulin prescription chart: effect 
on glycaemic control. Diabetes Res Clin Pract 
2011; 92: 337–341.
 20 Bersoux S, Cook CB, Kongable GL, et al. 
Benchmarking glycemic control in US hospitals. 
Endocr Pract 2014; 20: 876–883.
 21 Weinberg ME, Bacchetti P, Rushakoff RJ. 
Frequently repeated glucose measurements 
overestimate the incidence of inpatient 
hypoglycemia and severe hyperglycemia. 
J Diabetes Sci Technol 2010; 4: 577–582.
 22 Wagstaff AE, Cheung NW. Diabetes and 
hyperglycemia in the critical care setting: has the 
evidence for glycemic control vanished? (Or ... is 
going away?). Curr Diab Rep 2014; 14: 444.
 23 Perera NJ, Harding AJ, Constantino MI, et al. 
Triple- B (basal- bolus- booster) subcutaneous 
insulin regimen: a pragmatic approach to 
managing hospital inpatient hyperglycaemia. 
Practical Diabetes 2011; 28: 266–269.
 24 Roberts GW, Aguilar-Loza N, Esterman A, et al. 
Basal–bolus insulin versus sliding- scale insulin 
for inpatient glycaemic control: a clinical practice 
comparison. Med J Aust 2012; 196: 266–269. 
https ://www.mja.com.au/journ al/2012/196/4/
basal-bolus-insul in-versus-slidi ng-scale-insul 
in-inpat ient-glyca emic-control.
 25 Kyi M, Colman PG, Wraight PR, et al. Early 
intervention for diabetes in medical and 
surgical inpatients decreases hyperglycemia 
and hospital- acquired infections: a cluster 
randomized trial. Diabetes Care 2019; 42: 
832–840.
 26 Rajendran R, Kerry C, Rayman G, et al. Temporal 
patterns of hypoglycaemia and burden of 
sulfonylurea- related hypoglycaemia in UK 
hospitals: a retrospective multicentre audit of 
hospitalised patients with diabetes. BMJ Open 
2014; 4: e005165. ■
focus on identifying and targeting this subset of individuals at 
greater risk of glycaemic extremes.
Networked glucose meter technology was fundamental to our 
study, as it facilitated the automated collection of complete patient- 
level, point- of- care BG data. Its implementation required mul-
tidisciplinary cooperation between nursing, medical, diabetes 
education, information technology, and biomedical engineering 
teams. Glucometric assessment might be possible without net-
worked meter technology, but it would require more resources, 
and incomplete or inaccurate data would be more likely. Most 
importantly, networked meters contribute to improved glycaemic 
and clinical outcomes by enabling remote surveillance of BG mea-
surements and proactive glycaemic management programs.12,18,25
Conclusion
Auditing and benchmarking BG outcomes in hospital patients is 
essential for improving glycaemic control and ultimately for im-
proving patient outcomes. We undertook a detailed glucometric 
study of consecutive inpatients in an Australian hospital that 
was supported by point- of- care networked glucose meter tech-
nology. We propose that AGD incidence is a suitable measure of 
safe glucose control in hospital patients for future benchmark-
ing. With the increasing availability of networked glucose me-
ters, more health services in Australia will be able to implement 
this technology for local auditing and benchmarking of safe dia-
betes care for hospital patients.
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5. CHAPTER FIVE: 
EARLY INTERVENTION FOR DIABETES IN MEDICAL AND SURGICAL 
INPATIENTS: A CLUSTER RANDOMIZED TRIAL (RAPIDS) 
5.1 Introduction 
To overcome clinical inertia and increase diabetes specialist management for noncritical care inpatients, a 
comprehensive early intervention model of diabetes care was developed. Termed “Proactive Inpatient Diabetes 
Service”, this early intervention model of diabetes care comprised three components:  
1) Networked glucose meters enabling remote electronic surveillance of capillary glucose meter 
2) Glucose alert system to increase health professional response to adverse glycaemia and facilitate 
escalation to inpatient diabetes team (chapter 3); 
3) Proactive inpatient diabetes team which identified all patients with diabetes and hyperglycaemia and 
provided proactive model of care, and direct management within 24 hour of admission to hospital 
 
This model was investigated in a prospective cluster randomised trial to address the gap prospective randomised 
evidence on models of inpatient diabetes care. The study was designed to evaluate various levels of outcomes 
including processes of care, glycaemia and clinical outcomes. This study was named Randomised study of a 
Proactive Inpatient Diabetes Service (RAPIDS), and was prospective registered with the Australia New Zealand 
Clinical Trials Registry (ANZCTR).  
 
5.2 Manuscript 
The work presented in this chapter has been published in the peer-reviewed journal Diabetes Care. The citation is: 
 
Mervyn Kyi, Peter G. Colman, Paul R. Wraight, Jane Reid, Alexandra Gorelik, Anna Galligan, Shanal Kumar, 
Lois M. Rowan, Katie A. Marley, Alison J. Nankervis, David M. Russell, Spiros Fourlanos, Early intervention for 
diabetes in medical and surgical inpatients decreases hyperglycemia and hospital-acquired infections: a cluster 
randomized trial, Diabetes Care, 2019, May; 42(5): 832-40 
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Diabetes Association (ADA), publisher of Diabetes Care, is not responsible for any errors or omissions in this 
version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated 
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Objective: To investigate if early electronic identification and bedside management of inpatients with diabetes 
improves glycemic control in non-critical care. 
 
Research Design and methods: We investigated a proactive or early intervention model of care (whereby an 
inpatient diabetes team electronically identified individuals with diabetes and aimed to provide bedside 
management within 24-hours of admission), compared to usual care (a referral-based consultation service). We 
conducted a cluster randomized trial on eight wards, consisting of a 10-week baseline period (all clusters received 
usual care) followed by a 12-week active period (clusters randomized to early intervention or usual care). 
Outcomes were adverse glycemic days (AGD: patient-days with glucose <4or>15mmol/L [<72or>270mg/dL]) and 
adverse patient outcomes.  
 
Results: We included 1002 consecutive adult inpatients with diabetes or new hyperglycemia. More patients 
received specialist diabetes management (92% vs. 15%, p<0.001), and new insulin treatment (57% vs. 34%, 
p=0.001) with early intervention. At the cluster level, incidence of AGD decreased by 24%, from 243 to 186 per 
1000 patient-days in the intervention arm (p<0.001), with no change in the control arm. At the individual level, 
adjusted number of AGD per-person decreased from mean 1.4(sd. 1.6) to 1.0(0.9) days (-28% change, 95%CI -45 
to -11%, p=0.001) in the intervention arm, but did not change in the control arm [1.8(2.0) to 1.5(1.8), -9% change, 
CI -25 to +6%, p=0.23]. Early intervention reduced overt hyperglycemia (55% decrease in patient-days with mean 
glucose >15mmol/L, p<0.001), and hospital-acquired infections (odds ratio 0.20 [CI 0.07 to 0.58], p=0.003). 
 







Hyperglycemia and hypoglycemia are common events in hospital and are associated with adverse patient 
outcomes (1; 2). Acute hyperglycemia is independently associated with hospital-acquired infections, longer length 
of stay and greater mortality (1; 3). Multiple cellular and physiological mechanisms are implicated, particularly 
neutrophil and endothelial dysfunction, osmotic diuresis and pro-inflammatory changes (4). Treating 
hyperglycemia may improve clinical outcomes in the critical care (5), stroke care (6), and non-critical care settings 
(7). However, aggressive treatment of hyperglycemia can lead to hypoglycemia (7-9), which causes undesirable 
symptoms and adverse outcomes. Thus, a key target of inpatient diabetes care should be to avoid the glycemic 
extremes of both hyperglycemia and hypoglycemia, also described as adverse glycemia (10). Despite published 
guidelines on ideal blood glucose (BG) targets (11-13), glycemic control remains challenging due to multiple 
obstacles, and system-based solutions are needed (14).  
 
As most inpatients with diabetes are managed by hospitalists or parent (admitting) teams, diabetes specialists are 
seldom involved in their care. Many hospitals have implemented specialized inpatient diabetes teams (or glycemic 
management teams) to develop protocols, deliver education programs, and perform clinical audits, in addition to 
directly assisting in diabetes management. These teams usually consist of specialized diabetes nurses and 
diabetologists who provide management advice in response (or reactive) to referrals from the parent team (15-18). 
However, referrals to inpatient diabetes teams may be inconsistent due to clinical inertia (19). 
 
A more proactive model of diabetes care can be delivered by a diabetes team which autonomously provides early 
assessment and management without referral from the admitting team (20). Availability of networked BG meters 
(which electronically capture capillary BG measurements) has enabled remote electronic surveillance of glycemic 
control. Proactive models of care utilizing networked BG meters have demonstrated improved glycemic control in 
observational studies (21-23), but randomized studies are lacking (14). Therefore, we investigated the effect of 
early intervention, using a proactive model of inpatient diabetes care, on glycemic and clinical outcomes in a 
prospective cluster-randomized study.  
 
Methods 
Study design and participants 
Randomized study of a Proactive Inpatient Diabetes Service (RAPIDS) is an open-label, cluster-randomized 
controlled study with a baseline period, conducted over six months at the Royal Melbourne Hospital (tertiary-
referral hospital affiliated with the University of Melbourne). The intervention was implemented at the cluster 
level. Outcomes were assessed at both the cluster and individual levels. 
 
There were eight wards (clusters) involved in the study, comprising four medical wards (cardiology, neurology 
and two general medicine) and four surgical wards (orthopedic surgery, neurosurgery, abdominal surgery and 
emergency surgery).  The two general medical wards contained patients with similar characteristics and can be 
considered as sister (symmetrical) wards, however the remaining six wards had unique parent teams and patient 
characteristics. 
 
We included consecutive adult inpatients admitted over the study period, with pre-existing diabetes or new 




one day length of stay. Individuals admitted with glycemic emergencies, or those admitted under Endocrinology or 
Palliative Care teams were excluded. For individuals who were admitted more than once during the study period, 
only the first admission was included. The study was approved by Melbourne Health Human Research Ethics 
Committee with the waiver of individual consent and registered prospectively with Australian New Zealand 
Clinical Trials Registry (ACTRN12616000265471). 
 
Procedures, randomisation and masking 
Prior to the commencement of the study, we implemented networked BG meters (StatStrip®, Australasian 
Medical and Scientific Limited) on the study wards. These devices have recently become available in Australia, 
and facilitated accurate collection of capillary BG data and remote identification of inpatients with diabetes.  
 
At commencement of the study, and prior to randomisation, there was a 10-week baseline period where all eight 
clusters received usual care. The clusters were then randomized 1:1 into control and intervention arms, stratified 
by type of ward (medical or surgical) using a random number generator by a blinded statistician.  A 12-week 
active period then followed, where the four clusters randomized to the intervention arm received the proactive, 
early management model of care, and the four clusters randomized into the control arm continued with usual care 
(Supplemental figure 1). Treating staff and patients were not masked to the allocation of clusters to intervention or 
control arms.  
 
Usual inpatient diabetes management (usual care) 
Diabetes management is performed primarily by the hospital medical officers of the parent team.  A specialist 
inpatient diabetes team (IDT), consisting of a diabetes nurse and endocrinology fellow supervised by a 
diabetologist, provided a consultation service in response (or reactive) to referrals from the parent unit. Our 
institution had guidelines and protocols on inpatient diabetes management, but did not have insulin order sets or an 
electronic medical record for delivering inpatient care; therefore, written BG observation charts and medication 
orders at the bed-side were used. In accordance with local practice in Australia, United Kingdom and Europe, 
there is no standardized algorithm of discontinuing oral antidiabetic medications and routine prescription of a 
subcutaneous basal-bolus insulin regimen in all individuals with diabetes admitted to hospital.  
 
Early intervention (proactive model of care) 
The specialist IDT identified all consecutive inpatients with diabetes or hyperglycemia, and aimed to provide 
diabetes management within 24 hour of admission, without referral from the parent team. The IDT performed 
electronic surveillance of capillary BG measurements captured by networked BG meters which enabled early 
identification of inpatients with diabetes and ongoing electronic surveillance of glucose control. In addition, a 
structured clinical escalation pathway (Melbourne Glucose Alert Pathway) (10) was implemented on the 
intervention wards to encourage clinical escalation of patients with dysglycemia to the IDT.  
 
Prior to the intervention, the IDT undertook four training modules delivered by a senior diabetologist. Aimed at 
upskilling the team, training modules included insulin initiation guidelines and case-based discussions focussed on 
optimizing glycemic control.  During consultations, the IDT prescribed subcutaneous insulin and glucose lowering 
medications in an individualized manner, aiming to achieve safe glycemic control and avoiding glycemic 




optimized long-term diabetes control by intensifying or de-escalating diabetes treatment at the time of discharge, 
depending on admission HbA1c (24). The IDT regularly interacted with the parent teams’ medical and nursing 
staff providing an opportunity for ward-based education on inpatient diabetes management. A weekly audit 
meeting was led by a senior diabetologist, to discuss patient care and monitor outcomes. The proactive IDT 
operated during weekdays with an on-call endocrinologist available for advice after hours and on weekends.  
During the active period, the same IDT provided proactive care in the intervention wards and consultation service 
in response to referrals (usual care) in the control wards. 
 
Data collection  
A researcher independent of the IDT performed surveillance of capillary BG measurements to identify eligible 
patients. Patient information and clinical outcomes were collected from inpatient progress notes, pathology results 
system, and the patient administration database. Point-of-care BG measurements were collected by networked BG 
meters. BioViewer (© Bio-Asia Diagnostics) data manager was used to obtain BG measurements from day 1 of 
admission until discharge. BG measurements from day 0 were excluded, as glycemic control on the day of 
admission is influenced by treatment prior to admission, or in the emergency department, rather than ward 
management.  BG measurements were excluded after day 14 of admission to avoid skewing of BG data by the few 
individuals with prolonged hospital stay. In addition, we applied the glucometric technique to exclude repeated 
measurements from a single episode of hypo- or hyperglycemia as described by Weinberg et al (25).  
 
Outcomes measures 
The primary outcome was Adverse Glycemic Day (AGD) defined as a patient-day with any BG <4 or >15mmol/L 
(<72 or >270mg/dL). These pragmatic BG cut off points were used to define AGD as the aim of this trial was for 
‘safe’ glycemic control rather than ‘tight’ glycemic control. Although a target random BG <10mmol/L 
(<180mg/dL) is recommended in the non-critical care, this target is not based on strong experimental evidence and 
the target may vary depending on the individual’s comorbidities (13). However, BG >15mmol/l (>270mg/dL) may 
be associated with adverse pathophysiology (4), and should be avoided in most inpatients. Similarly, any degree of 
hypoglycemia (even BG <4mmol/L [<72 mg/dL]) in inpatients with complex comorbidities and concurrent illness 
is undesirable and should be avoided. Therefore, the AGD outcome reflects glycemic extremes that should be 
avoided for safe diabetes management in hospital (26). At the cluster level, the incidence of AGD is reported per 
1000 observed patient-days; and at the individual level, the number of AGD per person is reported. As BG 
measurements were excluded after day 14 of admission, each individual contributed to a maximum of 14 observed 
patient-days.  
 
The pre-specified secondary outcomes were process-of-care measures, glucometric measures, adverse patient 
outcomes, and length of stay. Adverse outcomes were analysed individually and as a composite of five items and 
included: hospital-acquired infections, acute kidney injury, acute myocardial infarct, unplanned critical care 
admission and in-hospital mortality. These outcomes were included as they were commonly associated with poor 
glycemic control (27). Hospital-acquired infection was defined as clinical or microbiological evidence of skin 
wound or surgical site infection, urinary tract infection, bacteremia or pneumonia that developed at least 48 hours 
after admission. Acute kidney injury was defined as rise in serum creatinine by more than 50% from admission, or 




electrocardiogram and a rise in troponin that developed at least 48 hours after admission. The adverse patient 




The primary outcome of AGD was analysed at the cluster level (proportion of the total number of AGD divided by 
the total number of observed days and reported as a rate per 1000 patient-days); and at the individual level (the 
number of AGD per patient). The number of AGD per patient was adjusted for patient covariates (age, gender, 
modified Charlson comorbidity index, creatinine, HbA1c, diabetes type, insulin treatment prior to admission); and 
hospital treatment covariates (number of days observed, admission unit, type of admission, type of ward) as fixed 
effects, and wards (clusters) as random effect using a mixed-effect Poisson regression model (supplemental table 
S1). The adjusted number of AGD per patient was then calculated using the predict function from the regression. 
We expected differences in patient characteristics between control and intervention arms due to enrolling clusters 
with unique clinical services. However, we expected well-matched patient characteristics between baseline and 
active periods within each treatment arm. Therefore, we planned to analyse the outcomes between treatment arms, 
and as a change from baseline within each treatment arm. To enable this analysis, we created four distinct groups 
depending on treatment arm (control vs. intervention) and time period (baseline period vs. active period). The four 
groups (control-baseline period, control-active period, intervention-baseline period, and intervention-active period) 
were used as a factor in the mixed-effect regression model to allow simultaneous comparison between treatment 
arms, and as a change between baseline and active periods within each treatment arm.  
 
Hospital-acquired infections were analysed using a mixed effects logistic regression model adjusting for covariates 
(post-hoc analysis). All analyses were performed using intention-to-treat approach, therefore if an individual 
crossed over treatment arms due to ward transfers, they were analysed in the initial treatment arm that was in place 
when first admitted. If an individual was transferred out of the study wards to a non-study ward in the hospital, 
subsequent BG measurements from the time of transfer were excluded, but clinical outcomes and hospital length 
of stay for the entire hospitalisation were analysed.  
 
This study was designed as a 24-week trial (the feasible duration of the study), recruiting consecutive inpatients. 
The power calculation was performed prospectively and estimated the minimum difference in AGD that can be 
detected, given the expected number of patient recruitment. A previous pilot study showed that the incidence of 
AGD was 300 per 1000 patient-days at our institution (10). On the eight wards, we expected to recruit 600 
individuals during baseline and 600 individual during active periods with a median of 3.5 observed days per 
patient. This entailed 300 patients and 1050 patient-days per treatment arm during the active period. For four 
clusters in each arm, using 0.01 intraclass correlation, and two-sided alpha of 0.05, this study had over 80% power 







There were 1019 unique patient admissions to the eight study wards between March and August 2016. After 
exclusion, the final sample comprised of 1002 individuals equally distributed across the study arms (Figure 1).  
Overall, 87% of the cohort had type 2 diabetes, mean HbA1c 58 (sd 18) mmol/mol [7.5 (1.7)%], and 30% were 
treated with insulin prior to admission. Patients were observed for a median of 4 (IQR: 2 to 8) days and had 3.5 
(1.7) capillary BG measurements per patient-day.  
 
There were differences in patient characteristics between control and intervention arms. Compared to the control 
arm, the intervention arm had a higher proportion of individuals with surgical and emergency admissions. The 
intervention arm had a lower proportion of patients with insulin treatment prior to admission, and a lower mean 
HbA1c (Table 1). However, patient characteristics were well-matched between the baseline and active periods 
within each treatment arm. There were more emergency admissions during the active period compared to the 
baseline period in the intervention arm.   
 
Early identification and management improved process of care outcomes (Figure 2). In the intervention arm, (1) 
the proportion of patients managed by the IDT increased from 8% during the baseline to 92% during the active 
period (p<0.001); (2) the proportion of patients managed within 24 hour of admission increased from 4% to 64%, 
(p<0.001); and (3) insulin treatment in insulin-naïve patients increased from 34% to 57%, (p<0.001). No changes 
were observed in the control arm. 
 
Over the study period, 5447 patient-days were observed. At the cluster level, there was a 24% decrease in the 
incidence of AGD (243 vs. 186 per 1000 patient-days, p<0.001) in the intervention arm with a non-significant 9% 
decrease observed in the control arm (291 vs. 261 per 1000 patient-days, p=0.09).  The decrease in incidence in 
the intervention arm (57 per 1000 patient-days) was significantly higher than decrease in the control arm (30 per 
1000 patient-day), (p=0.004).  
 
At the individual level, the adjusted number of AGD per patient decreased from mean 1.4 (sd 1.6) to 1.0 (0.9) days 
[-28% change, 95%CI (-45 to -11%), p=0.001] in the intervention arm, with a non-significant change in the 
control arm [1.8 (2.0) to 1.5 (1.8) days, -9% change, CI (-25 to +6%), p=0.23] (Table 2). Comparing parallel 
treatment groups during the active period, the number of AGD per patient was 23% lower (CI: 6 to 40%, p=0.008) 
in the intervention arm compared to control arm (supplemental table S1).  Comparison between the two 
symmetrical general medical clusters demonstrated that the cluster randomized to the intervention arm had a 
significant reduction in AGD per patient [2.2(2.3) to 1.4(1.3) days, p=0.010], while the cluster randomized to the 
control arm had no significant change [2.0(2.5) to 2.1(2.6) days, p=0.96)] (Supplementary table S2).  
 
On glucometric analyses, 19060 capillary BG measurements were observed during the study period. The patient-
day mean glucose decreased from 9.4(sd 3.3) to 9.0(2.7) mmol/L [169(59) to 162(49)mg/dL], p=0.003, in the 
intervention arm but remained stable in the control arm, 9.6(3.2) to 9.5(3.2)mmol/L [173(58) to 171(58) mg/dL], 
p=0.235. The proportion of patient-days with mean BG >10 and >15mmol/L (>180 and >270 mg/dL), decreased 
by 14% and 55%, respectively in the intervention arm, with no change in the control arm (Table 2 and Figure 2). 




BG >11mmol/L [198mg/dL]), a United Kingdom metric, (28) increased in the intervention arm (70% to 74%, 
p=0.020), but did not change in the control arm (65% to 66%, p=0.61). There was no change in the incidence of 
hypoglycemia in either of the treatment arms.  
 
The proportion of individuals with hospital-acquired infections decreased from 6.4% to 2.4% (p=0.035) in the 
intervention arm but did not change significantly in the control arm (8.6% to 7.0%, p=0.61). Post-hoc analyses 
using mixed-effect logistic regression adjusting for covariates (supplemental table S3) demonstrated that early 
diabetes management conferred a lower risk of developing hospital-acquired infection (adjusted odds ratio: 0.20 
(95% CI 0.07 to 0.58), p=0.003). Number needed to treat to prevent one hospital-acquired infection was 25. There 
was a strong correlation between number of AGD and hospital-acquired infection (each day increase in AGD 
conferred an odds ratio of 1.35 (95% CI 1.20, 1.51) for hospital-acquired infection). The reduction in infection rate 
remained consistent on subgroup analysis of only individuals with type 2 diabetes (supplemental table S4-S7). 
There was a higher baseline incidence of infections (hence greater reduction in infections) in medical compared to 
surgical patients (supplementary table S8). There were no differences in the remaining individual or composite 
clinical outcomes in either arm (Table 2).  
 
Conclusions 
RAPIDS is the first randomized trial to investigate the effect of comprehensive early intervention for all 
consecutive patients with diabetes to non-critical care wards, consisting of early electronic identification and 
bedside specialist IDT management. The RAPIDS study achieved its primary outcome of reducing adverse 
glycemic days, with no concomitant increase in hypoglycemia. 
 
This study used the primary outcome of AGD (with a more liberal glycemic target), as an index of safe glycemic 
control in hospital, to achieve the balance of decreasing overt hyperglycemia, whilst minimising hypoglycemia.  
This is similar to the concept of ‘good diabetes day’ used in the annual National Inpatient Diabetes Audit in the 
United Kingdom (28). Although there is no published data investigating AGD and clinical outcomes, we propose 
AGD is a clinical index of both hyperglycemia and hypoglycemia events, as well as being a tangible concept for 
educating health professionals about safe glycemic control in hospital.   
 
Early identification and management for diabetes decreased the number of AGD per patient by 28% in the 
intervention arm. There was a slight (but non-significant) 9% decrease in the control arm possibly related to 
contamination or a Hawthorne effect, but even after adjusting for this change, the intervention arm had a 23% 
lower number of AGD per person compared to control arm. In addition to AGD outcomes, traditional glucometric 
analyses also demonstrated improved glycemic control. With early identification and management, patient-day 
glucose was lower in both the mean (decreased by 0.4mmol/L [7.2mg/dL]), and the variance (standard deviation 
decreased by 0.6mmol/L [10.8mg/dL]). There was a 55% decrease in patient-days with mean glucose >15mmol/L. 
These findings are comparable to an observational study by Seheult et al, where a proactive diabetes team 
achieved 0.13mmol/L(2.3mg/dL) decrease in patient-day mean glucose and a 20% reduction in patient-days with 
mean glucose >15mmol/L (22). Similarly, Rushakoff et al, provided a virtual glucose monitoring service with 




0.24mmol/L(4.3mg/dL) and achieving 40% reduction in patient-days with hyperglycemia (2 or more BG measures 
>12.5mmol/L[>225mg/dL]) (21).   
 
In RAPIDS, early identification and management did not decrease hypoglycemia, in contrast to Rushakoff et al 
(21). The baseline incidence of hypoglycemia in our cohort (4.7% of patient-days), was lower than the mean 
incidence in 635 USA hospitals (6.1% of patient-days) (29). A more extensive multifaceted intervention including 
dedicated insulin prescription order sets, protocols and education campaigns (16), may be required to further 
decrease hypoglycemia from the current relatively low rates at our institution. Nevertheless, it is encouraging that 
early intervention and increased tailored insulin treatment did not increase hypoglycemia and thus did not pose any 
safety risk for inpatients.   
 
With early identification and management of diabetes, a 4% absolute risk reduction in hospital-acquired infection 
was observed. It is well known that poor glycemic control in the community (30) and in hospital (31; 32) is 
associated with increased risk for infection. There is strong evidence that intensive glycemic control decreases 
infections in cardiac and general surgery (33; 34), critical care (35), and non-critical care (7; 36). In a non-critical 
care study, basal-bolus insulin therapy improved a composite outcome but especially, decreased wound infections 
and hospital-acquired pneumonia (7).  A meta-analysis of non-critical care studies also demonstrated that intensive 
glycemic control was associated with 60% decreased risk of hospital-acquired infections (37). We found AGDs 
were strongly correlated with hospital-acquired infection, and that the decrease in hospital-acquired infections 
paralleled a decrease in AGD, despite a modest change in mean glucose. This suggests that eliminating glycemic 
extremes may be most effective at improving clinical outcomes. In addition, the RAPIDS study adds further 
evidence to support the notion that improving inpatient glycemic control decreases hospital-acquired infection; 
however, as one of several pre-specified secondary outcomes, this finding requires further confirmatory 
randomized studies.  
 
Of various models of inpatient diabetes care (16; 20-22; 38-40), the strengths of our intervention included remote 
surveillance and identification of hyperglycemia, and bedside consultations by a specialist IDT who directly 
prescribed insulin. The IDT used individualized treatment (rather than protocolized intensive insulin treatment), 
with the practical aim of decreasing both extremes of glycemia, rather than aiming for ‘tight glycemic control’. 
This approach successfully decreased hyperglycemia without increasing hypoglycemia. By providing bed-side 
management it was also possible to recognize and address any other relevant aspects of patient care in addition to 
diabetes management, which may have contributed to improved clinical outcomes.  
 
The RAPIDS study used a parallel cluster-randomized design with a baseline period, which was necessitated by 
several factors. It was only practical to deliver the proactive intervention at the ward level rather than individual 
patient level. Contamination was possible due to movement of patients and staff across wards, although the active 
period occurred during one resident staff rotation. In addition, increased presence of the IDT could result in 
increased awareness and upskilling of inpatient diabetes care. The study design which included baseline and active 
periods, allowed for comparison of the intervention against its own baseline, whilst a parallel control arm 





Limitations of this study include the relatively few clusters and some differences in patient characteristics between 
clusters due to our hospital structure with non-symmetrical specialist medical and surgical wards.  We used a 
mixed effects model, which accounted for clustering and adjusted for baseline patient characteristics, but it is 
possible that there are residual confounders that are unaccounted for. The Hawthorne effect may also have 
contributed to improved glycemic outcomes. This study was relatively short; therefore, the sustainability of the 
improvements is yet to be determined. A longer duration study was not feasible with the available resources and 
would be susceptible to further contamination.  
 
There are also limitations on the generalizability of our findings. Our hospital did not have a comprehensive 
electronic medical record including electronic medication prescription and order sets to assist with delivering 
inpatient care. The baseline proportion of inpatients managed by an IDT was modest. Therefore, the early 
intervention model may have less impact in a hospital with ‘state of the art’ hospital systems already in place. 
Furthermore, the IDT identified and provided consultation on all consecutive individuals with diabetes or new 
hyperglycemia (as a proof of concept of this model of care), but this was resource-intensive. However, we have 
since developed a risk-stratification tool to identify individuals at high-risk for adverse glycemia to enable a more 
sustainable model of care, and plan to evaluate the cost-effectiveness of targeted proactive intervention models. 
 
RAPIDS is the first cluster-randomized trial of an early intervention model of diabetes care in the non-critical 
setting. RAPIDS demonstrated early electronic identification of inpatients with diabetes and treatment by a 
specialist inpatient diabetes team decreased hyperglycemia without increasing hypoglycemia. In addition, early 
management of diabetes was associated with decreased hospital-acquired infection, but this important observation 
requires further confirmatory studies. This study provides evidence that early intervention models of diabetes care 
in hospital improve glycemia and patient outcomes. With the increasing prevalence of diabetes and complexity of 
hospital care, hospital clinicians should concentrate on early identification and management to improve the care of 
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Table 1: Patient characteristics 













 (n=221) (n=270)  (n=220) (n=291)   
Age (years)  70±14 70±14 0.726 70±15 71±16 0.292 0.124 
Male 135 (61) 166 (61) 0.929 112 (51) 156 (54) 0.545 0.039 
Modified Charlson* score 2 (1, 3.5) 2 (0, 3) 0.476 1 (0, 3) 1(0, 3) 0.525 0.066 
Admission creatinine (µmol/l) 111±57 107±59 0.430 102±59 104±68 0.742 0.477 
Type of Diabetes:   0.799   0.190 0.071 
  Type 2 diabetes 193 (87) 241 (89)  190 (86) 251 (86)   
  Type 1 diabetes 18 (8) 19 (7)  16 (7) 12 (4)   
  New hyperglycemia 10 (5) 10 (4)  14 (6) 28 (10)   
HbA1c:        
  mmol/mol 60±18 62±19 0.158 57±19 57±18 0.590 0.049 
  % 7.6±1.7 7.8±1.8  7.4±1.8 7.4±1.7   
Diabetes treatment prior to admission   0.960   0.843 0.007 
  No treatment 43 (19) 55 (20)  56 (25) 79 (27)   
  Oral agents & GLP1  99 (45) 121 (45)  113 (51) 142 (49)   
  Insulin (+/-oral agents & GLP1) 79 (36) 94 (35)  51 (23) 70 (24)   
Hospital stay (days)  5 (3, 5) 4 (2, 4) 0.064 4 (2, 7) 4 (2, 8) 0.964 0.335 
BG measurements/day 3.6±1.9 3.5±1.7 0.543 3.4±1.5 3.5±1.6 0.469 0.990 
Capillary glucose at admission         
  mmol/L 10.3±4.4 10.3±4.3 0.986 9.3±4.0 9.2±3.8 0.620 0.001 
  mg/dL 182±79 182±77  167±72 165±68   
Glucocorticoid treatment during 
admission † 
41 (19) 38 (14) 0.179 28 (13) 30 (10) 0.395 0.062 
Type of admission        
  Elective  31 (14) 35 (13) 0.731 26 (12) 15 (5) 0.006 0.003 
  Emergency  190 (86) 235 (87)  194 (88) 276 (95)   
Admission Parent Unit   0.294   0.159 <0.001 
  Medicine 168 (76) 194 (72)  106 (48) 122 (42)   
  Surgery 53 (24) 76 (28)  114 (52) 169 (58)   
Medical admissions by parent unit         
  General medicine 54 (24) 55 (20)  56 (25) 89 (31)   
  Cardiology 70 (32) 95 (35)  0 2 (1)   
  Neurology 0 3 (1)  49 (23) 71 (24)   
  Respiratory 21 (10) 22 (8)  0 1   
  Gastroenterology 15 (6) 9 (3)  5 (2) 5 (2)   
  Other medical 8 (4) 11 (5)  4 (2) 2 (1)   
Surgical admission by parent unit         
  Abdominal & emergency general 
surgery 
16 (7) 21 (8)  47 (21) 68 (23)   
  Neurosurgery 0 0  43 (19) 41 (14)   
  Orthopedics & Trauma 37 (17) 50 (19)  10 (5) 8 (3)   
  Other surgery 0 4 (1)  6 (3) 4 (1)   
Data presented as mean±sd, median (IQR), or n (%) or as appropriate. * modified Charlson index excluded items related to 
diabetes. † Glucocorticoid treatment was defined as treatment with a supra-physiological dose of glucocorticoid medication 
(dose equivalent >7.5 mg of prednisolone) for 24 hours or more during admission. ‡ p-value of difference between baseline and 




Table 2: Primary and secondary outcomes 








Active Period  p 





Primary outcome: Adverse Glycemic Days 
Cluster level: Incidence of AGD (per 
1000 patient-days) 
291 261 0.090 243 186 <0.001 
Individual level: Adjusted* number of 
AGD per patient: mean±sd,  
1.8±2.0 1.5±1.8 0.23† 1.4±1.6 1.0±0.9 0.001† 
median (Q1, Q3) 1.2 (0.7,1.9) 1.0 (0.6,1.7)  0.9 (0.5,1.7) 0.7 (0.4, 1.3)  
Secondary: Glucometric outcomes 
Patient-days n=1271 n=1394  n=1200 n=1582  
Patient-day mean BG (mean±sd) 9.6±3.2 9.5±3.2 0.23 9.4±3.3 9.0±2.7 0.003 
mean BG > 10 mmol/L [>180 mg/dL] 37% 37% 0.88 35% 30% 0.010 
mean BG > 15 mmol/L [>270 mg/dL] 6.9% 6.1% 0.39 7.3% 3.3% <0.001 
BG <4 mmol/L [<72 mg/dL] 5.6% 5.0% 0.52 3.8% 4.0% 0.69 
BG <3 mmol/L [<54 mg/dL] 1.6% 1.4% 0.75 1.0% 0.7% 0.40 
Secondary: Clinical outcomes 
Patients  n=221 n=270  n=220 n=291  
Any hospital-acquired infection 19 (8.6) 19 (7.0) 0.52 14 (6.4) 7 (2.4) 0.035 
  Skin wound & surgical site 5 (2.3) 8 (3.0)  2 (0.9) 2 (0.7)  
  Urinary tract 5 (2.3) 4 (1.5)  4 (1.8) 3 (1.0)  
  Bacteremia 1 (0.5) 0  1 (0.5) 0  
  Pneumonia 9 (4.1) 10 (3.7)  9 (4.1) 4 (1.4)  
Acute kidney injury 15 (6.8) 22 (8.1) 0.56 11 (5.0) 11 (3.8) 0.50 
Acute myocardial infarct 4 (1.8) 5 (1.9) 0.97 2 (0.9) 1(0.3) 0.40 
Unplanned critical care admission 12 (5.4) 12 (4.4) 0.61 2 (0.9) 3 (1.0) 0.89 
Hospital mortality 5 (2.3) 8 (3.0) 0.63 6 (2.7) 6 (2.1) 0.63 
Composite outcome (hospital acquired 
infection, acute kidney injury, acute 
myocardial infarct, unplanned critical 
care admission and mortality) 
39 (17.6) 51 (18.9) 0.72 28 (12.7) 26 (8.9) 0.17 
Length of stay (days) 6 (3, 11) 6 (3, 11) 0.60 6 (3, 10) 6 (3, 10) 0.19 
*adjusted for age, gender, modified Charlson index, creatinine, HbA1c, insulin treatment prior to admission, admission unit, 
admission type, ward type, days observed (fixed effects), and ward (random effect)  †mixed model Poisson regression. Data 














Figure2: Process of care & glucometric outcomes. (a) Proportion of patients who received management 
by the inpatient diabetes team during admission. (b) Proportion of patients who had diabetes team 
management within 24 hours of admission. (c) Proportion of insulin-naïve patients who had treatment with 
subcutaneous insulin during admission. X-axis represents the control and intervention arms during the 
baseline and active periods. Filled bars represent usual care, open bar represents proactive/early 
intervention model of care. * p<0.001. (d) Distribution of patient-day mean glucose. Patient-day mean 
glucose fit a lognormal distribution. There was no difference in the distribution in the groups that received 
usual care (interrupted lines and solid red line). The group that received early intervention (solid blue line) 











Supplementary Figure 5: RAPIDS study design: Parallel cluster-randomized study with a baseline period. 
There was a 10-week baseline period, and 12-weeks active period. Light shading represents clusters unexposed 
to the intervention (i.e. usual care). Dark shading represents clusters exposed to the intervention (i.e. early 
identification and management). Between weeks 10 to 12 constituted the transition period where 





Supplementary Table S1:  
Primary analysis Individual level: Number of Adjusted AGD per-patient. Mixed model Poisson regression 
where ward (cluster) was included as random variable. Group (control-baseline period, control-active period, 
intervention-baseline period, and intervention-active period) was included as a factor to allow simultaneous 
comparison across treatment arms and between baseline and active periods within each treatment arm. IRR = 
incidence rate ratio. 
 β-Coefficient (95%CI) IRR (95% CI) p-value 
Age 0.009 (0.004, 0.013) 1.009 (1.004, 1.013) <0.001 
Male  0.102 (-0.017, 0.221) 1.107 (0.983, 1.248) 0.094 
Modified Charlson Index *  0.062 (0.029, 0.094) 1.063 (1.029, 1.098) <0.001 
Creatinine 0.000 (0.000, 0.001) 1.000 (0.999, 1.001) 0.553 
HbA1c (each % increase) 0.203 (0.174, 0.232) 1.225 (1.190, 1.261) <0.001 
Diabetes Type -0.252 (-0.368, -0.137) 0.777 (0.692, 0.872) <0.001 
Insulin treatment prior to admission 0.601 (0.475, 0.727) 1.823 (1.607, 2.068) <0.001 
Surgical unit admission -0.111 (-0.336, 0.133) 0.895 (0.701, 1.143) 0.372 
Elective admission -0.246 (-0.500, 0.008) 0.782 (0.606, 1.008) 0.057 
Surgical ward 0.038 (-0.203, 0.278) 1.038 (0.817, 1.320) 0.759 
Number of observed days 0.148 (0.134, 0.163) 1.160 (1.143, 1.177) <0.001 
Constant -2.536 (-3.057, -2.014) 0.079 (0.047, 0.133) <0.001 
Ward (random variable) 9.37-33 0.000  
Group    
   Control-baseline (usual care) 0.038 (-0.122, 0.199) 1.039 (0.885, 1.220) 0.640 
   Control-active (usual care) -0.056 (-0.217, 0.106) 0.946 (0.805, 1.112) 0.501 
   Intervention-baseline (usual care) Ref Ref  
   Intervention-active (proactive care) -0.283 (-0.453, -0.112) 0.754 (0.636, 0.894) 0.001 
* modified Charlson index excludes items related to diabetes 
Comparison between groups β-coef (95%CI) IRR (95%CI) p 
Control-baseline period vs. Control-active period  (change 
in control arm) 
-0.094 (-0.248, +0.060) 0.910 (0.780, 1.062) 0.233 
Intervention-baseline period vs. Intervention-active period 
(change in intervention arm) 
-0.283 (-0.453, -0.112) 0.754 (0.636, 0.894) 0.001 
Control-active period vs. Intervention-active period 
(comparison of early intervention against parallel control 
group) 
-0.227 (-0.395, -0.059) 0.797 (0.674, 0.942) 0.008 
 
Supplementary Table S2: 
Adjusted* Adverse Glycaemic Days per patient during baseline and active periods by clusters 
Control Clusters Baseline Active P# Intervention Clusters Baseline Active P# 
C1-General medicine 2.0±2.5 2.1±2.6 0.96 I1-General Medicine 2.2±2.3 1.4±1.3 0.01 
C2-General surgery 1.8±1.9 1.0±0.6 0.05 I2-General Surgery 0.8±0.8 0.7±0.5 0.40 
C3-Cardiology 1.6±1.7 1.4±1.2 0.53 I3-Neurology 1.6±1.4 1.1±0.9 0.02 
C4-Orthopaedic 1.6±1.4 1.3±1.4 0.20 I4-Neurosurgery 0.9±0.8 0.8±0.7 0.43 
*adjusted for age, gender, modified Charlson index, creatinine, HbA1c, insulin treatment prior to admission,  admission unit, admission 




Supplementary Table S3:  
Post-hoc analysis: Hospital-acquired infections. Mixed model logistic regression where ward (cluster) was 
included as random variable. Group (control-baseline period, control-active period, intervention-baseline 
period, and intervention-active period) was included as a factor to allow simultaneous comparison across 
treatment arms and between baseline and active periods within each treatment arm. 
 Adj OR 95% CI p-value 
Age (each 1 year increase) 1.03 1.00, 1.06 0.033 
Male  1.65 0.84, 3.25 0.143 
Modified Charlson Index # (each 1 point increase) 1.08 0.90, 1.29 0.427 
Creatinine (each 10 umol/L increase) 1.00 1.00, 1.00 0.898 
HbA1c (each % increase) 1.13 0.92, 1.38 0.239 
Diabetes Type    
- Type 2 diabetes 1.00 ref ref 
- Type 1 diabetes 0.35 0.04, 3.03 0.343 
- New hyperglycaemia 3.79 1.12, 12.76 0.032 
Insulin treatment prior to admission 0.55 0.23, 1.34 0.188 
Surgical unit admission 0.76 0.19, 3.12 0.708 
Elective admission 1.50 0.47, 4.76 0.490 
Surgical ward 1.52 0.35, 6.52 0.577 
Number of observed days (each 1 day increase) 1.40 1.28, 1.54 <0.001 
Constant 0.00 0.000, 0.003 <0.001 
Ward (random variable) 0.08   
Group    
   Control-baseline (usual care) 1.24 0.48, 3.14 0.654 
   Control-active (usual care) 0.89 0.34, 2.28 0.792 
   Intervention-baseline (usual care) Ref Ref  
   Intervention-active (proactive care) 0.20 0.07, 0.58 0.003 
# modified Charlson index excludes items related to diabetes 
 
Comparison between groups Adj OR [95%CI] p 
Control-baseline period vs. Control-active period (change in control 
arm) 
0.71 [0.31, 1.63] 0.420 
Intervention-baseline period vs. Intervention-active  period (change in 
intervention arm) 
0.20 [0.07, 0.58] 0.003 
Control-active period vs. Intervention-active period (comparison of 
early intervention against parallel control group) 





Supplementary Table S4:  
Post-hoc analysis: Hospital-acquired infections (subgroup of patients with type 2 diabetes). Mixed model 
logistic regression where ward (cluster) was included as random variable. Group (control-baseline period, 
control-active period, intervention-baseline period, and intervention-active period) was included as a factor to 
allow simultaneous comparison across treatment arms and between baseline and active periods within each 
treatment arm. 
 Adj OR 95% CI p-value 
Age (each 1 year increase) 1.04 1.01, 1.08 0.016 
Male  1.71 0.83, 3.52 0.144 
Modified Charlson Index # (each 1 point increase) 1.08 0.90, 1.31 0.409 
Creatinine (each 10 umol/L increase) 1.00 0.99, 1.00 0.680 
HbA1c (each % increase) 1.18 0.95, 1.46 0.138 
Insulin treatment prior to admission 0.47 0.18, 1.21 0.117 
Surgical unit admission 0.77 0.18, 3.33 0.729 
Elective admission 1.34 0.39, 4.67 0.643 
Surgical ward 1.95 0.44, 8.62 0.378 
Number of observed days (each 1 day increase) 1.42 1.28, 1.56 <0.001 
Constant 0.00 0.000, 0.002 <0.001 
Ward (random variable) 0.04   
Group    
   Control-baseline (usual care) 1.37 0.55, 3.39 0.497 
   Control-active (usual care) 0.67 0.25, 1.78 0.420 
   Intervention-baseline (usual care) Ref Ref  
   Intervention-active (proactive care) 0.17 0.05, 0.56 0.003 
# modified Charlson index excludes items related to diabetes 
 
Comparison between groups Adj OR [95%CI] p 
Control-baseline period vs. Control-active period (change in control 
arm) 
0.49 [0.20, 1.19] 0.114 
Intervention-baseline period vs. Intervention-active  period (change in 
intervention arm) 
0.17 [0.05, 0.56] 0.003 
Control-active period vs. Intervention-active period (comparison of 
early intervention against parallel control group) 





Supplementary Table S5: Glycaemic and Clinical outcomes, patients with Type 2 diabetes 








Active Period  p 





Patient-days n=1131 n=1264  n=1053 n=1396  
Patient-day mean BG (mean±sd) 9.6±3.3 9.4±3.1 0.10 9.2±3.2 9.0±2.7 0.296 
mean BG > 10 mmol/L [>180 mg/dL] 36% 36% 0.90 32% 30% 0.370 
mean BG > 15 mmol/L [>270 mg/dL] 7.0% 5.6% 0.18 6.6% 3.2% <0.001 
BG <4 mmol/L [<72 mg/dL] 4.3% 4.1% 0.79 3.0% 3.9% 0.27 
BG <3 mmol/L [<54 mg/dL] 1.0% 1.0% 0.89 0.7% 0.4% 0.42 
Clinical outcomes 
Patients  n=193 n=241  n=190 n=247  
Any hospital-acquired infection 18 (9.3) 16 (6.4) 0.37 13 (6.8) 6 (2.4) 0.032 
Acute kidney injury 14 (7.3) 19 (7.9) 0.86 11 (5.8) 9 (3.7) 0.36 
Acute myocardial infarct 3 (1.6) 4 (1.7) 0.99 2 (1.1) 1 (0.4) 0.58 
Unplanned critical care admission 10 (5.1) 9 (3.7) 0.49 2 (1.1) 2 (0.8) 0.99 
Hospital mortality 3 (1.6) 7 (2.9) 0.52 5 (2.6) 4 (1.6) 0.51 
Composite outcome  35 (18.1) 43 (17.8) 0.99 26 (13.7) 21 (8.5) 0.09 
Length of stay (days) 6 (3, 11) 6 (3, 10) 0.47 5 (3, 10) 6 (3, 11) 0.14 
Data expressed as mean±sd, median (Q1, Q3), or n (%). P-values using t-test or Fisher’s exact test as appropriate 
 
Supplementary Table S6: Glycaemic and clinical outcomes, patients with Type 1 diabetes 








Active Period  p 





Patient-days n=55 n=53  n=34 n=28  
Patient-day mean BG (mean±sd) 10.6±3.1 10.5±3.0 0.88 10.3±3.2 10.7±3.3 0.64 
mean BG > 10 mmol/L [>180 mg/dL] 60% 57% 0.72 44% 54% 0.61 
mean BG > 15 mmol/L [>270 mg/dL] 9.1% 7.6% 0.99 15% 14% 0.99 
BG <4 mmol/L [<72 mg/dL] 22% 13% 0.31 29% 32% 0.82 
BG <3 mmol/L [<54 mg/dL] 11% 4% 0.27 12% 17% 0.72 
Clinical outcomes 
Patients  n=18 n=19  n=16 n=12  
Any hospital-acquired infection 0 0  1 (6) 0 0.99 
Acute kidney injury 0 2 (11) 0.49 0 0  
Acute myocardial infarct 1 (6) 0 0.49 0 0  
Unplanned critical care admission 2 (11) 1 (5) 0.60 0 0  
Hospital mortality 0 1 (5) 0.99 0 0  
Composite outcome  2 (11) 4 (21) 0.66 1 (6) 0 0.99 
Length of stay (days) 5 (3, 13) 4 (3, 9) 0.64 4 (2, 14) 5 (3, 5) 0.59 




Supplementary Table S7: Glycaemic and clinical outcomes, patients with New Hyperglycaemia  








Active Period  p 







Patient-days n=53 n=48  n=46 n=139  
Patient-day mean BG (mean±sd) 9.3±2.5 9.9±3.9 0.35 11.3±4.1 8.7±2.5 <0.001 
mean BG > 10 mmol/L [>180 mg/dL] 32% 38% 0.57 48% 22% 0.001 
mean BG > 15 mmol/L [>270 mg/dL] 1.9% 14.6% 0.03 17.4% 2.2% 0.001 
BG <4 mmol/L [<72 mg/dL] 0 2.1% 0.47 0 0  
BG <3 mmol/L [<54 mg/dL] 0 0  0 0  
Clinical outcomes 
Patients  n=10 n=10  n=14 n=28  
Any hospital-acquired infection 1 (10) 3 (30) 0.59 0  1 (4) 0.99 
Acute kidney injury 1 (10) 1 (10) 0.99 0 2 (7) 0.55 
Acute myocardial infarct 0 1 (10) 0.99 0 0  
Unplanned critical care admission 0 2 (20) 0.47 0 1 (4) 0.99 
Hospital mortality 2 (20) 0 0.47 1 (7) 2 (7) 0.99 
Composite outcome  2 (20) 4 (40) 0.63 1 (7) 5 (18) 0.65 
Length of stay (days) 5 (3, 7) 11 (4, 18) 0.31 7 (4, 11) 7 (3, 10) 0.97 





Supplementary Table S8: Clinical outcomes: medical vs. surgical patients 
 Control arm (4 clusters) Intervention arm (4 clusters) 
 Baseline 
Period 
Active Period p 
Baseline 
Period 
Active Period  p 




Medical Patients  n=168 n=194 p* n=114 n=169 p* 
Any hospital-acquired infection 12 (7.1) 9 (4.6) 0.37 12 (10.5) 6 (3.6) 0.025 
Acute kidney injury 12 (7.1) 12 (8.3) 0.84 9 (7.9) 7 (4.1) 0.20 
Acute myocardial infarct 2 (1.9) 4 (2.1) 0.69 1 (0.9) 1 (0.6) 0.99 
Unplanned critical care admission 9 (5.4) 9 (4.6) 0.81 1 (0.9) 2 (1.2) 0.99 
Hospital mortality 5 (3.0) 8 (4.1) 0.59 5 (4.4) 6 (3.6) 0.76 
Composite outcome  28 (16.7) 38 (19.6) 0.50 24 (21.1) 21 (12.4) 0.07 
Length of stay (days) 5 (3, 10) 6 (3, 12) 0.54 8 (4, 12) 8 (4, 14) 0.44 
       
Surgical Patients  n=53 n=76  n=106 n=122  
Any hospital-acquired infection 7 (13.2) 10 (13.2) 0.99 2 (1.9) 1 (0.8) 0.60 
Acute kidney injury 3 (5.7) 6 (7.9) 0.73 2 (1.9) 4 (3.3) 0.69 
Acute myocardial infarct 2 (3.8) 1 (1.3) 0.57 1 (0.9) 0 0.46 
Unplanned critical care admission 3 (5.7) 3 (4.0) 0.69 1 (0.9 1 (0.8) 0.99 
Hospital mortality 0 0  1 (9.4) 0 0.46 
Composite outcome  11 (20.8) 13 (17.1) 0.65 4 (3.8) 5 (4.1) 0.99 
Length of stay (days) 9 (4, 14) 5 (4, 9) 0.03 4 (2, 7) 5 (2, 7) 0.51 
Data expressed as mean±sd, median (Q1, Q3), or n (%). P-values using Fisher’s exact test. 
 
Supplementary Table S9: Insulin-naïve patients that received insulin treatment in 
hospital 
 Control arm (4 clusters) Intervention arm (4 clusters) 
 Baseline Period Active Period Baseline Period Active Period 
 (Usual care) (Usual care) (Usual care) (Early/ proactive 
intervention) 
Medical units      
- General medicine 12/34 (35) 17/40 (43) 18/42 (43) 47/67 (70) 
- Cardiology 13/41 (32) 25/61 (41) 0/0 1/1 (100) 
- Neurology 0/0 1/3 (33) 15/39 (39) 30/56 (54) 
- Respiratory 11/19 (58) 7/14 (50) 0/0 0/1 (0)  
- Gastroenterology 4/10 (40) 3/6 (50) 1/2 (50) 0/4 (0) 
- Other medical 1/3 (33) 1/1 (100) 1/3 (33) 0/0 
 Surgical units      
- Abdominal & emergency surgery 3/11 (27) 9/16 (56) 8/36 (22) 28/52 (50) 
- Neurosurgery 0/0 0/0 11/34 (32) 17/32 (53) 
- Orthopedics & Trauma 7/24 (29) 7/33 (21) 2/7 (29) 3/5 (60) 
- Other surgery 0/0 0/2 (0) 1/6 (17) 1/3 (33) 
TOTAL 51/142 (36) 70/176 (40) 57/169 (34) 127/221 (57) 




6. CHAPTER SIX: 
EARLY IDENTIFICATION OF HIGH-RISK DIABETES INPATIENTS 
6.1 Introduction 
With increasing prevalence of diabetes in hospitalised patients, specialist management of every diabetes 
inpatient is resource-intensive and impractical. Risk-stratification and targeted management of high-risk 
inpatients is becoming an important strategy for sustainable diabetes programs. Ideally, a risk-
stratification tool should aim to identify inpatients who develop adverse glycaemia to enable targeted 
management by inpatient diabetes services. In addition, a risk-stratification tool that predicts high-risk 
patients early in their admission could enable early and targeted intervention.  
 
Although prediction tools for inpatient hypoglycaemia have been developed, there are no prediction tools 
for the more common glycaemic extreme of inpatient hyperglycaemia. To address this gap in literature, 
we sought to develop a prediction tool for adverse glycaemia (which includes both hyperglycaemia and 
hypoglycaemia), using the patient cohort recruited in the RAPIDS trial. The prediction tool was designed 
to identify early in admission, inpatients who subsequently developed adverse glycaemia in hospital. The 
prediction tool can assist inpatient diabetes programs, and refine the proactive inpatient diabetes service 
developed in Chapter 5.  
 
6.2 Manuscript 
The material presented in this chapter has been submitted as a manuscript to the Journal of Diabetes and 
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Aims: Given the high incidence of hyperglycaemia and hypoglycaemia in hospital and lack of prediction 
tools for this problem, we developed a clinical tool to assist early identification of individuals at risk for 
persistent adverse glycaemia (AG) in hospital.  
 
Methods: We analysed a cohort of 594 consecutive adult inpatients with type 2 diabetes. We identified 
clinical factors available early in the admission course that were associated with persistent AG (defined as 
two or more days with capillary glucose <4 or >15 mmol/L during admission).  A prediction model for 
persistent AG was constructed using logistic regression and internal validation was performed using a 
split-sample approach. 
 
Results: Persistent AG occurred in 153 (26%) of inpatients, and was associated with dysglycaemia at 
admission (Odds Ratio 3.65); glycosylated haemoglobin ≥64 mmol/mol (≥8.1%) (OR 5.08); glucose-
lowering treatment regimen containing sulphonylurea (OR 3.50), or insulin (OR 4.22); glucocorticoid 
medication treatment (OR 2.27); Charlson comorbidity index; and the number of observed-days. An 
early-identification prediction tool, based on clinical factors reliably available at admission (dysglycaemia 
at admission, glycosylated haemoglobin, glucose-lowering regimen and glucocorticoid treatment), could 
accurately predict persistent AG (receiver operating characteristic area under curve: 0.806), and at the 
optimal cut off, the sensitivity, specificity and positive predictive value were 84%, 66% and 53% 
respectively. 
 
Conclusions: A clinical prediction tool based on clinical risk factors available at admission to hospital 
identified patients at increased risk for persistent adverse glycaemia and could assist early targeted 







hospital care; hyperglycaemia; hypoglycaemia; clinical prediction models; proactive care; risk factors 
 
Abbreviations 
AG adverse glycaemia (composite of hyper- and hypoglycaemia) 
AUC area under curve 
BG blood glucose 
IDT inpatient diabetes team 





 Despite the high incidence of hyperglycaemia in hospitalised individuals with diabetes, clinical 
tools to predict those at risk for hyperglycaemia are lacking.  
 We developed a practical clinical prediction model that identifies individuals at high risk for 
developing persistent hyperglycaemia and/or hypoglycaemia during their admission. 
 This clinical prediction tool allows early identification of the high-risk individual with diabetes, 







In many hospitals of developed nations, more than one in four individuals have diabetes and most are 
admitted under the care of hospitalists or non-diabetes specialist medical and surgical teams [1, 2].  
Hyperglycaemia in hospital is associated with adverse outcomes, such as healthcare-associated infection 
due to impaired immunity from neutrophil and macrophage dysfunction; and increased cardiovascular 
and renal pathology due to pro-thrombotic changes, endothelial dysfunction and oxidative stress [3]. 
Treatment of hyperglycaemia with glucose-lowering treatment can cause hypoglycaemia, which can also 
be associated with adverse outcomes, such as brain injury and cardiac arrhythmia [4]. The term Adverse 
Glycaemia (AG) can be used to encompass these glycaemic extremes of hyperglycaemia and 
hypoglycaemia [5]. Although ideal blood glucose (BG) targets in non-critical care have been published 
these targets are not based on high level evidence and may vary between guidelines [6, 7]. However, it is 
well-accepted that hypoglycaemia (<4 mmol/L) and severe hyperglycaemia (>15 mmol/L) should be 
avoided for the safe management of diabetes in hospital.  
 
Hyperglycaemia in hospital is common and affects up to 50% of inpatients [8].  Based on clinical 
experience, many factors are known to cause perturbation of glycaemia including patient factors (pre-
existing hyperglycaemia, counter-regulatory hormone ‘stress’ response, and the severity of illness); and 
hospital treatment factors (glucocorticoids, enteral and parenteral nutrition, and inappropriately withheld 
insulin). However, aside from glycosylated haemoglobin [9], and glucocorticoid treatment [10], risk 
factors for inpatient hyperglycaemia have not been formally investigated and there are no published 
clinical prediction tools for determining the risk of inpatient hyperglycaemia. 
 
Hypoglycaemia affects up to 20% of inpatients [1]. Risk factors for inpatient hypoglycaemia have been 
investigated and include: greater age and comorbidities, longer duration of diabetes, lower glycosylated 
haemoglobin, sulphonylurea or insulin treatment, renal or liver impairment, and longer length of stay 
[11]. In addition, hospital treatment factors such as interruption in nutrition, medication errors and 
inadequate blood glucose monitoring contribute to inpatient hypoglycaemia [4]. Several prediction 
models for inpatient hypoglycaemia have been reported utilising combinations of these risk factors [12-
15]. 
 
Early treatment of inpatient hyperglycaemia improves clinical outcomes [16-18] and many hospitals have 
implemented inpatient diabetes teams (IDT) to optimise glycaemic control. IDTs generally provide 
diabetes management in response to referrals from the treating teams [19, 20] or in response to the 
occurrence of AG during surveillance of capillary glucose measurements [21-23]. Therefore, IDT 
management typically occurs after the occurrence of AG, often later in the admission course. We 
previously reported an early intervention model of care whereby an IDT identified all patients with 
diabetes and provided bedside management within 24 hours of admission, even prior to occurrence of 
AG. In a cluster randomised study, this proactive model of care decreased hyperglycaemia and hospital-
acquired infections [18]. However, as not every inpatient with diabetes develops AG, we sought to 




and targeted management by IDTs. We investigated clinical risk factors that were associated with 
development of persistent AG, and subsequently developed a clinical prediction tool to assist early 
identification of high-risk patients, as part of ongoing efforts to optimise systematic approaches to 
inpatient diabetes care [24]. 
 
Materials and Methods 
This study is based on the patient cohort recruited in the Randomised study of a Proactive Inpatient 
Diabetes Service (RAPIDS): a cluster-randomised trial conducted between March and August 2016 at the 
Royal Melbourne Hospital, an acute care tertiary referral hospital (ANZCTR number 12616000265471) 
[18]. RAPIDS recruited consecutive adult inpatients with known diabetes or new hyperglycaemia 
(random capillary BG >11.1 mmol/L) admitted to one of eight medical and surgical wards. The 
intervention consisted of remote identification of diabetes inpatients and early bedside management by a 
specialist diabetes team. This analysis is based on patients who had the comparator of usual care (hence 
did not receive the intervention). Full details of the RAPIDS study have been previously reported [18]. 
 
Participants and data collection 
For this analysis we included individuals with type 2 diabetes who had a length of stay of two or more 
days. Although RAPIDS recruited individuals with all diabetes types, we excluded patients with type 1 
diabetes or type 3c (exocrine pancreatic disease) diabetes because these forms of diabetes are already 
known to have glycaemic instability and thus considered at high-risk for AG in hospital. The inpatient 
diabetes management was mostly performed by the treating team’s medical officers. As per usual practice 
in Australia, United Kingdom and Europe, there was no standardized algorithm recommending cessation 
of all glucose-lowering medications and prescription of subcutaneous basal-bolus insulin in all patients 
with diabetes. Therefore, inpatients were treated with an individualized approach using a variety of 
glucose-lowering medications and/or insulin regimens. Individuals with diabetes had BG measurements 
performed at least four times per day or 4-hourly while fasting. 
 
Recruitment and data collection was conducted prospectively. Capillary BG measurements from the time 
of admission until discharge were collected electronically using networked BG meters (Statstrip ®, 
Australasian Medical and Scientific Limited) and extracted for analysis using BioViewer (© Bio-Asia 
Diagnostics) data manager. We excluded BG measurements after day 14 of admission in patients with 
prolonged stay and excluded repeated BG measurements from a single clinical episode of hypo- or 
hyperglycaemia [25]. 
 
Outcome and risk factors 
The outcome of interest was persistent AG, defined as the occurrence of two or more days with capillary 
BG <4 or >15 mmol/L, as a composite measure of hypoglycaemia and hyperglycaemia that was persistent 




control in the first 24 hours is influenced by treatment before admission or in the emergency department 
rather than ward management.  
 
Putative clinical risk factors were investigated based on clinical experience and included patient factors 
(age, gender, modified Charlson Comorbidity Index), diabetes factors (glucose-lowering regimen prior to 
admission), hospital treatment factors (admission unit, admission type, glucocorticoid treatment), 
laboratory results (glycosylated haemoglobin and eGFR at admission), and the number of observed-days 
(calendar days that an individual had glucose observations performed). The modified Charlson 
Comorbidity Index excluded items related to diabetes. Glucose-lowering regimen prior to admission was 
categorised into four groups: 1) diet-controlled; 2) glucose-lowering medications excluding 
sulphonylurea; 3) glucose-lowering medications including sulphonylurea; and 4) insulin treatment. 
Glucocorticoid treatment was defined as oral or intravenous treatment with a glucocorticoid medication 
(equivalent to ≥7.5 mg of prednisolone) that was commenced within 24 hours of hospital admission and 
continued for at least 24 hours. We also evaluated dysglycaemia at admission (BG <4 or >15 mmol/L in 
the first 24 hours) as a putative risk factor for AG. Admission hyperglycaemia is a known risk factor for 
adverse clinical outcomes [26]. From clinical experience, dysglycaemia early in admission is an 
antecedent for subsequent AG, but surprisingly this has not been formally studied. 
 
Some potential clinical risk factors including duration of diabetes, patient weight, and sepsis were not 
included in the analyses as this clinical information were not collected or reliably available.  Treatment 
with enteral or total parenteral nutrition was not included as only a few individuals received this 
treatment.  
 
Prediction models for persistent adverse glycaemia 
We constructed two logistic regression models to predict persistent adverse glycaemia. The first (hospital-
stay) model used all clinical risk factors that were independently associated with persistent AG on 
multivariable analysis. The second (early-identification) model used clinical risk factors that were reliably 
and accurately available within 24 hours of admission. The early identification model excluded Charlson 
Comorbidity Index (a research tool which is difficult to accurately determine in routine clinical practice at 
admission), and observed-days (which depends on length of stay and difficult to predict at the time of 
admission). The early-identification model was used to develop a clinical prediction tool, based on 
clinical features available within 24 hours of admission, thus assisting early identification of patients at 
increased risk of persistent AG. 
 
Statistical approach 
Patient demographic, diabetes and treatment variables, and laboratory results were summarised using 
mean (SD), or median (inter quartile range) for continuous measures, and proportions for categorical 
measures. Odds ratios (ORs) (95% CI) were estimated using logistic regression models. For multivariable 




elimination performed for variables with p >0.1. As the prospectively collected data formed near-
complete data set, no imputations were performed. A 50/50 split cohort approach was used for model 
construction and internal validation. Therefore, the models were derived using a randomly selected 
subgroup of the half the cohort, and their performance tested on the remaining half of the cohort. Model 
performance was assessed by calculating the area under the curve (AUC) of a receiver operating 
characteristic (ROC) curve. C-statistics were compared between the hospital-stay and early identification 
models. Sensitivity, specificity, positive and negative predictive values, and likelihood ratios were 
reported at various predicted probability cut-offs. All analyses were performed using STATA 15 
(StataCorp LLC, College station, TX, USA). 
 
Results 
This analysis consisted of 594 consecutive individuals with type 2 diabetes admitted for a median of 4 (2 
to 7) days. In this cohort glucose-lowering regimen prior to admission consisted of: diet-controlled 
(21%), glucose-lowering medications excluding sulphonylurea (27%), glucose-lowering medications 
including sulphonylurea (24%), and insulin treatment (28%). Mean glycosylated haemoglobin (SD) at 
admission was 58 (19) mmol/mol or 7.5 (1.7) %. 216 (37%) individuals had dysglycaemia at admission, 
and 88 (15%) were treated with glucocorticoid medications.  
 
In this cohort, 210 (35%) had at least one episode of hyperglycaemia (>15.0 mmol/L), 62 (10%) had at 
least one episode of hypoglycaemia (<4.0mmol/L), and 25 (4%) had both. Persistent AG occurred in 153 
(26%) individuals. Patient characteristics and clinical variables for individuals with and without persistent 
AG are presented in Table 1.  
 
Risk factors for persistent adverse glycaemia 
Coefficients and the ORs for the clinical risk factors that were independently associated with persistent 
AG are presented in Table 2. Persistent AG was associated with dysglycaemia at admission (OR 3.65); 
admission glycosylated haemoglobin 7.1-8.0% (OR 2.15); >8.0% (OR 5.08); Glucocorticoid treatment 
(OR 2.27); pre-admission treatment with insulin (OR 4.22), and sulphonylurea (OR 3.50); observed-days; 
and modified Charlson Comorbidity index. Interestingly, treatment with non-sulphonylurea glucose-
lowering medications was not associated with persistent AG.  Age, gender, admission unit, admission 
type and admission eGFR were not associated with persistent AG. Risk factors independently associated 
with hyperglycaemia hypoglycaemia as separate outcomes are presented in supplemental tables 1 and 2.  
 
Prediction models for persistent adverse glycaemia 
The hospital-stay model for predicting persistent AG using six associated clinical variables (dysglycaemia 
at admission, glycosylated haemoglobin, glucose-lowering regimen, glucocorticoid treatment, modified 
Charlson Index and observed-days) had a ROC-curve AUC of 0.872 (95% CI 0.828-0.916) (Fig. 1). The 




of admission (dysglycaemia at admission, glycosylated haemoglobin, glucose-lowering regimen, 
glucocorticoid treatment) had a ROC-curve AUC of 0.806 (0.751-0.861) (Fig. 1 and supplementary table 
3). At the optimal cut-off point where the combined sensitivity and specificity total was maximal, early-
identification model had a sensitivity of 84%, specificity of 66%, positive predictive value of 53% and 
likelihood ratio of 2.5 (supplementary table 4). Although the early-intervention model had a slightly 
lower AUC than the hospital-stay model (C-statistic p=0.006), the early-intervention model was practical 
and relatively accurate (AUC >0.8) as a clinical tool to predict persistent AG.   
 
Figure 2 depicts an example of a clinical algorithm based on the early identification model which 
categorises individuals as low or high risk for persistent AG. Individuals not on sulphonylurea or insulin 
treatment and not dysglycaemic at admission are classified as low-risk. Individuals on sulphonylurea or 
insulin treatment, and dysglycaemic at admission are classified as high risk. For the remaining 
individuals, glucocorticoid treatment and admission glycosylated haemoglobin further categorise between 
low and high risk of persistent AG. 
 
Discussion 
Early treatment of hyperglycaemia improves glycaemic control and may improve clinical outcomes [16, 
18], thus there is a need for early identification and targeted management of individuals at high-risk for 
adverse glycaemia in hospital. Clinical prediction models in hospital diabetes patients have focussed on 
risk factors for adverse clinical outcomes [27], but there has been less focus on predicting adverse 
glycaemic outcomes. Although a few studies have developed prediction tools for inpatient hypoglycaemia 
[12-15], there are no published prediction tools for the more common glycaemic extreme of inpatient 
hyperglycaemia. To our knowledge this is the first prediction tool for both hyperglycaemia and/or 
hypoglycaemia which could practically assist to identify high-risk patients, early in the admission course. 
As hyperglycaemia was three times more prevalent than hypoglycaemia, this early prediction tool is 
particularly useful for predicting hyperglycaemia in hospital.  
 
In this well-characterized prospective cohort of consecutive inpatients with type 2 diabetes, 26% of 
individuals had two or more days of hyperglycaemia and/or hypoglycaemia. Variables that were 
independently associated with persistent AG (dysglycaemia at admission, glycosylated haemoglobin, 
glucose-lowering regimen, glucocorticoid treatment, modified Charlson Comorbidity Index and the 
number of observed-days) were consistent with anecdotal clinical experience, but only glycosylated 
haemoglobin, glucocorticoid treatment have been previously reported as risk factors for hyperglycaemia 
[9, 10].  
 
Although the hospital-stay model was more accurate at predicting persistent AG, it included clinical 
variables that were difficult to obtain early in the admission. Determining the Charlson Comorbidity 
Index is difficult given it requires accurate documentation of seventeen diagnostic codes, and it is also not 
possible to determine observed-days (length of stay) from the outset at admission to hospital. Hence, the 




course, was developed as a practical clinical prediction tool to identify high-risk individuals. The early-
identification model confirmed four factors that predicted persistent AG, a biologically plausible finding 
as each factor either directly reflects glycaemia (Dysglycaemia at admission and glycosylated 
haemoglobin) or influence glycaemia (glucose-lowering regimen and glucocorticoid treatment).  The 
early-identification model could be incorporated into an electronic medical record as a tool to flag 
individual at risk for persistent AG using variables from point-of-care glucose measurements, electronic 
prescription system, and pathology systems. Alternatively, in the absence of a fully-integrated electronic 
medical record, a clinical algorithm based on this model (such as depicted in Fig. 2) could be another tool 
used to identify high-risk individuals.  
 
Importantly, this clinical prediction tool also identifies individuals at low-risk for persistent AG. We 
observed that individuals who had pre-admission glucose-lowering regimens which did not contain 
sulphonylurea or insulin (e.g. metformin monotherapy, or dual metformin and dipeptidylpeptidase-4 
inhibitor therapy), and were not dysglycaemic at admission, were at low-risk of persistent AG. Hence, 
these individuals may not require aggressive and more expensive subcutaneous insulin treatment and this 
may decrease the risk of treatment-related hypoglycaemia in hospital.   
 
The standard of hospital diabetes care is to treat hyperglycaemia with insulin [6], and various models of 
IDTs have been developed to increase insulin use and optimise glycaemic control, but the majority 
provide specialist management after the occurrence of hyperglycaemia or hypoglycaemia [21-23]. In the 
UK, the ‘Think Glucose’ project and ‘Diabetes patient at risk’ (DPAR) score system use patient clinical 
factors to guide treating teams to make appropriate and early referrals to the IDTs [28, 29]. Similar to the 
DPAR score, we found admission hypoglycaemia <4 mmol/L or hyperglycaemia >15 mmol/L to be 
important variables that should trigger IDT management. A strength of our early prediction tool is that it 
allows an IDT to remotely identify at-risk patients and provide early specialist management without 
referrals from treating teams. The tool can help predict at risk patients, thereby allowing very early 
intervention prior to the development, and hence even prevent adverse glycaemic from occurring. As the 
tool identifies patients at risk of either hyperglycaemia or hypoglycaemia, early specialist management 
may decrease both glycaemic extremes and could assist an early intervention model of inpatient diabetes 
care that we previously described [18], or other targeted inpatient diabetes management strategies. 
Another strength of this study is the use of a prospectively recruited cohort of consecutive inpatients who 
underwent detailed clinical characterisation and glucometric analysis.  
 
A study limitation is that some potentially predictive clinical variables were not included, such as 
duration of diabetes, weight or sepsis. However, this reflects the ‘real world’ hospital clinical practice 
where these variables are often incompletely characterised and difficult to document electronically early 
in the admission course. We did not evaluate subsequent inpatient diabetes management such as changes 
in glucose-lowering medications, insulin, or nutrition, as the clinical prediction tool was designed to be 
used early in the admission course, and these variables can vary on a daily basis throughout the hospital 
stay. In this cohort, almost all glucocorticoid treatment was commenced within 24 hours of admission 




disease). However, in routine clinical practice, some individuals who have glucocorticoid treatment 
commenced later in the admission course may not be accurately categorised by the prediction tool. We 
used laboratory results including glycosylated haemoglobin in the prediction tool which may not be 
available in a rapid manner at every hospital, however recent glycosylated haemoglobin results from the 
community prior to hospital admission will be useful if this information can be obtained in a timely 
manner. In addition, glycosylated haemoglobin testing is recommended in all inpatients with diabetes [6], 
routine testing is performed for all inpatients at some hospitals [30], and rapid glycosylated haemoglobin 
measurement with point-of-care technology is also possible. A prediction model excluding glycosylated 
haemoglobin was found to be inferior and hence not pursued further. Lastly, this analysis included only 
patients with type 2 diabetes, to help identify high-risk patients out of this prevalent cohort. Individuals 
with type 1 and type 3c diabetes were not included in the prediction tool and could be considered already 
high-risk from a pathophysiological basis and from clinical experience. 
 
In conclusion, we describe an easily implementable clinical prediction tool which may assist early 
identification of inpatients with diabetes at high-risk of persistent hyperglycaemia and hypoglycaemia. 
Our findings confirm clinician experience that dysglycaemia at admission, glycosylated haemoglobin, 
pre-admission glucose-lowering treatment regimen, and glucocorticoid medication treatment best 
predicted persistent adverse glycaemia in hospital. Further studies should aim to externally validate this 
tool and demonstrate if case-finding and early intervention in high-risk patients improves glycaemic and 
clinical outcomes. Clinical prediction tools could become essential for early identification and targeted 
management of individuals at risk for adverse glycaemia in hospital, and ultimately improve the care and 
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Table 1 – Patient characteristics and clinical variables for all individuals; individuals without 
persistent glycaemia; and individuals with persistent adverse glycaemia 






Putative clinical risk factors n = 594 n = 441 n = 153  
Age (years) mean (SD) 72 (13) 71 (13) 73 (13) 0.04 
Men  341 (57) 253 (57) 88 (58) 0.99 
Glucose-lowering treatment regimen prior to admission    <0.001 
   Diet controlled 124 (21) 109 (25) 15 (10)  
   Glucose-lowering medications excluding sulphonylurea 161 (27) 136 (31) 25 (16)  
   Glucose-lowering medications including sulphonylurea 141 (24) 96 (22) 45 (29)  
   Insulin treatment 168 (28) 100 (22) 68 (45)  
Glycosylated haemoglobin    <0.001 
   ≤ 7.0% (≤53 mmol/mol) 265 (49) 228 (58) 37 (25)  
   7.1-8.0% (54-64 mmol/mol) 130 (24) 94 (24) 36 (25)  
   ≥ 8.1% (≥65 mmol/mol) 145 (27) 71 (18) 74 (50)  
Comorbidities     
Modified Charlson Comorbidity Index a    <0.001 
   0 to 1 points 263 (44) 221 (50) 42 (27)  
   2 to 3 points 190 (32) 126 (29) 64 (42)  
   4 to 5 points 105 (18) 73 (16) 32 (21)  
   6 or more points 39 (6) 21 (5) 15 (10)  
Admission eGFR (ml/min/1.73m2)    <0.001 
   ≥ 90 129 (25) 106 (25) 23 (15)  
   60 - 89 190 (33) 151 (35) 39 (26)  
   31 - 59 194 (34) 134 (32) 60 (40)  
   ≤ 30  64 (11) 35 (8) 29 (19)  
Dysglycaemia at admission b     
   Hypoglycaemia BG < 4 mmol/L  62 (10) 24 (5) 38 (25) <0.001 
   Hyperglycaemia BG > 15 mmol/L 210 (35) 72 (16) 138 (90) <0.001 
   Dysglycaemia BG <4 or >15 mmol/L  216 (37) 116 (26) 100 (65) <0.001 
Hospital Treatment      
Glucocorticoid medication 88 (15) 52 (12) 36 (24) 0.001 
Admission Unit     
   Medical units 398 (67) 214 (62) 117 (76) 0.004 
- cardiology 133 77 28  
- general medicine 150 72 56  
- other medical 115 65 33  
   Surgical 196 (33) 133 (38) 36 (23)  
- trauma/ orthopedic 83 49 19  
- general surgery 69 49 13  
- other surgical 44 35 4  
Admission Type    0.006 
   Elective admission 72 (12) 63 (14) 9 (6)  
   Emergency admission 522 (88) 378 (86) 144 (94)  
Observed-days    <0.001 
   3 to 4 days 186 (31) 179 (41) 7 (5)  
   5 to 7 days 189 (32) 138 (31) 51 (33)  
   8 to 10 days 104 (18) 66 (15) 38 (25)  
   11 or more days 115 (19) 58 (13) 57 (37)  
a Modified Charlson Comorbidity Index excludes items related to diabetes.  b Dysglycaemia at admission (In the first 24h of 
admission). c Persistent Adverse Glycaemia to or more days with BG<4 or >15 mmol/L. Data presented as mean (SD) for 




Table 2– Regression coefficients and odds ratios for Persistent Adverse Glycaemia 
 Persistent Adverse Glycaemia (≥2days) 
Putative clinical risk factor Coefficient OR (95% CI) p  
Dysglycaemia at admission a    
   No 0 1 1 
   Yes 1.293 3.65 (2.09, 6.37) <0.001 
Glycosylated Haemoglobin    
   ≤ 7.0% (≤53 mmol/mol) 0 1  
   7.1-8.0% (54-64 mmol/mol) 0.765 2.15 (1.13, 4.10) 0.020 
   ≥ 8.1% (≥65 mmol/mol) 1.627 5.08 (2.63, 9.87) <0.001 
Glucose-lowering treatment regimen prior to admission    
   Diet controlled 0 1  
Glucose-lowering medications excluding sulphonylurea 0.196 1.22 (0.52, 2.85) 0.652 
Glucose-lowering medications including sulphonylurea 1.252 3.50 (1.57, 7.77) 0.002 
   Insulin treatment 1.440 4.22 (1.84, 9.70) 0.001 
Glucocorticoid medication treatment     
   No 0 1  
   Yes 0.819 2.27 (1.17, 4.40) 0.015 
Modified Charlson Comorbidity Index b    
   0 to 1 points 0 1  
   2 to 3 points 0.671 1.96 (1.09, 3.53) 0.026 
   4 to 5 points 0.725 2.06 (0.98, 4.34) 0.056 
   6 or more points 1.069 2.91 (1.02, 8.33) 0.046 
Observed-days    
   3 to 4 days 0 1  
   5 to 7 days 2.363 10.6 (4.33, 26.1) <0.001 
   8 to 10 days 3.276 26.5 (9.84, 71.2) <0.001 
   11 or more days 3.980 53.5 (19.6, 146.3) <0.001 







Fig. 1: Receiver operating characteristic (ROC) curves of models for predicting persistent adverse glycaemia. 
Hospital-stay model used six putative factors (dysglycaemia at admission, glycosylated haemoglobin, glucose-
lowering treatment regimen prior to admission, glucocorticoid medication treatment, modified Charlson score 
and observed-days). Early identification model used four factors reliably available within 24 hours of 








Fig.2: An algorithm based on the Melbourne Clinical Prediction Tool for predicting inpatients at high-risk 
for persistent adverse glycaemia during hospitalisation. Actual observed proportions of patients with 






6.3 Supplemental material 
 
Supplementary Figure 2: Adjusted odds ratio for Persistent Adverse Glycemia. 





Supplementary table 1: 
Regression coefficients and odds ratios for developing hyperglycaemia (BG >15.0 mmol/L) 
 Hyperglycaemia (>15.0 mmol/L) 
Putative clinical risk factor 
Coefficien
t 
OR (95% CI) P value 
Dysglycaemia at admission *    
>15.0 mmol/L    
   No 0 1  
   Yes 1.308 3.70 (2.27, 6.02) <0.001 
Glycosylated hemoglobin     
   ≤ 7.0% (≤53 mmol/mol) 0 1  
   7.1-8.0% (54-64 mmol/mol) 1.067 2.91 (1.71, 4.94) <0.001 
   ≥ 8.1% (≥65 mmol/mol) 1.607 4.99 (2.83, 8.80) <0.001 
Glucose-lowering treatment regimen prior to admission    
   Diet controlled 0 1  
Glucose-lowering medications excluding sulphonylurea 0.155 1.17 (0.60, 2.29) 0.650 
Glucose-lowering medications including sulphonylurea 0.994 2.70 (1.39, 5.25) 0.003 
   Insulin treatment 0.801 2.23 (1.14, 4.35) 0.019 
Observed-days    
   3 to 4 days 0 1  
   5 to 7 days 1.117 3.06 (1.72, 5.43) <0.001 
   8 to 10 days 1.920 6.82 (3.49, 13.3) <0.001 
   11 or more days 2.002 7.41 (3.84, 14.3) <0.001 
* In the first 24h of admission  
Supplementary table 2 
Regression coefficients and odds ratios for developing hypoglycaemia (BG <4.0 mmol/L) 
 Hypoglycemia (<4.0 mmol/L) 
Putative clinical risk factor Coefficient OR (95% CI) P value 
Dysglycaemia at admission*    
<4.0 mmol/L    
   No 0 1  
   Yes 1.775 5.90 (2.45, 14.3) <0.001 
Glucose-lowering treatment regimen prior to admission    
   Diet controlled 0 1  
   Glucose-lowering medications excluding sulphonylurea -0.629 0.53 (0.15, 1.92) 0.336 
   Glucose-lowering medications including sulphonylurea 0.526 1.69 (0.63, 4.54) 0.296 
   Insulin treatment 1.565 4.78 (1.96, 11.7) 0.001 
Modified Charlson Comorbidity Index †    
   0 to 1 points 0 1  
   2 to 3 points 0.934 2.54 (1.11, 5.83) 0.028 
   4 to 5 points 0.801 2.23 (0.88, 5.65) 0.091 
   6 or more points 2.061 7.86 (2.77, 22.3) <0.001 
Observed-days    
   3 to 4 days 0 1  
   5 to 7 days 0.898 2.45 (0.99, 60.7) 0.052 
   8 to 10 days 1.100 3.00 (1.11, 8.11) 0.030 
   11 or more days 1.829 6.23 (2.46, 15.8) <0.001 




Supplementary table 3  
Early identification model for persistent Adverse Glycaemia 
 Persistent Adverse Glycaemia 
Clinical risk factor Coefficient OR (95% CI) P value 
Dysglycaemia at admission*    
<4.0 or >15.0 mmol/L    
   No 0 1  
   Yes 0.982 2.67 (1.69, 4.22) <0.001 
Glycosylated haemoglobin    
   ≤ 7.0% (≤53 mmol/mol) 0 1  
   7.1-8.0% (54-64 mmol/mol) 0.618 1.85 (1.07, 3.23) 0.029 
   ≥ 8.1% (≥65 mmol/mol) 1.219 3.38 (2.00, 5.73) <0.001 
Glucose-lowering treatment prior to admission  
(sulphonylurea or insulin) 
   
   No 0 1  
Yes 1.043 2.84 (1.76, 4.57) <0.001 
Glucocorticoid treatment    
   No 0 1  
   Yes 0.835 2.31 (1.32, 4.04) 0.003 
Constant -2.776   
* BG<72 mg/dL in the first 24h of admission. 
 
Regression equation: 
Pr (persistent AG) = 
𝑒(𝑦)
(1+𝑒𝑦)
  where 
𝑦 = −2.776 + 0.982(𝑖𝑓 𝑑𝑦𝑠𝑔𝑙𝑦𝑐𝑎𝑒𝑚𝑖𝑎 𝑎𝑡 𝑎𝑑𝑚𝑖𝑠𝑠𝑖𝑜𝑛) + 0.618(𝑖𝑓 𝐺𝐻𝑏 = 7.1 − 8.0%)
+ 1.219(𝑖𝑓 𝐺𝐻𝑏 ≥ 8.1%) + 1.043(𝑖𝑓 𝑜𝑛 𝑠𝑢𝑙𝑓𝑜𝑛𝑦𝑙𝑢𝑟𝑒𝑎 𝑜𝑟 𝑖𝑛𝑠𝑢𝑙𝑖𝑛  𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)






Supplementary table 4: 
Discriminating ability of the early-identification model 
Cut off point for 
the probability of 
persistent AG Sensitivity Specificity PPV NPV LR+ LR- 
Correctly 
classified 
0.05 1 0 0.31 - 1 - 0.31 
0.10 0.92 0.43 0.43 0.92 1.61 0.19 0.59 
0.15 0.88 0.47 0.43 0.90 1.66 0.26 0.60 
0.20 0.84 0.66 0.53 0.90 2.47 0.24 0.72 
0.25 0.67 0.72 0.52 0.83 2.39 0.46 0.70 
0.30 0.61 0.79 0.57 0.82 2.90 0.49 0.73 
0.35 0.55 0.86 0.65 0.81 3.93 0.52 0.76 
0.40 0.48 0.91 0.72 0.79 5.33 0.57 0.78 
0.45 0.48 0.91 0.72 0.79 5.33 0.57 0.78 
0.50 0.14 0.99 0.86 0.71 14.00 0.87 0.72 
0.55 0.14 0.99 0.86 0.71 14.00 0.87 0.72 
0.60 0.11 1.00 1.00 0.71 - 0.89 0.72 
0.65 0.06 1.00 1.00 0.70 - 0.94 0.70 
0.70 0.06 1.00 1.00 0.70 - 0.94 0.70 
0.75 0.00 1.00 - 0.69 - 1.00 0.69 
0.80 0.00 1.00 - 0.69 - 1.00 0.67 
0.85 0.00 1.00 - 0.69 - 1.00 0.67 
0.90 0.00 1.00 - 0.69 - 1.00 0.67 
0.95 0.00 1.00 - 0.69 - 1.00 0.67 
1.00 0.00 1.00 - 0.69 - 1.00 0.67 
PPV – Positive predictive value 
NPV – Negative predictive value 
LR+ positive likelihood ratio 





7. CHAPTER SEVEN: DISCUSSION AND CONCLUSIONS 
7.1 Synopsis 
Diabetes affects approximately one quarter of individuals in hospital, and contributes to worse clinical 
and economic outcomes. Hyperglycaemia causes adverse pathophysiological changes, including immune 
dysfunction, proinflammatory and prothrombotic changes and endothelial dysfunction, leading to 
increased risk of hospital-acquired infections, cardiovascular complications, longer length of stay and 
increased mortality. Hypoglycaemia also causes proinflammatory, prothrombotic, proarrhythmic and 
neuroglycopenic changes leading to adverse outcomes and increased mortality. The term ‘adverse 
glycaemia’ is used to describe both hypoglycaemia and hyperglycaemic extremes (defined as BG <4 or 
>15 mmol/L) that should be avoided for safe management of individuals in hospital.  
 
Despite the importance of safe glycaemic control, adverse glycaemia continues to be common, 
particularly in noncritical care wards. Hyperglycaemia occurs in 50% of patients or 30% of patient-days, 
while hypoglycaemia occurs in 20% of patients or 10% of patient-days. Multiple barriers contribute to 
ongoing high rates of adverse glycaemia, including patient and illness-related factors, treatment-related 
factors, health professional-related factors and hospital system-related factors. A significant common 
barrier is clinical inertia in diabetes management, largely due to a lack of diabetes specialist involvement 
or guidance. To overcome clinical inertia, the aims of this thesis were to develop and investigate 
proactive or early intervention models of inpatient diabetes care to address adverse glycaemia. 
 
This thesis investigated three different proactive interventions: a glucose alert system, a comprehensive 
proactive inpatient diabetes service, and a prediction tool for early identification of high-risk inpatients. 
The studies utilised networked blood glucose meter technology to develop the glucose alert system, to 
enable remote identification of inpatients with diabetes, and to ensure comprehensive glucometric data 
collection and analyses. In addition, this thesis presents the first detailed glucometric outcomes and 





7.1.1 Early intervention using a glucose alert system decreases clinical inertia 
A glucose alert system designed to increase health professional responses to adverse glycaemia (i.e. to 
decrease clinical inertia) was described in Chapter 3. The alert system consisted of a novel clinical 
escalation tool (Melbourne Glucose Alert Pathway), coupled with alert-capable networked glucose meters 
which provided visual alerts for adverse glycaemia. In a pre- and post-implementation study (n=148 
patients), the use of this alert system demonstrated improvement in recognition and management of 
adverse glycaemia by health professionals. In response to episodes of adverse glycaemia, nursing staff 
increased notification to medical officers, and medical officers increased actions to address glucose 
control. The Hawthorne effect may have contributed to improvement in action, as the ward staff were 
aware that a clinical study was taking place. Indeed, the Hawthorne effect is an important aspect of 
remote glucose monitoring offered by networked glucose meters.  Clinicians are more likely to be 
accountable for glucose measurements and subsequent actions if they are aware remote surveillance of 
glucose measurements could be taking place. Increased action led to decreased hyperglycaemia. 
Specifically, patient-days with BG >15 mmol/L decreased from 24% to 16%, and patient-days with mean 
BG >15 mmol/L decreased from 7.4% to 2.5%. There was no change in the incidence of hypoglycaemia. 
Adverse glycaemic days (patient-days with BG <4 or >15 mmol/L) decreased from 290 per 1000 patient-
days to 215 per 1000 patient-days.  
 
The glucose alert system is an example of a proactive intervention for inpatient diabetes care, as it 
encourages earlier recognition and treatment of adverse glycaemia. Although there was improved medical 
staff action, most actions were temporary or ‘Band-Aid’ solutions, such as prescription of correctional (or 
once off, stat dose) insulin. Referrals to the inpatient diabetes team did not increase. Furthermore, the 
cohort consisted of predominantly elective surgical patients with relatively uncomplicated diabetes, and it 
is unclear if the same efficacy of glycaemic improvement would be observed in more complex diabetes 
patients. This study did not evaluate the relative impact of glucose alert pathway vs. alert capable 
networked glucose meters in improving clinical care. A clinical study comparing glucose alert pathway 
with and without networked glucose meters could be performed to address this question. None-the-less 
this study demonstrates the importance of alert systems in decreasing clinical inertia. Both the networked 
glucose meters and Glucose Alert Pathway are essential components of the early intervention model 
developed for the RAPIDS trial.   
 
7.1.2 Glucometric assessment demonstrated high incidence of adverse glycaemia at the 
Royal Melbourne Hospital 
Detailed glucometric analysis of a cohort of consecutive noncritical care patients (n=465 admissions) was 
described during the baseline period of the RAPIDS trial (Chapter 4). Well-established glucometric 
reporting techniques were applied to capillary glucose data obtained by the networked glucose meters. 
This was also the first report of detailed glucometric outcomes at an Australian hospital. Compared to the 




incidence of hyperglycaemia (e.g. patient-days with mean BG >10 mmol/L: 37.0% vs. 32.3%, p<0.001), 
but a lower incidence of hypoglycaemia (e.g. patient-days with BG<3.9 mmol/L: 4.1% vs. 6.1%, 
p<0.001). The findings were potentially influenced by the differences in routine clinical practice between 
US and Australian hospitals. In particular, the practice of cessation of all GLM and prescription of 
subcutaneous insulin in all patients with diabetes admitted to hospital is widely promoted in the US but 
not in Australia. Our cohort has relatively fewer patients with type 1 diabetes (4%) compared to 8% in the 
UK which may account for lower rates of hypoglycaemia. In addition, other differences in patient 
characteristics including number of comorbidities, glucocorticoid treatment and readmissions may 
account for the differences in the rates of hypoglycaemia and hyperglycaemia.  
 
We propose the concept of adverse glycaemic day (AGD), as novel metric of unsafe levels of 
hypoglycaemia and hyperglycaemia, which can be used for future benchmarking. The metric of AGD has 
advantages over traditional metrics as it encompasses both hyperglycaemic and hypoglycaemic extremes. 
AGD is a tangible concept that can help educate health professionals about glucose extremes that should 
be avoided in hospital. The incidence of AGD was 260 per 1000 patient-days in the cohort of medical and 
surgical patients, slightly lower than observed in the cohort of mostly surgical patients in Chapter 3. 
Accordingly, AGD formed the primary outcome measure used to investigate the proactive model of care 
in the RAPIDS study. Finally, Chapter 4 also demonstrated that the majority (80%) of observed AGDs 
occurred in a subgroup (25%) of individuals, suggesting a strategy of identifying and targeting high-risk 
individuals may be possible. 
 
7.1.3 Early intervention (RAPIDS) model of inpatient diabetes care decreased adverse 
glycaemia 
A comprehensive early intervention model of inpatient diabetes care was developed (Chapter 5) and 
investigated in the large-scale prospective cluster randomised (RAPIDS) trial. The RAPIDS model 
comprised a bundle of three interventions: 1) glucose alert system developed in chapter 3; 2) networked 
BG meters which enabled remote surveillance and identification of patients with diabetes; and 3) 
proactive IDT which delivered proactive care (without referral from treating teams) and direct 
management (directly prescribed medication and insulin). The proactive IDT aimed to provide 
management within 24 hours of admission to all patients with diabetes and hyperglycaemia, as a proof of 
concept for this model of care. As the IDT operated during business hours on weekdays, not all patients 
had management within 24 hours, particularly those that were admitted over the weekend.  
 
This model of care was investigated in an open-label cluster randomised study with a baseline period. 
This complex study design was necessitated by the nature of the intervention which could only be 
delivered at the cluster level, and due to enrolment of eight hospital wards with unique medical and 




to account for baseline clinical differences and effects of clustering, and included assessment of outcomes 
as change from baseline within each treatment arm.  
 
With the early intervention model of care, almost all individuals with diabetes received specialist 
management (two thirds of patients receiving specialist management within 24 hours of admission), and 
more individuals received insulin treatment. The intervention decreased the incidence of AGD from 240 
to 190 per 1000 patient-days at the cluster level and by 28% at the individual patient level. There was a 
decrease in patient-day mean BG from 9.4±3.3 to 9.0±2.7 mmol/L, and a 55% reduction in severe 
hyperglycaemia (patient-days with mean BG >15mmol/L) from 7.3% to 3.3%. The intervention was 
particularly effective at decreasing extremes of hyperglycaemia despite a modest reduction in patient-day 
mean glucose. There was no difference in the incidence of hypoglycaemia; however, this is in the context 
of relatively low incidence of hypoglycaemia at baseline compared to US and UK hospitals as 
demonstrated in Chapter 4.  
 
RAPIDS is one of only two completed prospective randomised trials of an IDT published to date. Almost 
two decades ago, Davies et al., reported a RCT (n=300 patients) of a diabetes nurse education service 
which resulted in a reduction in median hospital LOS from 11 to 8 days [264]. Other subsequent studies 
of IDTs were observational studies with only a few reporting glycaemic, clinical and LOS outcomes 
concurrently. Compared to RCTs of insulin regimens, which enrolled between 50 and 400 participants, 
RAPIDS included 1002 participants and is one of the largest randomised trials of diabetes care in the 
noncritical care setting.   
 
RAPIDS provided prospective RCT evidence on the efficacy of IDTs, particularly an early intervention 
model of care, at improving glycaemic control and decreasing adverse glycaemia. AGD reduction was 
driven by improvement in hyperglycaemia as a result of increased insulin treatment, without a concurrent 
increase in hypoglycaemia. Chapter 3 demonstrated the glucose alert system decreased AGD from 290 to 
215 per 1000 patient days. RAPIDS was conducted on different wards and included a different patient 
cohort to chapter 3; therefore, the baseline incidence of AGD cannot be directly compared. Nonetheless, 
the comprehensive intervention in RAPIDS appeared to decrease AGD even further (from 240 to 190 per 
1000 patient-days). This reduction was both statistically and clinically significant compared to the parallel 
control group. As a proof-of-concept of proactive care, the IDT provided management to all inpatients 
with diabetes but this was resource intensive. Further refinement of the intervention will be required to 
ensure a sustainable model of care. None-the-less, RAPIDS clearly demonstrated the efficacy of diabetes 
specialist management in decreasing clinical inertia, increasing insulin treatment, and subsequently 





7.1.4 Early intervention (RAPIDS) model of inpatient diabetes care decreased hospital-
acquired infections  
In the RAPIDS cohort, the baseline incidence of hospital-acquired infection (7.5%) is consistent with 
published incidence in Australian hospitals [302]. RAPIDS demonstrated a significant reduction in 
hospital-acquired infections with early intervention, which was a secondary outcome verified by blinded 
adjudication. The magnitude of change was an 80% relative risk reduction (adjusted odds ratio 0.20 after 
adjustment for covariates), and a 4% absolute risk reduction, equating to a number needed to treat of 25 
for preventing one hospital-acquired infection. Reduction in hospital-acquired infection was observed 
with a modest decrease in mean glucose, but a marked decrease in severe hyperglycaemia. This suggests 
that targeting extremes of hyperglycaemia may be more efficacious than achieving reductions in mean 
glucose.  
 
There is a strong biological basis which supports the link between decreased hyperglycaemia and 
decreased infections. Acute hyperglycaemia causes impaired immunity due to neutrophil and phagocyte 
dysfunction, which increases vulnerability to bacterial infections. Immune dysfunction appears to occur at 
a threshold of 12 to 14 mmol/L, although different thresholds exist in people with and without pre-
existing diabetes (section 1.4.1.1). Immune dysfunction can be reversed upon resolution of 
hyperglycaemia [303]. Therefore, it is biologically plausible that early intervention, which decreased 
episodes of severe hyperglycaemia, resulted in decreased hospital-acquired infections. The findings are 
also in concordance with previous results in noncritical care. In RABBIT2-surgery study, a reduction in 
hyperglycaemia led to a decrease in hospital-acquired pneumonia and wound infections [143]. A meta-
analysis in noncritical care inpatients demonstrated decreased infection with intensive insulin treatment 
[147]. Reducing perioperative hyperglycaemia using a glycaemic alert system also demonstrated 
improvement in post-operative wound infections [256]. RAPIDS study adds to the growing evidence that 
reduction in infection may be a standout benefit of treating inpatient hyperglycaemia. 
 
RAPIDS included inpatients with all diabetes types but it could be postulated that acute hyperglycaemia 
during hospitalisation has different biological consequences between patients with T1D, T2D and new 
hyperglycaemia. Therefore, clinical outcomes including hospital-acquired infections were subjected to 
exploratory subgroup analyses (chapter 5 supplementary materials) to delineate outcomes in a more 
homogenous group containing only type 2 diabetes patients. Indeed, improvement in hospital-acquired 
infections was confirmed in a pure cohort of individuals with type 2 diabetes. Furthermore, subgroup 
analyses between medical and surgical patients demonstrated hospital-acquired infections were more 
prevalent in medical patients at baseline, and the greatest reduction in hospital-acquired infections 
occurred in medical patients. This is contrary to the observations that hyperglycaemia is a risk factor for 
wound and surgical site infections, and contrary to the previous meta-analysis demonstrating benefit in 
mainly surgical patients [147]. However, given that hospital-acquired infection was one of a number of 
secondary outcomes, results should be regarded as hypothesis generating, and should be subjected to 




7.1.5 Generalisability of early intervention (RAPIDS) model of inpatient diabetes care  
Although early intervention decreased adverse glycaemia and hospital-acquired infections, there are 
limitations to the generalisability of the RAPIDS early intervention model. It was a single centre study 
performed in a hospital without a pre-existing comprehensive EMR or insulin order sets. As a result, our 
findings may not be generalisable to all health systems. The early intervention model of care may have 
less efficacy in some large US academic hospitals with fully integrated electronic systems, insulin order 
sets and pre-existing glycaemic management teams. However, many other hospitals in Australia, Asia, 
Europe and the United Kingdom possess similar clinical systems, infrastructure and approach to inpatient 
diabetes care. 
 
The RAPIDS model of care was resource-intensive as the proactive IDT provided management to all 
inpatients with diabetes or hyperglycaemia. Further refinement of this model of care will be necessary for 
a sustainable proactive inpatient service. One approach is to selectively target the subgroups of patients 
who had persistent AGDs or those who were at high-risk of adverse outcomes. In addition, it will be 
important to perform health economic analyses to inform the costs vs. benefits of a refined model of early 
intervention. Nonetheless, RAPIDS demonstrated that early intervention and proactive management by a 
specialist diabetes teams improve glycaemic control and clinical outcomes.  
 
7.1.6 A prediction tool can facilitate targeted and early management of high-risk 
inpatients with diabetes 
The clinical characteristics of high-risk patients, defined as those who developed persistent adverse 
glycaemia during hospitalisation was investigated in Chapter 6. In addition, we investigated whether it 
was possible to identify these high-risk patients at the time of admission. The analysis was based on the 
cohort of patients who received usual care during the RAPIDs trial. It identified four clinical variables, 
which were readily available early in admission, that were associated with subsequent development of 
persistent adverse glycaemia. These four variables were glucose at admission (BG <4 or >15 mmol/L in 
the first 24 hours); glucose-lowering treatment regimen containing insulin or sulphonylurea; glycosylated 
haemoglobin; and glucocorticoid treatment. Based on these four factors, a clinical prediction model 
accurately identified patients who subsequently developed persistent adverse glycaemia with a ROC-
AUC of 0.806. This prediction tool can be built into an EMR which can generate an alert system to 
identify high-risk patients. Alternatively, these patients can be identified using a flowchart algorithm as 
described in Chapter 6 figure 2. 
 
Although prediction tools for hypoglycaemia have been described, this is the first description of a clinical 
tool to predict the more common glycaemic extreme of hyperglycaemia. Additional novelty of this tool is 
the ability to identify high-risk inpatients early (within 24 hours) of admission; therefore, it is well-placed 
to refine the RAPIDS early intervention model of care. For example, using the optimal cut-off of 0.20 




focus management on this cohort with a sensitivity of 84% and specificity of 66% for identifying patients 
with persistent hyperglycaemia. Depending on available resources the threshold probability can be shifted 
to select a smaller or larger subgroup for proactive intervention. Conversely, the clinical prediction tool 
also identifies the patients who are at low-risk of developing adverse glycaemia (i.e. patients who may not 
need glycaemic intervention), and this may decrease aggressive insulin therapy in this cohort which may 
decrease the risk of treatment-related hypoglycaemia. The prediction tool can facilitate any number of 
inpatient diabetes interventions which aims to provide early targeted management. With increasing 
prevalence of diabetes in hospital, identification and targeted management is expected to become an 





7.2 Clinical implications 
The findings described in this thesis have immediate and practical clinical utility, and have the potential 
to transform clinical practice. Firstly, diabetes inpatients at our Australian hospital had a high incidence 
of adverse glycaemia. Indeed, our incidence of hyperglycaemia was significantly higher than US hospital 
benchmarks, although this was partially offset by our lower incidence of hypoglycaemia. Nonetheless, it 
confirmed the need to improve glycaemic control, and also highlighted the need to establish local 
benchmarking of glycaemic control in Australian hospitals.  
 
Secondly, our findings demonstrated proactive care interventions can decrease clinical inertia, decrease 
adverse glycaemia and improve clinical outcomes. Each of the three examples of proactive interventions 
can be implemented either as stand-alone systems or as a bundle of interventions to help decrease adverse 
glycaemia. The Melbourne Glucose Alert Pathway and the glucose alert system are simple interventions 
that can be implemented at many hospital systems with or without electronic clinical systems. 
Implementation of such an alert system has the potential to decrease clinical inertia and increase health 
professional action to address adverse glycaemia. The prediction tool for high-risk diabetes inpatients is 
another readily implementable tool which can assist a variety of glycaemic interventions to provide 
targeted management.  
 
Thirdly, the RAPIDS early intervention model of inpatient diabetes care, consisting of remote 
surveillance and proactive management by an IDT, can be implemented in many hospitals. Although the 
IDT in RAPIDS managed every patient with diabetes or hyperglycaemia, a targeted management 
approach on the high-risk subgroup will be less resource intensive and more sustainable. Indeed, the 
Department of Diabetes and Endocrinology at RMH now provides a targeted clinical service of proactive 
management in high-risk individuals in the cardiology wards following the completion of RAPIDS.  
 
Early or ‘proactive’ intervention is a common theme in this thesis. This approach is particularly important 
as blood glucose is a highly dynamic variable, and can be affected by many clinical factors, often early in 
the admission course. For this reason, it is believed that early specialist management can have greatest 
efficacy at improving clinical outcomes. This is in contrast to the traditional ‘reactive’ model of care 
which relies on referrals from treating teams, which often occur many days into the admission course, 
often after many days of persistent adverse glycaemia. Although several models of early intervention are 
presented in this thesis, other alternative approaches of proactive care may be efficacious at improving 
glycaemic control. None-the-less proactive models developed in this thesis provide tangible and practical 
interventions, which can be implemented in a variety of hospital settings to assist improving inpatient 
glycaemia.  
 
From a conceptual point of view, our findings suggest addressing adverse glycaemia, potentially with any 




demonstrated in this thesis was consistent with the literature in cardiac surgery [116], perioperative 
services [256], critical care [130] and noncritical care [147]. Any clinical improvement programs or 
models of care which decrease hyperglycaemia may decrease the risk of infection. A benefit of the 
RAPIDS model of care, which provides autonomous proactive management of patients, is the ability for 
the IDT to incorporate latest glycaemic management practices and emerging technologies in diabetes 
treatment. 
 
7.3 Future research suggestions 
Suggested future research to build on our findings can be summarised into the following six themes. 
 
1. To investigate the efficacy of early identification and targeted management of high-risk 
inpatients using the clinical prediction tool to refine the RAPIDS model of care. Chapter 6 
described a practical clinical prediction tool which can be used to risk categorise inpatients 
between low and high risk of persistent adverse glycaemia. An early intervention model of 
proactive care can be delivered by an IDT to the subgroup of ‘high-risk’ patients to improve 
glycaemic outcomes. Targeted management is expected to be less resource intensive and more 
sustainable than universal management of all diabetes inpatients. Indeed, as part of ongoing 
clinical research programme, an observational study evaluating proactive care in high-risk 
patients in cardiology wards has been conducted. 
 
2. To investigate long-term outcomes of the RAPIDS intervention at the patient level and at the 
ward level. To evaluate long-term outcomes for patients included in RAPIDS, a follow-up study 
will evaluate readmission and mortality at 30-days and at 1-year post discharge from hospital. 
Data linkage with state-wide hospital admission database and with the national death registry 
will be conducted to assess these outcomes. HbA1c at 3 months following discharge from 
hospital will be evaluated to assess longer term glycaemic outcomes for patients who received 
proactive care vs. usual care. At the ward level, an observational extension study has been 
underway assessing ward glucometrics to assess whether improvements in glycaemic outcomes 
are sustained following the cessation of proactive care.   
 
3. To analyse the health economics of a targeted proactive model of care. Decreased incidence of 
hospital-acquired infection translates to cost savings for the health system. Cost savings will 







4. To refine the clinical practice of hospital glycaemic control. Although different insulin regimens 
have been compared in pre-existing literature, further studies are required to optimise insulin 
dose initiation and dose adjustment in various settings. For example, there is a need to 
investigate insulin adjustment protocols in situations such as: 1) glucocorticoids commencement 
or dose adjustment; 2) GLMs (especially metformin) cessation or recommencement. These 
clinical studies can be pre- and post- implementation studies, or randomised trials of different 
algorithms. These studies should inform clinical practice to optimise guidelines and algorithms, 
in addition to upskilling IDTs 
 
5. To investigate the biological and clinical link between adverse glycaemia and adverse clinical 
outcomes, especially hospital-acquired infections. This can consist of an observational study of 
inpatients with or without diabetes or new hyperglycaemia; and inpatients with or without 
hospital-acquired infections. The aim of such a study would be to identify the specific patient 
cohorts that are particularly susceptible to hyperglycaemia-related hospital-acquired infection 
and those who are most likely to benefit from improved glycaemic control. This will enable a 
definitive study to confirm improvements in clinical outcomes observed in RAPIDS. 
 
6. To perform a large-scale intervention study aimed at early intervention to improve glycaemic 
control with the primary outcome of decreasing infection complications. To confirm RAPIDS 
findings, a prospective multi-centre randomised controlled trial of early intervention by a 
proactive inpatient diabetes service should be conducted. This trial would ideally involve a 
parallel or stepped wedged, cluster randomised design involving multiple clusters at multiple 
hospitals. Indeed, our research group continues to seek funding from the National Health and 





7.4 Concluding remarks 
Despite the importance of glycaemic control in hospital inpatients, adverse glycaemia and associated 
clinical complications remain common. This thesis aimed to better understand glycaemic landscape in 
hospital and to develop proactive or early intervention models of diabetes care to address adverse 
glycaemia. Networked glucose meter technology was used to perform detailed glucometric assessment, 
and to develop proactive interventions to overcome clinical inertia and improve inpatient glycaemia.  
 
Three examples of proactive diabetes interventions were developed and investigated. A glucose system 
improved health professional action to address adverse glycaemia. A comprehensive early intervention 
model of diabetes care, comprising remote glucose surveillance and proactive management by an 
inpatient diabetes team, was investigated in a large-scale cluster randomised trial. This model of care 
decreased extremes of hyperglycaemia, and demonstrated a reduction in hospital-acquired infections. A 
practical clinical tool was then developed for early identification of high-risk patients to assist early and 
targeted management for sustainable proactive interventions.  
 
This thesis demonstrates early intervention for diabetes care improves inpatient glycaemic control. It 
suggests that reducing adverse glycaemia may decrease hospital-acquired infection and improve clinical 
outcomes. The findings are clinically relevant and may assist transforming the approach to hospital 
diabetes management. Proactive and early intervention approaches to diabetes care in hospital should be 
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